Quorum Health (QHCCQ) 10-K 15 Mar 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Mar. 12, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	QUORUM HEALTH CORPORATION
Entity Central Index Key	1,650,445
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Current Fiscal Year End Date	--12-31
Trading Symbol	QHC
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Amendment Flag	false
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 118.3
Entity Common Stock, Shares Outstanding		30,201,415

CONSOLIDATED AND COMBINED STATE

CONSOLIDATED AND COMBINED STATEMENTS OF INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Operating revenues, net of contractual allowances and discounts									$ 2,327,655	$ 2,419,053	$ 2,445,858
Provision for bad debts									255,485	280,586	258,520
Net operating revenues	$ 515,082	$ 499,302	$ 530,146	$ 527,640	$ 515,240	$ 543,939	$ 529,737	$ 549,551	2,072,170	2,138,467	2,187,338
Operating costs and expenses:
Salaries and benefits									1,034,797	1,057,119	1,016,696
Supplies									250,523	258,639	249,792
Other operating expenses									623,063	645,802	634,233
Depreciation and amortization									82,155	117,288	128,001
Rent									50,230	49,883	48,729
Electronic health records incentives earned									(4,745)	(11,482)	(25,779)
Legal, professional and settlement costs									6,001	7,342	0
Impairment of long-lived assets and goodwill									47,281	291,870	13,000
Loss (gain) on sale of hospitals, net									(5,243)	2,150	0
Transaction costs related to the Spin-off									253	5,488	16,337
Total operating costs and expenses									2,084,315	2,424,099	2,081,009
Income (loss) from operations									(12,145)	(285,632)	106,329
Interest expense, net									122,077	113,440	98,290
Income (loss) before income taxes									(134,222)	(399,072)	8,039
Provision for (benefit from) income taxes									(21,865)	(53,875)	3,304
Net income (loss)	(26,023)	(28,554)	(30,575)	(27,205)	(90,092)	(6,452)	(243,966)	(4,687)	(112,357)	(345,197)	4,735
Less: Net income (loss) attributable to noncontrolling interests	785	637	55	356	574	507	1,095	315	1,833	2,491	3,398
Net income (loss) attributable to Quorum Health Corporation	$ (26,808)	$ (29,191)	$ (30,630)	$ (27,561)	$ (90,666)	$ (6,959)	$ (245,061)	$ (5,002)	$ (114,190)	$ (347,688)	$ 1,337
Earnings (loss) per share attributable to Quorum Health Corporation stockholders:
Basic and diluted	$ (0.95)	$ (1.03)	$ (1.09)	$ (0.99)	$ (3.19)	$ (0.24)	$ (8.63)	$ (0.18)	$ (4.06)	$ (12.24)	$ 0.05
Weighted-average shares outstanding:
Basic and diluted	28,248,527	28,245,833	28,145,215	27,800,597	28,416,801	28,413,532	28,412,720	28,412,054	28,113,566	28,413,247	28,412,054

CONSOLIDATED AND COMBINED STAT3

CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ (26,023)	$ (28,554)	$ (30,575)	$ (27,205)	$ (90,092)	$ (6,452)	$ (243,966)	$ (4,687)	$ (112,357)	$ (345,197)	$ 4,735
Amortization and recognition of unrecognized pension cost (credit) components, net of income taxes									804	(2,760)	0
Comprehensive income (loss)									(111,553)	(347,957)	4,735
Less: Comprehensive income (loss) attributable to noncontrolling interests									1,833	2,491	3,398
Comprehensive income (loss) attributable to Quorum Health Corporation									$ (113,386)	$ (350,448)	$ 1,337

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 5,617	$ 25,455
Patient accounts receivable, net of allowance for doubtful accounts of $352,509 and $360,796 at December 31, 2017 and 2016, respectively	343,145	380,685
Inventories	53,459	58,124
Prepaid expenses	21,167	23,028
Due from third-party payors	97,202	116,235
Current assets of hospitals held for sale	8,112	1,502
Other current assets	47,440	57,942
Total current assets	576,142	662,971
Property and equipment, at cost	1,405,184	1,519,975
Less: Accumulated depreciation and amortization	(729,905)	(786,075)
Total property and equipment, net	675,279	733,900
Goodwill	409,229	416,833
Intangible assets, net	64,850	84,982
Long-term assets of hospitals held for sale	7,734	6,851
Other long-term assets	95,607	88,833
Total assets	1,828,841	1,994,370
Current liabilities:
Current maturities of long-term debt	1,855	5,683
Accounts payable	171,250	169,684
Accrued liabilities:
Accrued salaries and benefits	77,803	98,803
Accrued interest	10,466	19,915
Due to third-party payors	47,705	42,537
Current liabilities of hospitals held for sale	2,577	492
Other current liabilities	43,687	53,268
Total current liabilities	355,343	390,382
Long-term debt	1,212,035	1,241,142
Deferred income tax liabilities, net	7,774	31,474
Other long-term liabilities	137,954	108,996
Total liabilities	1,713,106	1,771,994
Redeemable noncontrolling interests	2,325	6,807
Commitments and Contingencies (Note 19)
Quorum Health Corporation stockholders' equity:
Preferred stock, $0.0001 par value per share; 100,000,000 shares authorized; none issued	0	0
Common stock, $0.0001 par value per share; 300,000,000 shares authorized; 30,294,895 shares issued and outstanding at December 31, 2017 and 29,482,050 shares issued and outstanding at December 31, 2016	3	3
Additional paid-in capital	549,610	537,911
Accumulated other comprehensive income (loss)	(1,956)	(2,760)
Accumulated deficit	(448,216)	(334,026)
Total Quorum Health Corporation stockholders' equity	99,441	201,128
Nonredeemable noncontrolling interests	13,969	14,441
Total equity	113,410	215,569
Total liabilities and equity	$ 1,828,841	$ 1,994,370

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Apr. 29, 2016	Dec. 31, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Allowance for doubtful patient accounts	$ 352,509	$ 360,796		$ 346,507	$ 341,527
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	30,294,895	29,482,050
Common stock, shares outstanding	30,294,895	29,482,050	28,412,054

CONSOLIDATED AND COMBINED STAT6

CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]	Parent [Member]	Nonredeemable Noncontrolling Interests [Member]
Stockholders' equity, beginning balance at Dec. 31, 2014	$ 7,918					$ 3,109	$ 4,809
Comprehensive income (loss)	4,905					1,337	3,568
Transfers to Parent (prior to the Spin-off)	(1,337)					(1,337)
Cash distributions to noncontrolling investors	(1,124)						(1,124)
Purchases of shares from noncontrolling investors	132					217	(85)
Redemption of shares from noncontrolling interests	5,586						5,586
Reclassifications of noncontrolling interests	5						5
Adjustments to redemption values of redeemable noncontrolling interests	(142)					(142)
Stockholders' equity, ending balance at Dec. 31, 2015	15,943					3,184	12,759
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2014	2,362
Redeemable Noncontrolling Interests, Comprehensive income (loss)	(170)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(499)
Redeemable Noncontrolling Interests, Purchases of shares from noncontrolling investors	(543)
Redeemable Noncontrolling Interests, Redemption of shares from noncontrolling interests	5,955
Redeemable Noncontrolling Interests, Reclassifications of noncontrolling interests	(5)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests	142
Redeemable Noncontrolling Interests, Noncontrolling interest in acquired entity	1,716
Redeemable noncontrolling interests, ending balance at Dec. 31, 2015	8,958
Comprehensive income (loss)	(346,893)			$ (2,760)	$ (334,026)	(13,662)	3,555
Transfers to Parent (prior to the Spin-off)	13,662					13,662
Changes in equity related to the Spin-off	527,425	$ 3	$ 530,559			(3,137)
Change in equity related to the spin-off, shares		28,412,054
Stock-based compensation expense	7,441		7,441
Stock-based compensation expense, shares		1,072,987
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(13)		(13)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares, shares		(2,991)
Cash distributions to noncontrolling investors	(2,464)						(2,464)
Purchases of shares from noncontrolling investors	1					19	(18)
Reclassifications of noncontrolling interests	609						609
Adjustments to redemption values of redeemable noncontrolling interests	(142)		(76)			$ (66)
Stockholders' equity, ending balance at Dec. 31, 2016	$ 215,569	$ 3	537,911	(2,760)	(334,026)		14,441
Stockholders' equity, ending balance, shares at Dec. 31, 2016	29,482,050	29,482,050
Redeemable Noncontrolling Interests, Comprehensive income (loss)	$ (1,064)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(386)
Redeemable Noncontrolling Interests, Purchases of shares from noncontrolling investors	(102)
Redeemable Noncontrolling Interests, Reclassifications of noncontrolling interests	(609)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests	142
Redeemable Noncontrolling Interests, Noncontrolling interest in acquired entity	(132)
Redeemable noncontrolling interests, ending balance at Dec. 31, 2016	6,807
Comprehensive income (loss)	(110,335)			804	(114,190)		3,051
Changes in equity related to the Spin-off	1,563		1,563
Stock-based compensation expense	9,952		9,952
Stock-based compensation expense, shares		1,031,753
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,508)		(1,508)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares, shares		(218,908)
Cash distributions to noncontrolling investors	(3,809)						(3,809)
Redemption of shares from noncontrolling interests	2,158		2,235				(77)
Reclassifications of noncontrolling interests	363						363
Adjustments to redemption values of redeemable noncontrolling interests	(543)		(543)
Stockholders' equity, ending balance at Dec. 31, 2017	$ 113,410	$ 3	$ 549,610	$ (1,956)	$ (448,216)		$ 13,969
Stockholders' equity, ending balance, shares at Dec. 31, 2017	30,294,895	30,294,895
Redeemable Noncontrolling Interests, Comprehensive income (loss)	$ (1,218)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(42)
Redeemable Noncontrolling Interests, Redemption of shares from noncontrolling interests	(3,402)
Redeemable Noncontrolling Interests, Reclassifications of noncontrolling interests	(363)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests	543
Redeemable noncontrolling interests, ending balance at Dec. 31, 2017	$ 2,325

CONSOLIDATED AND COMBINED STAT7

CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net income (loss)	$ (112,357)	$ (345,197)	$ 4,735
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	82,155	117,288	128,001
Non-cash interest expense	5,770	2,496	0
Provision for (benefit from) deferred income taxes	(22,137)	(56,339)	2,542
Stock-based compensation expense	9,952	7,441	0
Impairment of long-lived assets and goodwill	47,281	291,870	13,000
Loss (gain) on sale of hospitals, net	(5,243)	2,150	0
Changes in reserves for self-insurance claims, net of payments	22,519	27,994	0
Changes in reserves for legal, professional and settlement costs, net of payments	(3,651)	3,651	0
Other non-cash expense (income), net	190	(575)	380
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Patient accounts receivable, net	29,091	10,205	(16,639)
Due from and due to third-party payors, net	24,201	7,005	(18,198)
Inventories, prepaid expenses and other current assets	673	1,457	8,000
Accounts payable and accrued liabilities	(14,743)	20,760	(78,944)
Long-term assets and liabilities, net	3,269	(9,120)	12
Net cash provided by (used in) operating activities	66,970	81,086	42,889
Cash flows from investing activities:
Capital expenditures for property and equipment	(61,530)	(79,920)	(59,455)
Capital expenditures for software	(6,898)	(7,269)	(8,845)
Acquisitions, net of cash acquired	(1,920)	(785)	(8,019)
Proceeds from the sale of hospitals	32,081	13,746	0
Proceeds from asset sales	0	1,082	3,114
Other investing activities	0	0	(5,387)
Net cash provided by (used in) investing activities	(38,267)	(73,146)	(78,592)
Cash flows from financing activities:
Borrowings under revolving credit facilities	508,000	50,000	0
Repayments under revolving credit facilities	(508,000)	(50,000)	0
Borrowings of long-term debt	376	1,256,281	372
Repayments of long-term debt	(39,195)	(15,222)	(1,563)
Increase in Due to Parent, net	0	24,796	262,775
Increase (decrease) in receivables facility, net	0	0	(224,774)
Payments of debt issuance costs	(3,119)	(29,146)	0
Cash paid to Parent related to the Spin-off	0	(1,217,336)	0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,508)	(13)	0
Cash distributions to noncontrolling investors	(3,851)	(2,850)	(1,623)
Purchases of shares from noncontrolling investors	(1,244)	(101)	(937)
Net cash provided by (used in) financing activities	(48,541)	16,409	34,250
Net change in cash and cash equivalents	(19,838)	24,349	(1,453)
Cash and cash equivalents at beginning of period	25,455	1,106	2,559
Cash and cash equivalents at end of period	5,617	25,455	1,106
Supplemental cash flow information:
Interest payments, net	125,775	90,909	98,290
Income tax payments, net (after the Spin-off)	196	0	0
Non-cash purchases of property and equipment under capital lease obligations	$ 54	$ 6,579	$ 15,448

Description of the Business and

Description of the Business and the Spin-Off	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of the Business and the Spin-off	NOTE 1 — DESCRIPTION OF THE BUSINESS AND THE SPIN-OFF Description of the Business The principal business of Quorum Health Corporation, a Delaware corporation, and its subsidiaries (collectively, “QHC” or the “Company”) is to provide hospital and outpatient healthcare services in its markets across the United States. As of December 31, 2017, the Company owned or leased a diversified portfolio of 31 hospitals in rural and mid-sized markets, which are located in 15 states and have a total of 2,979 licensed beds. The Company provides outpatient healthcare services through its hospitals and their affiliated facilities, including urgent care centers, diagnostic and imaging centers, physician clinics and surgery centers. The Company’s wholly-owned subsidiary, Quorum Health Resources, LLC (“QHR”), provides hospital management advisory and healthcare consulting services to non-affiliated hospitals located throughout the United States. Over 95% of the Company’s net operating revenues for each of the years ended December 31, 2017, 2016 and 2015 are attributable to its hospital operations business. Description of the Spin-off On April 29, 2016, Community Health Systems, Inc. (“CHS”, or “Parent” when referring to the carve-out period prior to April 29, 2016) completed the spin-off of 38 hospitals, including their affiliated facilities, and QHR to form Quorum Health Corporation through the distribution of 100% of the common stock of QHC, issued at a par value of $0.0001 per share, to CHS stockholders of record as of the close of business on April 22, 2016 (the “Record Date”) and cash proceeds to CHS of $1.2 billion (the “Spin-off”). Each CHS stockholder received a distribution of one share of QHC common stock for every four shares of CHS common stock held as of the Record Date plus cash in lieu of fractional shares. Quorum Health Corporation began trading on the New York Stock Exchange (“NYSE”) under the ticker symbol “QHC” on May 2, 2016. In connection with the Spin-off, QHC issued $400 million in aggregate principal amount of 11.625% Senior Notes due 2023 (the “Senior Notes”) on April 22, 2016, pursuant to an indenture (the “Indenture”) by and between the Company and Regions Bank, as Trustee. The Senior Notes were issued at a discount of $6.9 million, or 1.734%. The gross offering proceeds of the Senior Notes were deposited into a segregated escrow account at the closing of the offering on April 22, 2016. On April 29, 2016, the Company entered into a credit agreement (the “Senior Credit Facility”) consisting of an $880 million senior secured term loan facility (the “Term Loan Facility”), which was issued at 98% of par value, or a discount of $17.6 million, and a $100 million senior secured revolving credit facility (the “Revolving Credit Facility”). In addition, the Company entered into a $125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”) on April 29, 2016. The net offering proceeds of the Senior Notes were released to QHC from the escrow account on April 29, 2016. The net offering proceeds of the Senior Notes, together with the net borrowings under the Term Loan Facility, were used to pay $1.2 billion of the cash proceeds to CHS, as mentioned above, and to pay the Company’s fees and expenses related to the Spin-off. The cash proceeds paid to CHS were characterized as a one-time, tax-free cash distribution. In connection with the Spin-off, QHC and CHS entered into a Separation and Distribution Agreement, a Tax Matters Agreement and an Employee Matters Agreement on April 29, 2016, which, collectively, governed or continue to govern the allocation of employees, assets and liabilities that were transferred to QHC from CHS, including but not limited to investments, working capital, property and equipment, employee benefits and deferred tax assets and liabilities. In addition, QHC and CHS entered into various transition services agreements and other ancillary agreements that govern certain relationships and activities of QHC and CHS for five years following the Spin-off. See Note 18 — Related Party Transactions for additional information on the agreements that exist between QHC and CHS after the Spin-off. In connection with the Spin-off, CHS contributed $530.6 million of additional paid-in capital to QHC and made a $13.5 million cash contribution to QHC, pursuant to the Separation and Distribution Agreement. This contribution consisted of $20.0 million of cash contributed to fund a portion of QHC’s initial working capital, reduced by $6.5 million for the difference in estimated and actual financing transaction fees related to the Spin-off. The following table provides a summary of the major transactions to effect the Spin-off of QHC as a newly formed, independent company (dollars in thousands): Additional Long-Term Due to Common Stock Paid-in Parent's Debt Parent, Net Shares Amount Capital Equity Balances at April 29, 2016 (prior to the Spin-off) $ 24,179 $ 1,813,836 — $ — $ — $ 3,137 Borrowings of long-term debt, net of debt issuance discounts 1,255,464 — — — — — Payments of debt issuance costs (29,146 ) — — — — — Cash proceeds paid to Parent — (1,217,336 ) — — — — Transfer of liabilities from Parent — (22,292 ) — — — — Net deferred income tax liability resulting from the Spin-off — (46,783 ) — — — — Non-cash capital contribution from Parent — (527,425 ) — — 530,562 (3,137 ) Distribution of common stock — — 27,719,645 3 (3 ) — Distribution of restricted stock awards — — 692,409 — — — Balances at April 29, 2016 (after the Spin-off) $ 1,250,497 $ — 28,412,054 $ 3 $ 530,559 $ —

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	NOTE 2 — Basis of Presentation The consolidated and combined financial statements and accompanying notes of the Company presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”). In the opinion of the Company’s management, the consolidated and combined financial information presented herein includes all adjustments necessary to present fairly the results of operations, financial position and cash flows of the Company for the periods presented. Prior to its separation from CHS on April 29, 2016, QHC did not operate as a separate company and stand-alone financial statements were not historically prepared; however, QHC was comprised of certain stand-alone legal entities for which discrete financial information was available under CHS’ ownership. The accompanying consolidated and combined financial statements include amounts and disclosures for QHC that have been derived from the consolidated financial statements and accounting records of CHS for the periods prior to the Spin-off in combination with the amounts and disclosures related to the stand-alone financial statements and accounting records of QHC after the Spin-off. The accompanying consolidated and combined financial statements may not necessarily be indicative of the results of operations, financial position and cash flows of QHC in the future or those that would have occurred had the Company operated on a stand-alone basis during the entirety of the periods presented herein. See Note 18 — Related Party Transactions for additional information on the carve-out of financial information from CHS. Principles of Consolidation and Combination The consolidated and combined financial statements include the accounts of the Company and its subsidiaries in which it holds either a direct or indirect ownership of a majority voting interest. Investments in less-than-wholly-owned consolidated subsidiaries of QHC are presented separately in the equity component of the Company’s consolidated balance sheets to distinguish between the interests of QHC and the interests of the noncontrolling investors. Revenues and expenses from these subsidiaries are included in the respective individual line items of the Company’s consolidated and combined statements of income, and net income is presented both in total and separately to distinguish the amounts attributable to the Company and the amounts attributable to the interests of the noncontrolling investors. Noncontrolling interests that are redeemable, or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company, are presented in mezzanine equity in the consolidated balance sheets. Intercompany transactions and accounts of the Company are eliminated in consolidation. Additionally, all significant transactions with CHS that occurred prior to the Spin-off have been included in the consolidated balance sheets within Due to Parent, net. This liability to CHS was settled in the Spin-off. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated and combined financial statements and accompanying notes. Actual results could differ from those estimates under different assumptions or conditions. Reclassifications and Immaterial Restatements Certain revisions have been made to the prior period balances as follows: Beginning in 2017, the Company has reclassified and separately presented on the consolidated and combined statements of cash flows the borrowings and repayments of the revolving credit facilities. Both items are included in cash flows from financing activities. This restatement of the consolidated and combined statement of cash flows as of December 31, 2016 was considered immaterial and had no effect on the Company’s results of operations or financial position as of December 31, 2016. Beginning in 2017, the Company reclassified and separately presented in the notes to the consolidated and combined financial statements the components of deferred income tax assets and liabilities based on their type of asset and liability. Previously, deferred tax assets and liabilities were classified as either other current or other long-term assets or liabilities. The Company believes the current presentation helps distinguish the types of deferred tax assets and liabilities. Revenues and Accounts Receivable Revenue Recognition The Company recognizes revenues from patient services at its hospitals and affiliated facilities in the period services are performed and reports these revenues at the net realizable amount expected to be collected from patients and third-party payors. Billings and collections are outsourced to CHS under the transition services agreements that were entered into by CHS in connection with the Spin-off. See Note 18 — Related Party Transactions for additional information on these agreements. The amounts that are collected for patient services are generally less than established billing rates, or standard billing charges, due to contractual agreements with third-party payors, governmental programs that require reduced billing rates, discounts offered as incentives for payment, and a portion related to bad debts. The Company recognizes revenues related to its QHR business when management advisory and consulting services are provided and reports these revenues at the net realizable amount expected to be collected from the non-affiliated hospital clients of the Company’s QHR business. The following table provides a summary of the components of net operating revenues, before the provision for bad debts (in thousands): Year Ended December 31, 2017 2016 2015 Operating revenues $ 11,930,145 $ 12,104,580 $ 11,613,826 Less: Contractual allowances (9,173,711 ) (9,247,789 ) (8,795,674 ) Less: Discounts (428,779 ) (437,738 ) (372,294 ) Total net operating revenues, before the provision for bad debts $ 2,327,655 $ 2,419,053 $ 2,445,858 During the fourth quarter of 2017, the Company analyzed self-pay patient accounts receivable at a more comprehensive and disaggregated level and refined its estimate of the collectability of the portion of self-pay accounts receivable related to insured patients, primarily co-pays and deductibles. The Company’s analysis also included an evaluation of patient accounts receivable retained in the divestitures of six of the Company’s seven divested hospitals. As a result of these efforts, the Company recorded a change in estimate of $21.0 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the consolidated and combined statement of income for the year ended December 31, 2017. As of December 31, 2016, the Company recorded a change in estimate of $11.4 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the statement of income for the year ended December 31, 2016. This change in estimate related to an assessment of the collectability of managed care and commercial accounts receivable aged greater than one year based on the Company’s review of historical cash collections for these accounts. Payor Sources The primary sources of payment for patient healthcare services are third-party payors, including federal and state agencies administering the Medicare and Medicaid programs, other governmental agencies, managed care health plans, commercial insurance companies, workers’ compensation carriers and employers. Self-pay revenues are the portion of patient service revenues derived from patients who do not have health insurance coverage and the patient responsibility portion of services that are not covered by health insurance plans. Non-patient revenues primarily include revenues from QHR’s hospital management advisory and consulting services business, rental income and hospital cafeteria sales. The following table provides a summary of net operating revenues, before the provision for bad debts, by payor source (dollars in thousands): Year Ended December 31, 2017 2016 2015 $ Amount % of Total $ Amount % of Total $ Amount % of Total Medicare $ 656,843 28.2 % $ 673,074 27.8 % $ 656,799 26.9 % Medicaid 425,943 18.3 % 446,273 18.4 % 443,479 18.1 % Managed care and commercial plans 921,503 39.6 % 952,535 39.4 % 984,480 40.3 % Self-pay 226,043 9.7 % 242,095 10.1 % 247,234 10.0 % Non-patient 97,323 4.2 % 105,076 4.3 % 113,866 4.7 % Total net operating revenues, before the provision for bad debts $ 2,327,655 100.0 % $ 2,419,053 100.0 % $ 2,445,858 100.0 % The table above includes an $11.4 million change in estimate the Company recorded as of December 31, 2016 to reduce the net realizable value of patient accounts receivable due to increasing delays associated with collections on accounts receivable under the Illinois Medicaid program. This change in estimate impacted contractual allowances associated with Medicaid revenues. For the years ended December 31, 2017, 2016 and 2015, Medicare revenues related to Medicare Advantage Programs were $186.7 million, $170.4 million and $146.9 million, respectively. Contractual Allowances and Discounts The net realizable amount of patient service revenues due from third-party payors is subject to complexities and interpretations of payor-specific contractual agreements and governmental regulations that are frequently changing. The Medicare and Medicaid programs, which represent a large portion of the Company’s operating revenues, are highly complex programs to administer and are subject to interpretation of federal and state-specific reimbursement rates, new legislation and final cost report settlements. Contractual allowances, or differences in standard billing rates and the payments derived from contractual terms with governmental and non-governmental third-party payors, are recorded based on management’s best estimates in the period in which services are performed and a payment methodology is established with the patient. Recorded estimates for past contractual allowances are subject to change, in large part, due to ongoing contract negotiations and regulation changes, which are typical in the U.S. healthcare industry. Revisions to estimates are recorded as contractual allowance adjustments in the periods in which they become known and may be subject to further revisions. Billing and collections are outsourced to CHS under the transition services agreements that were put in place by CHS in connection with the Spin-off. The Company’s contractual allowances are impacted by the timing and ability of CHS to monitor the classification and collection of our patient accounts receivable. Self-pay and other payor discounts are incentives offered to uninsured or underinsured payors to reduce their costs of healthcare services. Third-Party Program Reimbursements Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans are estimated and recorded in the period the related services are performed and are adjusted in future periods, as needed, until the final cost report settlements are determined. ontractual allowance adjustments related to previous program reimbursements and final cost report settlements favorably (unfavorably) impacted net operating revenues by $2.0 million, $(5.8) million and $(15.1) million, respectively. Currently, several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of federal and state resources, including, in certain instances, taxes, fees or other program expenses (collectively, “provider taxes”) levied on the providers. The receivables and payables associated with these programs are included in due from and due to third-party payors in the consolidated balance sheets. The following table provides a summary of the components of amounts due from and due to third-party payors, as presented in the consolidated balance sheets (in thousands): December 31, 2017 2016 Amounts due from third-party payors: Previous program reimbursements and final cost report settlements $ 17,383 $ 23,876 State supplemental payment programs 79,819 92,359 Total amounts due from third-party payors $ 97,202 $ 116,235 Amounts due to third-party payors: Previous program reimbursements and final cost report settlements $ 33,163 $ 33,366 State supplemental payment programs 14,542 9,171 Total amounts due to third-party payors $ 47,705 $ 42,537 After a state supplemental payment program is approved and fully authorized by the appropriate state legislative or governmental agency, the Company recognizes the revenues and related expenses based on the terms of each program in the period in which amounts are estimable and revenue collection is reasonably assured. The revenues earned by the Company under these programs are included in net operating revenues and the expenses associated with these programs are included in other operating expenses in the consolidated and combined statements of income. The following table provides a summary of the portion of Medicaid reimbursements included in the consolidated and combined statements of income that are attributable to state supplemental payment programs (in thousands): Year Ended December 31, 2017 2016 2015 Medicaid revenues $ 211,448 $ 220,389 $ 211,696 Provider taxes and other expenses 75,388 76,616 75,929 Reimbursements attributable to state supplemental payment programs, net of expenses $ 136,060 $ 143,773 $ 135,767 The California Department of Health Care Services implemented the HQAF Program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California’s Medi-Cal and uninsured patients. Under Phase IV of the program, covering the period from January 2014 through December 2016, and Phase V of the program, covering the period from January 2017 through June 2019, the Company recognized $22.0 million, $34.4 million and $31.5 million of operating revenues, net of provider taxes, for the years ended December 31, 2017, 2016 and 2015, respectively. Charity Care In the ordinary course of business, the Company provides services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the poverty level guidelines established by the federal government. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at the standard billing rates and fully offset in contractual allowances. The Company’s gross amounts of charity care revenues were $34.0 million, $34.6 million and $30.4 million for the years ended December 31, 2017, 2016 and 2015, respectively. The Company estimates the cost of providing charity care services utilizing a ratio of cost to gross charges and applying this ratio to the gross charges associated with providing care to charity patients for the period. The estimated costs of providing charity care services was $5.6 million, $5.7 million and $5.0 million for the years ended December 31, 2017, 2106 and 2015, respectively. To the extent the Company receives reimbursement from any of the various governmental assistance programs to subsidize its care of indigent patients, the Company excludes the charges for such patients from the cost of care provided under its charity care program. Accounts Receivable and Allowance for Doubtful Accounts Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated outpatient facilities. The following table provides a summary of the components of patient accounts receivable before contractual allowances, discounts and allowance for doubtful accounts (dollars in thousands): December 31, 2017 2016 $ Amount % of Total $ Amount % of Total Third-parties $ 1,796,852 75.1 % $ 1,930,103 74.6 % Self-pay 596,863 24.9 % 656,373 25.4 % Total patient accounts receivable, gross $ 2,393,715 100.0 % $ 2,586,476 100.0 % Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Receivables from third-parties include the non-self-pay receivables due to the Company from providers of governmental and non-governmental programs and plans. For insured receivables, the Company estimates the allowance for doubtful accounts based on a model that considers the uncontractualized portion of all accounts aging over 365 days from the date of patient discharge, reduced by an estimate of recoveries. For self-pay receivables, the Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category. The allowance percentage is based on a model that considers historical write-off activity and is adjusted for expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the allowance for doubtful accounts is not significantly impacted by the aging of accounts receivable, as management believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. Collections are impacted by the economic ability of patients to pay, the effectiveness of CHS’ billing and collection efforts, including their current policies on collections, and the ability of the Company to further attempt collection efforts. Billings and collections are outsourced to CHS under the transition services agreements that were established with the Spin-off. See Note 18 — Related Party Transactions for additional information on these agreements. Significant changes in payor mix, CHS’s business office operations, including the CHS shared services centers’ efforts in collecting the Company’s accounts receivables, economic conditions, or trends in federal and state governmental healthcare coverage, among others, could affect the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall allowance adequacy by monitoring historical cash collections as a percentage of trailing net operating revenues after the provision for bad debts, as well as by analyzing current period net operating revenues and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, and the impact of recent divestitures. The following table provides a summary of the changes in the allowance for doubtful accounts (in thousands): December 31, 2017 2016 2015 Balance at beginning of period $ 360,796 $ 346,507 $ 341,527 Provision for bad debts 255,485 280,586 258,520 Amounts written off, net of recoveries (263,772 ) (266,297 ) (253,540 ) Balance at end of period $ 352,509 $ 360,796 $ 346,507 During the fourth quarter of 2017, the Company analyzed self-pay patient accounts receivable at a more comprehensive and disaggregated level and refined its estimate of the collectability of the portion of self-pay accounts receivable related to insured patients, primarily co-payments and deductibles. The Company’s analysis also included an evaluation of patient accounts receivable retained in the divestitures of six of the Company’s seven divested hospitals. As a result of these efforts, the Company recorded a change in estimate of $21.0 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the consolidated and combined statement of income for the year ended December 31, 2017. As of December 31, 2016, the Company recorded a change in estimate of $11.4 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the consolidated and combined statement of income for the year ended December 31, 2016. This change in estimate related to the Company’s assessment of the collectability of managed care and commercial accounts receivable aged greater than one year based on the Company’s review of historical cash collections for these accounts. Concentration of Credit Risk The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s hospitals and affiliated facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s markets and non-governmental third-party payors, Medicare receivables are a significant concentration of credit risk. Accounts receivable, net of contractual allowances, from Medicare were $70.4 million and $72.6 million, or 10.0% and 9.8% of total patient accounts receivable, net as of December 31, 2017 and 2016, respectively. Additionally, the Company believes Illinois Medicaid represents a concentration of credit risk to the Company due to the fiscal problems in the state of Illinois that affect the timing and extent of payments due to providers which are administered by the state of Illinois under the Medicaid program. The Company’s accounts receivable, net of contractual allowances, from Illinois Medicaid were $29.6 million and $34.8 million, or 4.2% and 4.7% of total patient accounts receivable, net as of December 31, 2017 and 2016, respectively. The Company’s state supplemental program receivables from Illinois Medicaid were $22.9 million and $16.6 million, or 23.5% and 14.3% of total due from third-party payors, as of December 31, 2017 and 2016, respectively. The Company’s state supplemental program receivables from California Medicaid were $48.4 million and $66.2 million, or 49.8% and 57.0% of total due from third-party payors, as of December 31, 2017 and 2016, respectively. The Company’s revenues are particularly sensitive to regulatory and economic changes in certain states where the Company generates significant revenues. Accordingly, any changes in the current demographic, economic, competitive or regulatory conditions in certain states in which revenues are significant could have an adverse effect on the Company’s results of operations, financial condition or cash flows. Changes to the Medicaid and other government-managed payor programs in these states, including reductions in reimbursement rates or delays in reimbursement payments under state supplemental payment or other programs, could also have a similar adverse effect. The following table provides a summary of the states in which the Company generates more than 5% of total net patient revenues, before the provision for bad debts, as determined in each year (dollars in thousands): Number of Year Ended December 31, Hospitals at 2017 2016 2015 December 31, 2017 $ Amount % of Total $ Amount % of Total $ Amount % of Total Illinois 9 $ 829,473 37.2 % $ 811,565 35.1 % $ 822,501 35.3 % Oregon 1 218,653 9.8 % 210,818 9.1 % 201,610 8.6 % California 2 195,725 8.8 % 199,743 8.6 % 209,500 9.0 % Georgia 2 148,353 6.7 % 216,745 9.4 % 224,330 9.6 % Kentucky 3 124,317 5.6 % 121,988 5.3 % 131,077 5.6 % Other Operating Expenses The following table provides a summary of the major components of other operating expenses (in thousands): Year Ended December 31, 2017 2016 2015 Purchased services $ 168,711 $ 180,672 $ 176,758 Taxes and insurance 131,734 129,775 124,635 Medical specialist fees 111,840 106,803 85,042 Transition services agreements and allocations from Parent 63,470 66,441 60,166 Repairs and maintenance 41,048 42,986 45,945 Utilities 27,324 29,833 29,856 Management fees from Parent — 11,792 36,466 Other miscellaneous operating expenses 78,936 77,500 75,365 Total other operating expenses $ 623,063 $ 645,802 $ 634,233 Following the Spin-off, the Company began recording costs associated with the transition services agreements and other ancillary agreements with CHS in accordance with the terms of these agreements. These costs, which primarily include the costs of providing information technology, patient billing and collections and payroll services, are included in “Transition services agreements and allocations from Parent” in the table above. Amounts allocated to the Company by CHS for periods prior to the Spin-off are also included in “Transition services agreements and allocations from Parent” in the table above. Prior to the Spin-off, QHC recorded a monthly corporate management fee from CHS that represented a portion of CHS’ corporate office costs, and this fee was included in other operating expenses. Following the Spin-off, the costs for corporate office functions are primarily included in salaries and benefits expenses in the consolidated and combined statements of income. See Note 18 — Related Party Transactions for additional information on the allocated costs from CHS. General and Administrative Costs Substantially all of the Company’s operating costs and expenses are “cost of revenues” items. Operating expenses that could be classified as general and administrative by the Company are costs related to corporate office functions, including, but not limited to tax, treasury, audit, risk management, legal, investor relations and human resources. These costs are primarily salaries and benefits expenses associated with these corporate office functions. General and administrative costs of the Company were $52.7 million, $55.2 million and $43.5 million during the years ended December 31, 2017, 2016 and 2015, respectively. Prior to the Spin-off, the majority of these costs were allocations from CHS. See Note 18 — Related Party Transactions for additional information on the allocated costs from CHS. Electronic Health Records Incentives Earned Pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”) and other laws, HHS has established Medicare and Medicaid incentive programs to encourage adoption of Electronic Health Records (“EHR”) technology. The Company is eligible to receive incentive payments under these programs for its eligible hospitals and physician clinics that demonstrate meaningful use of certified EHR technology. EHR incentive payments paid to the Company are subject to audit and potential recoupment if it is determined that the applicable meaningful use standards were not met. EHR incentive payments are also subject to retrospective adjustment because the cost report data upon which the incentive payments are based are further subject to audit. The Company utilizes a gain contingency model to recognize EHR incentive payments. When the recognition criteria have been fully met, the Company recognizes the income from EHR incentives payments as a part of operating costs and expenses in the consolidated and combined statements of income. Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals demonstrate meaningful use of certified EHR technology. Medicare EHR incentive payments are calculated when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year used to determine the final incentive payment is available. In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the income from EHR incentive payments is deferred until all recognition criteria are met. The Company recognizes r eceivables for EHR incentive payments that have been earned, but are uncollected at period end, as other current assets in the consolidated balance sheets. The receivables are adjusted for any known audit or retrospective adjustments related to prior periods. Deferred revenue from EHR incentive payments is recorded in other current liabilities in the consolidated balance sheets. The Company incurs both capital expenditures and operating expenses in connection with the implementation of EHR technology initiatives. The amounts and timing of these expenditures does not directly correlate with the timing of the Company’s receipt or recognition of EHR incentive payments as earned. As the Company completes its full implementation of certified EHR technology in accordance with all three phases of the program, its EHR incentive payments will decline and ultimately end. The following table provides a summary of activity related to EHR incentives (in thousands): Year Ended December 31, 2017 2016 2015 Electronic health records incentives receivable at beginning of period $ 4,189 $ 11,227 $ 12,204 Electronic health records incentives earned 4,489 7,843 11,428 Cash incentive payments received (5,796 ) (13,808 ) (10,084 ) Adjustments to receivable based on final cost report settlement or audit (1,103 ) (1,073 ) (2,321 ) Electronic health records incentives receivable at end of period $ 1,779 $ 4,189 $ 11,227 Deferred revenue related to electronic health records incentives at beginning of period $ — $ — $ (14,351 ) Cash received and deferred during period (256 ) (3,639 ) — Recognition of deferred incentives as earned 256 3,639 14,351 Deferred revenue related to electronic health records incentives at end of period $ — $ — $ — Total electronic health records incentives earned during period $ 4,745 $ 11,482 $ 25,779 Total cash incentive payments received during period 6,052 17,447 10,084 Legal, Professional and Settlement Costs Legal, professional and settlement costs in the consolidated and combined statements of income primarily include legal costs and related settlements, if any, associated with regulatory claims, government investigations into reimbursement payments, claims associated with QHR’s hospital management contracts and professional costs of projects approved by the Company’s Board of Directors (the “Board”). Loss (Gain) on Sale of Hospitals, Net Loss (gain) on sale of hospitals, net is the loss (gain) incurred by the Company’s divestiture of hospitals and their related outpatient facilities. It is calculated as the difference between the cash proceeds from the sale and the carrying values of the associated net assets sold at the date of sale, less certain incremental direct selling costs. Transaction Costs Related to the Spin-off Transaction costs related to the Spin-off consists of QHC’s portion of the costs to effect the Spin-off and the costs associated with forming a new company. These costs include audit, management advisory and consulting costs, investment advisory costs, legal expenses and other miscellaneous costs. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the provision for (benefit from) income taxes in the consolidated and combined statements of income in the period that includes the enactment date. The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income. To the extent the Company believes that recovery is not likely, a valuation allowance is established. To the extent the Company establishes a valuation allowance or increases this allowance, the related expense is included in the provision for (benefit from) income taxes in the consolidated and combined statements of income. The Company classifies interest and penalties, if any, related to its tax positions as a component of provision for (benefit from) income taxes. See Note 12 — Income Taxes for information on

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets and Goodwill	12 Months Ended
	Dec. 31, 2017
Disclosure Text Block Supplement [Abstract]
Impairment of Long-Lived Assets and Goodwill	NOTE 3 — IMPAIRMENT OF LONG-LIVED ASSETS AND GOODWILL 2017 Impairment During the three months ended December 31, 2017, the Company evaluated the fair value of hospitals classified as held for sale and evaluated other hospitals intended for potential divestiture. In connection with this evaluation, the Company recognized long-lived asset impairment of $25.8 million during the three months ended December 31, 2017, which consisted of $23.7 million of property and equipment and $2.1 million of intangible assets impairment During the three months ended September 30, 2017, the Company evaluated the fair value of hospitals classified as held for sale and evaluated other hospitals intended for potential divestiture. In connection with this evaluation, the Company recognized long-lived asset and goodwill impairment of $5.3 million during the three months ended September 30, 2017, which consisted of $3.7 million of property and equipment, $1.0 million of intangible assets and $0.6 million of goodwill impairment. During the three months ended June 30, 2017, the Company evaluated the fair value of hospitals classified as held for sale and evaluated other hospitals intended for potential divestiture. In connection with this evaluation, the Company recognized $12.9 million of impairment to property and equipment during the three months ended June 30, 2017. During the three months ended March 31, 2017, management made a decision to classify certain additional hospitals as held for sale. In connection with this decision, the Company evaluated the estimated relative fair value of the hospitals classified as held for sale in relation to the overall fair value of the hospital operations reporting unit utilizing a September 30, 2016 measurement date, which was the measurement date of the Company’s most recent annual goodwill impairment analysis. As a result, the Company recognized long-lived asset and goodwill impairment of $3.3 million during the three months ended March 31, 2017, which consisted of $1.1 million of property and equipment, $0.8 million of intangible assets and $1.4 million of goodwill impairment. 2016 Impairment During the second quarter of 2016, management made a decision to classify certain hospitals as held for sale and evaluate other hospitals for potential divestiture. Due to the increase in net operating losses associated with these hospitals, the Company analyzed the long-lived assets of all of its hospitals to test for impairment and recorded $45.4 million of long-lived asset impairment in this quarter. In addition, the Company evaluated the estimated relative fair value of the hospitals classified as held for sale in relation to the overall fair value of the hospital operations reporting unit utilizing a September 30, 2015 measurement date, which was the measurement date of the Company’s most recent annual goodwill impairment analysis, and recognized $5.0 million of goodwill impairment in this quarter. In this same quarter, management identified certain indicators of goodwill impairment related to the hospital operations reporting unit and concluded that such indicators necessitated an interim goodwill impairment evaluation. The primary indicators were declining market capitalization, as compared to the carrying value of equity, and a decrease in estimated future earnings of the hospital operations reporting unit. The Company performed a calculation of the overall fair value of this reporting unit in step one of the impairment test and concluded that the carrying value of its hospital operations reporting unit as of June 30, 2016 exceeded the estimated fair value. The Company performed a preliminary step two calculation of goodwill impairment to determine the implied fair value of goodwill of the hospital operations reporting unit in a hypothetical purchase price allocation. Based on this preliminary analysis, the Company estimated and recorded additional goodwill impairment of $200 million in the second quarter of 2016. For step two goodwill impairment testing, the Company engaged a professional valuation firm to perform a hypothetical purchase price valuation of each of its hospitals utilizing a September 30, 2016 measurement date. The results of the third-party valuation, which was completed in the fourth quarter of 2016, indicated that the carrying values of certain of the Company’s individual hospitals exceeded their fair values. Considering these results to be an indicator of potential impairment and to assess whether any additional impairment of long-lived assets existed, the Company utilized a September 30, 2016 measurement date to perform an analysis of undiscounted cash flows for each hospital in which an indicator of impairment was identified. Based on the results of these analyses, the Company recorded impairment of $82.7 million related to long-lived assets at certain hospitals and a downward adjustment to its previously recorded goodwill impairment estimate of $80 million in the fourth quarter of 2016. The net impact to the Company’s consolidated and combined financial statements was $2.7 million of additional impairment in the fourth quarter of 2016 beyond the initial estimate of $200 million estimate recorded as the preliminary step-two calculation in the second quarter of 2016. In addition to the above, the Company experienced a decline in operating results at several hospitals in the fourth quarter of 2016. This led management to perform additional testing for impairment using a December 31, 2016 measurement date. As a result of this analysis, the Company recorded additional impairment of $38.8 million related to long-lived assets in the fourth quarter of 2016. The carrying values of long-lived assets, including those classified as held for sale, are reported net of impairment in the consolidated balance sheet as of December 31, 2016. 2015 Impairment During the year ended December 31, 2015, the Company recorded impairment of $13.0 million to reduce the carrying values of certain long-lived assets at seven of its hospitals to their estimated fair values. The impairment for 2015 was identified because of declining operating results and projections of future cash flows at these hospitals, which were caused by competitive and operational challenges specific to the markets in which these hospitals operate.

Acquisitions and Divestitures

Acquisitions and Divestitures	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisitions and Divestitures	NOTE 4 —ACQUISITIONS AND DIVESTITURES Acquisitions During the years ended December 31, 2017, 2016 and 2015, the Company acquired operating assets and the related businesses of certain physician practices, clinics and other ancillary businesses that operate within communities served by the Company’s hospitals. Prior to the Spin-off, the Company was allocated the consideration paid for these facilities through Due to Parent, net. The following table provides a summary of the combined purchase price allocation by year for the Company’s acquisitions (in thousands): Year Ended December 31, 2017 2016 2015 Current assets $ 142 $ (343 ) $ 422 Property and equipment 695 851 3,190 Goodwill 1,211 129 6,788 Other long-term assets — — 564 Liabilities (128 ) 16 (1,229 ) Noncontrolling interests — 132 (1,716 ) Total consideration paid or allocated from CHS $ 1,920 $ 785 $ 8,019 The table above includes adjustments to estimated amounts recognized, if any, that were recorded by the Company within the measurement period from the date of the respective acquisition. In some cases, the adjustments may be negative. Divestitures Vista Medical Center West On March 1, 2018, the Company sold 70-bed Vista Medical Center West and its affiliated facilities (“Vista West”), located Waukegan, Illinois, for proceeds of $1.2 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax gains (losses) of $(2.3) million, $4.9 million, and $5.7 million, respectively, related to Vista West. In addition, the Company recorded impairment to property, equipment and capitalized software costs of $11.1 million and $4.1 million related to Vista West during the years ended December 31, 2017 and 2016, respectively. L.V. Stabler Memorial Hospital On October 31, 2017, the Company sold 72-bed L.V. Stabler Memorial Hospital and its affiliated facilities (“L.V. Stabler”) located in Greenville, Alabama for $2.8 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax losses of $5.3 million, $4.0 million, and $0.7 million, respectively, related to L.V. Stabler. In addition to the above, the Company recorded a loss on sale of less than $0.1 million in the year ended December 31, 2017. The Company also recorded impairment to property, equipment and capitalized software costs of $2.5 million and $2.9 million related to L.V. Stabler in the years ended December 31, 2017 and 2016, respectively. Sunbury Community Hospital and Lock Haven Hospital On September 30, 2017, the Company sold 70-bed Sunbury Community Hospital and its affiliated facilities (“Sunbury”), located in Sunbury, Pennsylvania, and 47-bed Lock Haven Hospital and its affiliated facilities (“Lock Haven”), located in Lock Haven, Pennsylvania, for combined proceeds of $9.1 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax losses of $8.8 million, $9.4 million, and $8.7 million, respectively, related to Sunbury and Lock Haven on a combined basis. In addition to the above, the Company recorded a $0.1 million loss on the sale in the year ended December 31, 2017. The Company also recorded impairment to property, equipment and capitalized software costs of $1.9 million, $12.7 million and $3.0 million of impairment to property, equipment and capitalized software costs related to Sunbury and Lock Haven during the years ended December 31, 2017, 2016 and 2015, respectively. The Company also recorded impairment to property and equipment of $3.0 million and $6.0 million for the years ended December 31, 2013 and 2012, respectively. Trinity Hospital of Augusta On June 30, 2017, the Company sold 231-bed Trinity Hospital of Augusta and its affiliated facilities (“Trinity”), located in Augusta, Georgia, for $15.9 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax losses of $9.7 million, $9.5 million and $2.8 million, respectively, related to Trinity. In addition to the above, the Company recorded a $5.3 million gain on the sale in the year ended December 31, 2017. The Company also recorded impairment to property, equipment and capitalized software costs of $33.9 million related to Trinity during the year ended December 31, 2016. As part of the sale of Trinity, the Company redeemed shares valued at $3.5 million from minority interest partners, which included cash distributions of $1.2 million related to the dissolution of the partnership. Cherokee Medical Center On March 31, 2017, the Company sold 60-bed Cherokee Medical Center and its affiliated facilities (“Cherokee”), located in Centre, Alabama, for $4.3 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax losses of $1.0 million, $3.7 million and $1.6 million, respectively, related to Cherokee. In addition to the above, the Company recorded a $0.2 million gain on the sale in the year ended December 31, 2017. The Company also recorded impairment to property, equipment and capitalized software costs of $3.9 million and $2.0 million of Cherokee during the years ended December 31, 2016 and 2015, respectively. The Company also recorded impairment to property and equipment of $1.0 million for the year ended December 31, 2012. Barrow Regional Medical Center On December 31, 2016, the Company sold 56-bed Barrow Regional Medical Center and its affiliated facilities (“Barrow”), located in Winder, Georgia, for $6.6 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax losses of $2.4 million, $14.5 million and $6.2 million, respectively, related to Barrow. In addition to the above, the Company recorded a $1.2 million net loss on the sale in the year ended December 31, 2016. The Company also recorded impairment to property, equipment and capitalized software costs of $4.0 million related to Barrow during the year ended December 31, 2016. Sandhills Regional Medical Center On December 1, 2016, the Company sold 64-bed Sandhills Regional Medical Center and its affiliated facilities (“Sandhills”), located in Hamlet, North Carolina, for $7.2 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax losses of $0.2 million, $6.9 million and $2.0 million, respectively, related to Sandhills. In addition to the above, the Company recorded a $1.0 million net loss on the sale in the year ended December 31, 2016. The Company also recorded impairment to property, equipment and capitalized software costs of $4.8 million related to Sandhills during the year ended December 31, 2016.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	NOTE 5 — PROPERTY AND EQUIPMENT The following table provides a summary of the components of property and equipment (in thousands): December 31, 2017 2016 Property and equipment, at cost: Land and improvements $ 70,731 $ 84,474 Building and improvements 790,619 782,892 Equipment and fixtures 529,150 592,463 Construction in progress 14,684 60,146 Total property and equipment, at cost 1,405,184 1,519,975 Less: Accumulated depreciation and amortization (729,905 ) (786,075 ) Total property and equipment, net $ 675,279 $ 733,900 Depreciation expense was $58.6 million, $83.0 million and $90.9 million for the years ended December 31, 2017, 2016 and 2015, respectively. See Note 6 — Goodwill and Intangible Assets for information on amortization expense recorded for property and equipment held under capital lease obligations. The total amount of assets held under capital lease obligations, at cost, was $29.2 million and $30.2 million at December 31, 2017 and 2016, respectively, and $25.6 million and $27.5 million, net of accumulated amortization, at December 31, 2017 and 2016, respectively. Purchases of property and equipment accrued in accounts payable were $6.8 million and $15.7 million as of December 31, 2017 and 2016, respectively. See Note 3 — Impairment of Long-Lived Assets and Goodwill for information on impairment related to property and equipment recorded in the consolidated and combined statements of income for the years ended December 31, 2017, 2016 and 2015.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 6— GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a summary of the changes in goodwill (in thousands): December 31, 2017 2016 Balance at beginning of period $ 416,833 $ 541,704 Acquisitions 1,211 129 Divestitures (5,293 ) — Reclass to held for sale (1,593 ) — Impairment (1,929 ) (125,000 ) Balance at end of period $ 409,229 $ 416,833 Goodwill related to the hospital operations reporting unit was $375.9 million and $383.5 million as of December 31, 2017 and December 31, 2016, respectively. Goodwill related to the management advisory and consulting services reporting unit was $33.3 million at both December 31, 2017 and December 31, 2016. Goodwill related to divestitures was associated with the sale of Trinity and Sunbury. See Note 4 — See Note 3 — Impairment of Long-Lived Assets and Goodwill for additional information on impairment to goodwill recorded by the Company in 2017, 2016 and 2015. Intangible Assets The following table provides a summary of the components of intangible assets (in thousands): December 31, 2017 2016 Finite-lived intangible assets: Capitalized software costs: Cost $ 159,449 $ 180,855 Accumulated amortization (111,661 ) (118,391 ) Capitalized software costs, net 47,788 62,464 Physician guarantee contracts: Cost 7,489 11,355 Accumulated amortization (4,290 ) (6,329 ) Physician guarantee contracts, net 3,199 5,026 Other finite-lived intangible assets: Cost 43,376 44,342 Accumulated amortization (34,668 ) (33,059 ) Other finite-lived intangible assets, net 8,708 11,283 Total finite-lived intangible assets Cost 210,314 236,552 Accumulated amortization (150,618 ) (157,779 ) Total finite-lived intangible assets, net $ 59,696 $ 78,773 Indefinite-lived intangible assets: Tradenames $ 4,000 $ 4,000 Medical licenses and other indefinite-lived intangible assets 1,154 2,209 Total indefinite-lived intangible assets $ 5,154 $ 6,209 Total intangible assets: Cost $ 215,468 $ 242,761 Accumulated amortization (150,618 ) (157,779 ) Total intangible assets, net $ 64,850 $ 84,982 During the years ended December 31, 2017 and 2016, the Company recorded $3.4 million and $18.9 million, respectively, of impairment related to capitalized software costs. See Note 3 — Impairment of Long-Lived Assets and Goodwill for additional information on these impairment charges. As of December 31, 2017, the Company had $0.7 million of capitalized software costs that are currently in the development stage. Amortization of these costs will begin once the software projects are complete and ready for their intended use. Amortization Expense The following table provides a summary of the components of amortization expense (in thousands): Year Ended December 31, 2017 2016 2015 Amortization of finite-lived intangible assets: Capitalized software costs $ 15,879 $ 25,193 $ 27,317 Physician guarantee contracts 2,032 3,108 3,951 Other finite-lived intangible assets 2,594 2,866 3,334 Total amortization expense related to finite-lived intangible assets 20,505 31,167 34,602 Amortization of leasehold improvements and property and equipment assets held under capital lease obligations 3,038 3,111 2,496 Total amortization expense $ 23,543 $ 34,278 $ 37,098 As of December 31, 2017, the weighted-average remaining amortization period of the Company’s intangible assets subject to amortization, except for capitalized software costs and physician guarantee contracts, was approximately 4.6 years. The following table provides a summary of estimated future amortization expense for the next five years and thereafter related to intangible assets (in thousands): 2018 $ 18,898 2019 14,475 2020 11,791 2021 9,378 2022 3,900 Thereafter 1,254 Total estimated future amortization expense $ 59,696

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt	NOTE 7 — LONG-TERM DEBT The following table provides a summary of the components of long-term debt (in thousands): December 31, 2017 2016 Senior Credit Facility: Revolving Credit Facility, maturing 2021 $ — $ — Term Loan Facility, maturing 2022 831,158 868,419 ABL Credit Facility, maturing 2021 — — Senior Notes, maturing 2023 400,000 400,000 Unamortized debt issuance costs and discounts (42,934 ) (48,764 ) Capital lease obligations 24,411 25,588 Other miscellaneous debt 1,255 1,582 Total debt 1,213,890 1,246,825 Less: Current maturities of long-term debt (1,855 ) (5,683 ) Total long-term debt $ 1,212,035 $ 1,241,142 In connection with the Spin-off, the Company entered into two credit agreements and issued senior notes. In addition, the previous indebtedness with CHS, which was classified in the consolidated balance sheets as Due to Parent, net was fully settled in the Spin-off. See Note 1 — Description of the Business and Spin-off and Note 18 — Related Party Transactions for additional information on the use of proceeds from the new debt instruments and the settlement of Due to Parent, net. Senior Credit Facility On April 29, 2016, the Company entered into a credit agreement (the “CS Agreement”), among the Company, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch (“Credit Suisse”), as administrative agent and collateral agent. On April 11, 2017, the Company executed an agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Amendment”), as described below. On March 14, 2018, the Company executed a second agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Second Amendment”), as described below. The CS Agreement provides for an $880 million senior secured term loan facility (the “Term Loan Facility”) and a $100 million senior secured revolving credit facility (the “Revolving Credit Facility” and, together with the Term Loan Facility, the “Senior Credit Facility”). The Term Loan Facility was issued at a discount of $17.6 million, or 98% of par value, and has a maturity date of April 29, 2022, subject to customary acceleration events and repayment, extension or refinancing. The Revolving Credit Facility has a maturity date of April 29, 2021, subject to certain customary acceleration events and repayment, extension or refinancing. The CS Amendment reduced the Revolving Credit Facility’s capacity from $100 million to $87.5 million until December 31, 2017, at which time the capacity decreased to $75.0 million through maturity. The CS Second Amendment reduced the Revolving Credit Facility’s capacity to $62.5 million through maturity, effective with the amendment executed on March 14, 2018. The CS Agreement contains customary covenants, including a maximum permitted Secured Net Leverage Ratio, as determined based on 12 month trailing Consolidated EBITDA, as defined in the CS Agreement. On April 11, 2017, the Company executed the CS Amendment with its Senior Credit Facility lenders to amend the calculation of the Secured Net Leverage Ratio beginning July 1, 2017 through maturity, among other provisions. In addition, the CS Amendment raised the minimum Secured Net Leverage Ratio required for the Company to remain in compliance for certain periods, and also changed the calculation of compliance for specified periods. The CS Second Amendment, which was executed on March 14, 2018, amended the Secured Net Leverage Ratio for the period July 1, 2017 through maturity. As of December 31, 2017 and 2016, the Company had a Secured Net Leverage Ratio of 3.87 to 1.00 and 3.93 to 1.00, respectively, implying additional borrowing capacity of $193.3 million as of December 31, 2017. After giving effect to the CS Amendment and the CS Second Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA, which is defined in the CS Agreement, follows: Maximum Secured Net Period Leverage Ratio Period from January 1, 2017 to June 30, 2017 4.50 to 1.00 Period from July 1, 2017 to June 30, 2018 4.75 to 1.00 Period from July 1, 2018 to December 31, 2019 5.00 to 1.00 Period from January 1, 2020 and thereafter 4.50 to 1.00 In addition to amending the calculation of the Secured Net Leverage Ratio and the Maximum Secured Net Leverage Ratio, the CS Amendment and the CS Second Amendment also affected other terms of the CS Agreement as follows: • Through April 29, 2022, the Company is required to use asset sales proceeds to make mandatory redemptions under the Term Loan Facility. • Through December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments for the greater of $100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00. • Through December 31, 2018, the Company is allowed to incur Permitted Additional Debt, as defined in the CS Agreement, only if the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, the Company may incur Permitted Additional Debt so long as the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00. Prior to the CS Amendment, interest under the Term Loan Facility accrued, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 5.75%, or the alternate base rate plus 4.75%. Following the CS Amendment, interest under the Term Loan Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 6.75%, or the alternate base rate plus 5.75%. The effective interest rate on the Term Loan Facility was 8.77% as of December 31, 2017. Interest on outstanding borrowings under the Revolving Credit Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 0% plus 2.75%, or the alternate base rate plus 1.75%, and remains unchanged under the CS Amendment. The CS Second Amendment did not alter these provisions. Borrowings from the Revolving Credit Facility are used for working capital and general corporate purposes. As of December 31, 2017, the Company had no borrowings outstanding on the Revolving Credit Facility and had $10.2 million of letters of credit outstanding that were primarily related to the self-insured retention levels of professional and general liability and workers’ compensation liability insurance as security for the payment of claims. As of December 31, 2017, the Company had borrowing capacity under its Revolving Credit Facility of $77.3 million. ABL Credit Facility On April 29, 2016, the Company entered into an ABL Credit Agreement (the “UBS Agreement,” and together with the CS Agreement, collectively, the “Credit Agreements”), among the Company, the lenders party thereto and UBS AG, Stamford Branch (“UBS”), as administrative agent and collateral agent. The UBS Agreement provides for a $125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”). The available borrowings from the ABL Credit Facility, which are based on eligible patient accounts receivable, are used for working capital and general corporate purposes. As of December 31, 2017, the Company had no borrowings outstanding on the ABL Credit Facility and borrowing capacity of $124 million. On April 11, 2017, the Company executed an amendment to the UBS Agreement with its lender party thereto, which aligned the provisions of the UBS Agreement with the CS Agreement. There were no changes to the UBS Agreement that impact the Company’s current interest or covenant calculations associated with the ABL Credit Facility. The ABL Credit Facility has a maturity date of April 29, 2021, subject to customary acceleration events and repayment, extension or refinancing. Interest on outstanding borrowings under the ABL Credit Facility accrues, at the option of the Company, at a base rate or LIBOR, subject to statutory reserves The ABL Credit Facility has a “Covenant Trigger Event” definition that requires the Company to maintain excess availability under the ABL Credit Facility equal to or greater than the greater of (i) $12.5 million and (ii) 10% of the aggregate commitments under the ABL Credit Facility. If a Covenant Trigger Event occurs, then the Company is required to maintain a minimum Consolidated Fixed Charge Ratio of 1.10 to 1.00 until such time that a Covenant Trigger Event is no longer continuing. In addition, if excess availability under the ABL Credit Facility were to fall below the greater of (i) 12.5% of the aggregate commitments under the ABL Credit Facility and (ii) $15.0 million, then a “Cash Dominion Event” would be triggered upon which the lenders could assume control of the Company’s cash. Credit Agreement Covenants In addition to the specific covenants described above, the Credit Agreements contain customary negative covenants which limit the Company’s ability to, among other things, incur additional indebtedness, create liens, make investments, transfer assets, merge or acquire assets, and make restricted payments, including dividends, distributions and specified payments on other indebtedness. They include customary events of default, including payment defaults, material breaches of representations and warranties, covenant defaults, default on other material indebtedness, customary Employee Retirement Income Security Act (“ERISA”) Senior Notes On April 22, 2016, QHC issued $400 million aggregate principal amount of 11.625% Senior Notes due 2023, pursuant to the Indenture. The Senior Notes were issued at a discount of $6.9 million, or 1.734%, in a private placement and are senior unsecured obligations of the Company guaranteed on a senior basis by certain of the Company’s subsidiaries (the “Guarantors”). The Senior Notes mature on April 15, 2023 and bear interest at a rate of 11.625% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2016. Interest on the Senior Notes accrues from the date of original issuance and is calculated on the basis of a 360-day year comprised of twelve 30-day months. The effective interest rate on the Senior Notes was 12.49% as of December 31, 2017. The Indenture contains covenants that, among other things, limit the ability of the Company and certain of its subsidiaries to incur or guarantee additional indebtedness, pay dividends or make other restricted payments, make certain investments, create or incur certain liens, sell assets and subsidiary stock, transfer all or substantially all of its assets or enter into merger or consolidation transactions. On May 17, 2017, the Company exchanged the 11.625% Senior Notes due 2023 (the “Initial Notes”) in the aggregate principal amount of $400 million, which were not registered under the Securities Act of 1933, as amended (the “Securities Act”), for a like principal amount of 11.625% Senior Notes due 2023 (the “Exchange Notes”), which have been registered under the Securities Act. The Initial Notes were substantially identical to the Exchange Notes, except that the Exchange Notes are registered under the Securities Act and are not subject to the transfer restrictions and certain registration rights agreement provisions applicable to the Initial Notes. On and after April 15, 2019, the Company is entitled, at its option, to redeem all or a portion of the Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices specified in the table below, plus accrued and unpaid interest, if any, to the redemption date. The redemption prices are expressed as a percentage of the principal amount on the redemption date. Holders of record on the relevant record date have the right to receive interest due on the relevant interest payment date. In addition, prior to April 15, 2019, the Company may redeem some or all of the Senior Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, plus a “make whole” premium, as set forth in the Indenture. The Company is entitled to redeem up to 35% of the aggregate principal amount of the Senior Notes until April 15, 2019 with the net proceeds from certain equity offerings at the redemption price set forth in the Indenture. The following table provides a summary of the redemption periods and prices related to the Senior Notes: Redemption Period Prices Period from April 15, 2019 to April 14, 2020 108.719 % Period from April 15, 2020 to April 14, 2021 105.813 % Period from April 15, 2021 to April 14, 2022 102.906 % Period from April 15, 2022 to April 14, 2023 100.000 % Debt Issuance Costs and Discounts The following table provides a summary of unamortized debt issuance costs and discounts (in thousands): December 31, 2017 2016 Debt issuance costs $ 32,265 $ 29,146 Debt discounts 24,536 24,536 Total debt issuance costs and discounts at origination 56,801 53,682 Less: Amortization of debt issuance costs and discounts (13,867 ) (4,918 ) Total unamortized debt issuance costs and discounts $ 42,934 $ 48,764 Capital Lease Obligations and Other Debt The Company’s debt arising from capital lease obligations primarily relates to its corporate office in Brentwood, Tennessee. As of December 31, 2017 and 2016, this capital lease obligation was $17.9 million and $18.7 million, respectively. The remainder of the Company’s capital lease obligations relate to property and equipment at its hospitals and corporate office. Other debt consists of physician loans and miscellaneous notes payable to banks. Debt Maturities The following table provides a summary of debt maturities for each of the next five years and thereafter (in thousands): 2018 $ 1,855 2019 1,486 2020 1,517 2021 3,329 2022 830,796 Thereafter 417,841 Total debt, excluding unamortized debt issuance costs and discounts $ 1,256,824 Interest Expense, Net The following table provides a summary of the components of interest expense, net (in thousands): Year Ended December 31, 2017 2016 2015 Senior Credit Facility: Revolving Credit Facility $ 528 $ 330 $ — Term Loan Facility 66,111 40,719 — ABL Credit Facility 1,854 342 — Senior Notes 46,516 32,166 — Amortization of debt issuance costs and discounts 8,949 4,918 — All other interest expense (income), net (1,881 ) (849 ) 283 Total interest expense, net, from long-term debt 122,077 77,626 283 Due to Parent, net — 35,814 98,007 Total interest expense, net $ 122,077 $ 113,440 $ 98,290

Other Long-Term Assets and Othe

Other Long-Term Assets and Other Long-Term Liabilities	12 Months Ended
	Dec. 31, 2017
Other Noncurrent Assets And Other Noncurrent Liabilities Disclosure [Abstract]
Other Long-Term Assets and Other Long-Term Liabilities	NOTE 8 — OTHER LONG-TERM ASSETS AND OTHER LONG-TERM LIABILITIES The following table provides a summary of the major components of other long-term assets (in thousands): December 31, 2017 2016 Receivable for professional and general liability insurance reserves indemnified by CHS $ 44,377 $ 59,652 Receivable for workers' compensation liability insurance reserves indemnified by CHS 14,545 15,958 Assets of Nonqualified Deferred Compensation Plan 23,052 69 Other miscellaneous long-term assets 13,633 13,154 Total other long-term assets $ 95,607 $ 88,833 The following table provides a summary of the components of other long-term liabilities (in thousands): December 31, 2017 2016 Professional and general liability insurance reserves $ 76,993 $ 74,194 Workers' compensation liability insurance reserves 18,558 17,416 Benefit plan liabilities 36,103 10,722 Deferred rent 4,268 4,001 Other miscellaneous long-term liabilities 2,032 2,663 Total other long-term liabilities $ 137,954 $ 108,996 See Note 19 — Commitments and Contingencies for additional information about the Company’s insurance reserves and Note 17 — Benefit Plans for additional information about the Company’s benefit plan liabilities.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 9 — FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying values of the Company’s cash and cash equivalents, patient accounts receivable, amounts due from and due to third-party payors, and accounts payable approximate their fair values due to the short-term maturity of these financial instruments. The Company recorded impairment related to long-lived assets and goodwill during the years ended December 31, 2017 2016 and 2015. See Note 3 — Impairment of Long-Lived Assets and Goodwill for additional information on these impairments. The assessment of fair value was based on Level 3 inputs, as the valuation methodologies used to determine impairment were based on internal projections and unobservable inputs. The portion of the impairment related to hospital assets held for sale was determined based on Level 2 inputs, as the valuation methodologies used to determine impairment considered letters of intent received on these hospitals. The following table provides a summary of the carrying values and estimated fair values of the Company’s long-term debt (in thousands): December 31, 2017 2016 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Revolving Credit Facility $ — $ — $ — $ — Term Loan Facility 831,158 838,954 868,419 849,427 ABL Credit Facility — — — — Senior Notes 400,000 393,396 400,000 334,720 Other debt 25,666 25,666 27,170 27,170 Total long-term debt, excluding debt issuance costs and discounts $ 1,256,824 $ 1,258,016 $ 1,295,589 $ 1,211,317 The Company considers its long-term debt instruments to be measured based on Level 2 inputs. Information about the valuation methodologies used in the determination of the estimated fair values for the Company’s long-term debt instruments follows: • Term Loan Facility . • Senior Notes . • All other debt .

Leases

Leases	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Leases	NOTE 10 — LEASES The Company leases certain property and equipment under capital and operating lease agreements. The Company’s lease commitments typically require the Company, as lessee, to pay maintenance, repairs, property taxes and insurance costs. The following table provides a summary of the Company’s commitments relating to non-cancellable operating and capital leases for each of the next five years and thereafter (in thousands): Year Ending December 31, Operating (1) Capital 2018 $ 32,253 $ 2,531 2019 25,568 2,552 2020 19,673 2,590 2021 12,722 2,628 2022 8,294 2,332 Thereafter 17,236 20,707 Total minimum future payments obligations $ 115,746 33,340 Less: Imputed interest (8,929 ) Total capital lease obligations 24,411 Less: Current portion of capital lease obligations (1,140 ) Total long-term capital lease obligations $ 23,271 (1) Minimum lease payments obligations have not been reduced by minimum sublease rentals due in the future of $5.2 million.

Equity

Equity	12 Months Ended
	Dec. 31, 2017
Equity [Abstract]
Equity	NOTE 11 — EQUITY Preferred Stock In connection with the Spin-off, the Company authorized 100,000,000 shares of preferred stock, par value of $0.0001 per share. No shares have been issued as of December 31, 2017. The Board has the discretion, subject to limitations prescribed by Delaware law and by its amended and restated certificate of incorporation, to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock, when and if issued. Common Stock In connection with the Spin-off, the Company authorized 300,000,000 shares of common stock, par value of $0.0001 per share, and issued 28,412,054 shares of common stock on April 29, 2016 to CHS stockholders of record as of the Record Date, or April 22, 2016. The Company’s common stock began trading on the NYSE on May 2, 2016 under the ticker symbol “QHC.” As of December 31, 2017 and 2016, the Company had 30,294,895 shares and 29,482,050 shares, respectively, of common stock issued and outstanding. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters for which stockholders may vote. Holders of the Company’s common stock do not have cumulative voting rights in the election of directors. There are no preemptive rights, conversion, redemption or sinking fund provisions applicable to the common stock. In the event of liquidation, dissolution or winding up, holders of common stock are entitled to share ratably in the assets available for distribution. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Company’s Credit Agreements impose restrictions on its ability to pay dividends. Additional Paid-in Capital In connection with the Spin-off, the Company issued common stock, as described above, to CHS stockholders. In addition, pursuant to the Separation and Distribution Agreement, CHS contributed capital of $530.6 million, in lieu of a cash settlement payment, related to the remaining intercompany indebtedness with CHS and the Parent’s equity attributable to CHS. See Note 1 — Description of the Business and Spin-off for additional information on the major transactions that occurred on April 29, 2016 to effect the Spin-off. Accumulated Deficit Accumulated deficit of the Company, as shown in the consolidated balance sheets as of December 31, 2017 and 2016, represents the Company’s cumulative net losses since the Spin-off. The cumulative earnings and losses of the Company prior to the Spin-off were included in Due to Parent, net in the consolidated balance sheets prior to April 29, 2016. Parent’s Equity Prior to the Spin-off, the purchase of shares from noncontrolling interest partners and the changes in valuation of redeemable shares of noncontrolling interests investments were accounted for as Parent’s equity in the consolidated balance sheets. Parent’s equity was reclassified as additional paid-in capital in connection with the Spin-off.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 12 — INCOME TAXES The Company and its subsidiaries are subject to U.S. federal income tax and income taxes of multiple state and local jurisdictions. The Company provides for income taxes based on enacted tax laws and tax rates in jurisdictions in which it conducts its operations. Prior to the Spin-off, the Company was included in the consolidated federal, state and local income tax returns filed by CHS and calculated income taxes for the purpose of carve-out financial statements using the “separate return method.” The Company deemed the amounts that it would have paid to or received from the U.S. Internal Revenue Service and other jurisdictions, had QHC not been a member of CHS’ consolidated tax group, to be immediately settled with CHS through Due to Parent, net in the consolidated balance sheets. Since the Spin-off, the Company has been filing its own consolidated federal, state and local income tax returns. The following table provides a summary of the components of the provision for (benefit from) income taxes (in thousands): Year Ended December 31, 2017 2016 2015 Current: Federal $ — $ — $ — State 271 530 762 Total provision for (benefit from) current income taxes 271 530 762 Deferred: Federal (22,540 ) (51,177 ) 1,749 State 404 (3,228 ) 793 Total provision for (benefit from) deferred income taxes (22,136 ) (54,405 ) 2,542 Total provision for (benefit from) income taxes $ (21,865 ) $ (53,875 ) $ 3,304 On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law. The Tax Act includes a number of changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate tax rate from 35% to 21% for tax years after December 31, 2017. As a direct result of changes in tax law due to the passage of the Tax Act, the Company recorded a total tax benefit of $24.0 million during 2017 which is composed of two amounts: a tax benefit of $10.9 million in deferred income tax expense for the net change in its deferred tax liabilities at the new 21% tax rate, and a $13.1 million tax benefit in deferred income tax expense for the reduction in valuation allowance attributable to the change in net realizability of deferred tax assets. The Tax Act also provides for acceleration of depreciation for certain assets placed into service after September 27, 2017, as well as prospective changes beginning in 2018. These prospective changes include an increased limitation on the deductibility of executive compensation, a limitation on the deductibility of interest expense, new rules surrounding meals and entertainment expense and fines and penalties. Also, while net operating losses generated in the future may by carried forward indefinitely under the new law, there is a limitation on the amount that may be used in any given year. The Tax Act may also have an impact on projected future taxable income that could further affect valuation allowance considerations. In addition to the federal law, the Company awaits guidance from the states in which it files on how components of the Tax Act may be treated in these jurisdictions. The $24.0 million tax benefit represents what the Company believes is the impact of the Tax Act, the key components being the re-measurement of deferred tax balances to the new corporate rate and reduction in valuation allowance as a result of anticipated realizability of deferred tax assets due to the change in tax law. As the benefit is based on currently available information and interpretations, which are continuing to evolve, the benefit should be considered provisional. The Company will continue to analyze additional information and guidance related to the Tax Act as supplemental legislation, regulatory federal or state guidance, or evolving technical interpretations become available. The final impacts may differ from the recorded amounts as of December 31, 2017, and the Company will continue to refine such amounts within the measurement period provided by Staff Accounting Bulletin No. 118. The Company expects to complete the analysis by the end of 2018. The following table reconciles the provision for (benefit from) income taxes utilizing the statutory federal income tax rate to the Company’s effective income tax rate (dollars in thousands): Year Ended December 31, 2017 2016 2015 Amount % Amount % Amount % Provision for (benefit from) income taxes at statutory federal tax rate $ (46,978 ) 35.0 % $ (139,685 ) 35.0 % $ 2,814 35.0 % State income taxes, net of federal income tax benefit (6,137 ) 4.6 % (47,749 ) 12.0 % (171 ) (2.1 )% Net (income) loss attributable to noncontrolling interests (641 ) 0.5 % (872 ) 0.2 % (1,189 ) (14.8 )% Non-deductible goodwill and Spin-off costs 535 (0.4 )% 36,009 (9.0 )% — — % Change in valuation allowance (pre Tax Act) 53,470 (39.8 )% 94,745 (23.7 )% 1,459 18.2 % Change in rate due to Tax Act (10,934 ) 8.1 % — — % — — % Change in valuation allowance due to Tax Act (13,121 ) 9.8 % — — % — — % All other items 1,941 (1.5 )% 3,677 (1.0 )% 391 4.8 % Total provision for (benefit from) income taxes and effective tax rate $ (21,865 ) 16.3 % $ (53,875 ) 13.5 % $ 3,304 41.1 % Deferred income taxes are determined based on the estimated future tax effects of differences between the financial statement carrying values and tax bases of the Company’s assets and liabilities under the provisions of the enacted tax laws. The following table provides a summary of the components of deferred income tax assets and liabilities (in thousands): December 31, 2017 2016 Assets Liabilities Assets Liabilities Net operating loss and credit carryforwards $ 83,879 $ — $ 72,195 $ — Property and equipment 2,039 1,416 — 10,447 Prepaid expenses — 2,836 — 6,874 Goodwill and intangible assets — 18,544 — 27,193 Investments in unconsolidated affiliates 140 — 298 — Accounts receivable 4,928 — 1,532 10,290 Accrued compensation and recruiting accruals 8,743 828 14,968 965 Other accruals 175 — 251 — Deferred compensation 9,160 — 10,208 — Debt issuance costs — 7,756 — 53 Insurance and settlement reserves 31,322 — 39,112 — Total deferred income tax assets and liabilities, before valuation allowance 140,386 31,380 138,564 55,822 Valuation allowance (116,780 ) — (114,216 ) — Total deferred income tax assets and liabilities $ 23,606 $ 31,380 $ 24,348 $ 55,822 Total deferred income tax liabilities, net $ 7,774 $ 31,474 As of December 31, 2017, the Company had federal net operating loss carryforwards of approximately $125 million, which will begin expiring in 2035. The Company’s valuation allowance increased $2.6 million during the year ended December 31, 2017 from $114.2 million to $116.8 million. This net increase was comprised of several factors. Prior to any consideration for any changes resulting from the effects of the Tax Act, the Company recorded an increase in its valuation allowance of $53.4 million through deferred tax expense to offset additional deferred tax assets generated during the year resulting from the Company’s 2017 net operating loss. The Company recorded this valuation allowance because it has concluded that it is not more likely than not that it will realize the benefits of its deferred tax assets. In addition, the Company recorded a deferred tax benefit for a decrease of $37.7 million in its valuation allowance to offset a decrease in its deferred tax assets for the same amount to account for the Tax Act’s reduction in the federal tax rate from 35% to 21%. The Company also recorded an income tax benefit through a reduction in its valuation allowance of $13.1 million to account for the change in net realizability of deferred tax assets since the Tax Act has made the net operating loss carryforward period indefinite and has limited the amount of net operating loss usage to 80% of taxable income starting in 2018. In the ordinary course of business, there is inherent uncertainty in quantifying the Company’s income tax positions. The Company assesses its income tax positions and records tax benefits for all tax years subject to examination based on management’s evaluation of the facts, circumstances, and information available at the reporting date. The Company is not aware of any unrecognized tax benefits; and therefore has not recorded any such amounts for the years ended December 31, 2017, 2016 and 2015. The Company classified interest and penalties, if any, related to its tax positions as a component of the provision for (benefit from) income taxes in the consolidated and combined statements of income.

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 13 — EARNINGS PER SHARE The following table provides a summary of the computation of basic and diluted earnings (loss) per share (in thousands, except earnings per share and shares): Year Ended December 31, 2017 2016 2015 Numerator: Net income (loss) $ (112,357 ) $ (345,197 ) $ 4,735 Less: Net income (loss) attributable to noncontrolling interests 1,833 2,491 3,398 Net income (loss) attributable to Quorum Health Corporation $ (114,190 ) $ (347,688 ) $ 1,337 Denominator: Weighted-average shares outstanding - basic and diluted 28,113,566 28,413,247 28,412,054 Earnings (loss) per share attributable to Quorum Health Corporation stockholders - basic and diluted $ (4.06 ) $ (12.24 ) $ 0.05 For comparative purposes, the Company used 28,412,054 shares as the number of basic and diluted shares outstanding for all periods prior to the Spin-off in calculating basic and diluted earnings (loss) per share. This number of shares represents the number of shares issued on the Spin-off date. Due to the net loss attributable to Quorum Health Corporation for the years ended December 31, 2017 and 2016, no incremental shares were included in diluted earnings (loss) per share for these periods because the net effect of the shares would be anti-dilutive. No incremental shares were considered for any periods prior to the Spin-off.

Additional Cash Flow Informatio

Additional Cash Flow Information	12 Months Ended
	Dec. 31, 2017
Significant Non Cash Transactions [Abstract]
Additional Cash Flow Information	NOTE 14 — ADDITIONAL CASH FLOW INFORMATION During the years ended December 31, 2017 and 2016, the Company reclassified certain assets and liabilities as held for sale, which are included as separate line items in the consolidated balance sheets as of December 31, 2017 and 2016. In addition, the Company recorded certain opening balance sheet adjustments in the second and fourth quarters of the year ended December 31, 2016, which included non-cash components that were primarily transfers of assets and liabilities from CHS to effect the Spin-off. See Note 1 — Description of the Business and Spin-off for additional information on the Spin-off.

Segments

Segments	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Segments	NOTE 15 — SEGMENTS The Company’s operations consist of two distinct operating segments, its hospital operations business and its hospital management advisory and healthcare consulting services business. The hospital operations segment includes the operations of the Company’s owned and leased hospitals and their affiliated outpatient facilities that provide inpatient and outpatient healthcare services. The hospital management advisory and healthcare consulting services segment includes the operations of QHR. Both segments meet the criteria to be classified as a separate reportable segment. The financial information for the Company’s corporate functions has been reported in the tables below as part of the all other reportable segment. Prior to the Spin-off, the Company included management fees allocated from Parent in the operating expenses of the hospital operations segment. Following the Spin-off, the Company began presenting general and administrative costs for corporate functions in the operating expenses of the all other reportable segment. The following tables provide a summary of financial information related to the Company’s reportable segments (in thousands): Year Ended December 31, 2017 2016 2015 Net operating revenues: Hospital operations $ 1,987,973 $ 2,052,751 $ 2,096,831 QHR operations 80,863 85,533 90,507 All other 3,334 183 — Total net operating revenues $ 2,072,170 $ 2,138,467 $ 2,187,338 Adjusted EBITDA: Hospital operations $ 175,597 $ 184,000 $ 249,375 QHR operations 20,599 16,980 14,246 All other (54,351 ) (38,058 ) 46 Total Adjusted EBITDA $ 141,845 $ 162,922 $ 263,667 December 31, 2017 2016 Assets: Hospital operations $ 1,687,576 $ 1,802,121 QHR operations 61,752 75,113 All other 79,513 117,136 Total assets $ 1,828,841 $ 1,994,370 The following table provides a reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable U.S. GAAP financial measure (in thousands): Year Ended December 31, 2017 2016 2015 Adjusted EBITDA $ 141,845 $ 162,922 $ 263,667 Interest expense, net (122,077 ) (113,440 ) (98,290 ) (Provision for) benefit from income taxes 21,865 53,875 (3,304 ) Depreciation and amortization (82,155 ) (117,288 ) (128,001 ) Legal, professional and settlement costs (6,001 ) (7,342 ) — Impairment of long-lived assets and goodwill (47,281 ) (291,870 ) (13,000 ) Loss (gain) on sale of hospitals, net 5,243 (2,150 ) — Transaction costs related to the Spin-off (253 ) (5,488 ) (16,337 ) Post-spin headcount reductions (2,543 ) (1,617 ) — Change in estimate related to collectability of patient accounts receivable (21,000 ) (22,799 ) — Net income (loss) $ (112,357 ) $ (345,197 ) $ 4,735

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	NOTE 16 — STOCK-BASED COMPENSATION On April 1, 2016, the Company adopted the Quorum Health Corporation 2016 Stock Award Plan (the “2016 Stock Award Plan”). The Company filed a Registration Statement on Form S-8 on April 29, 2016 to register 4,700,000 shares of QHC common stock that may be issued under the plan. As defined in the Separation and Distribution Agreement, QHC and CHS employees who held CHS restricted stock awards on the Record Date received QHC restricted stock awards for the number of whole shares, rounded down, of QHC common stock that they would have received as a shareholder of CHS as if the underlying CHS stock were unrestricted on the Record Date, except, that with respect to a portion of CHS restricted stock awards granted to any QHC employees on March 1, 2016 that were cancelled and forfeited on the Spin-off date. The QHC restricted stock awards received by QHC and CHS employees in connection with the Spin-off vest on the same terms as the CHS restricted stock awards to which they relate, through the continued service by such employees with their respective employer. CHS restricted stock awards were adjusted by increasing the number of shares of CHS stock subject to restricted stock awards by an amount of whole shares, rounded down, necessary to preserve the intrinsic value of such awards at the Spin-off date. QHC did not issue any stock options as part of the distribution of shares to holders of CHS stock options in connection with the Spin-off. The following table provides a summary of the activity related to unvested QHC restricted stock awards held by QHC and CHS employees from the Spin-off date through December 31, 2017 (in shares): QHC Awards Distributed in Spin-off QHC Employees CHS Employees Total Unvested restricted stock awards at Spin-off date 54,321 638,088 692,409 Vested (1,317 ) (6,098 ) (7,415 ) Forfeited (542 ) (10,465 ) (11,007 ) Unvested restricted stock awards at December 31, 2016 52,462 621,525 673,987 Vested (34,131 ) (204,858 ) (238,989 ) Forfeited (14,174 ) (153,944 ) (168,118 ) Unvested restricted stock awards at December 31, 2017 4,157 262,723 266,880 The following table provides a summary of the activity related to unvested restricted stock awards granted subsequent to the Spin-off: QHC Awards Granted Subsequent to Spin-off Weighted- Average Grant Date Fair Value Shares Per Share Unvested restricted stock awards at Spin-off date — $ — Granted 1,081,005 12.77 Vested — — Forfeited — — Unvested restricted stock awards at December 31, 2016 1,081,005 12.77 Granted 1,142,571 7.54 Vested (282,582 ) 12.77 Forfeited (161,506 ) 10.90 Unvested restricted stock awards at December 31, 2017 1,779,488 $ 9.58 During the year ended December 31, 2017, the Company granted 230,000 performance-based restricted stock awards to certain of its executive officers. If the performance-based objectives are attained in accordance with the targets set forth in the performance-based restricted stock award agreement, the restrictions on the restricted stock awards will lapse on the second anniversary of the grant date. In addition, the Company granted 720,000 time-based restricted stock awards which will lapse in equal installments on each of the first three anniversaries of the grant date. In addition, the Company granted 192,571 time-based restricted stock awards to its non-employee directors which will lapse on February 22, 2018. During the year ended December 31, 2016, the Company granted 460,000 performance-based restricted stock awards to certain of its executive officers. The performance-based objectives set forth in the performance-based restricted stock award agreement were achieved; therefore, the restrictions on the restricted stock awards will lapse in equal installments on each of the first three anniversaries of the grant date. In addition, the Company granted 551,005 time-based restricted stock awards of which 445,000 will lapse in equal installments on each of the first three anniversaries of the grant date and 106,005 will lapse in equal installments on the second and third anniversaries of the grant date. In addition, the Company granted 70,000 time-based restricted stock to its non-employee directors which will lapse on the first anniversary of the grant date. Following the Spin-off, the Company began recording stock-based compensation expense related to the vesting of QHC restricted stock awards issued to QHC employees on the Spin-off date, CHS restricted stock awards held by QHC employees on the Spin-off date, and all restricted stock awards granted by QHC after the Spin-off. Stock-based compensation expense is recognized as a component of salaries and benefits expense in the consolidated and combined statements of income. Prior to the Spin-off, an estimated portion of CHS’ stock-based compensation expense was allocated to QHC through the monthly corporate management fee from CHS, which was recorded in other operating expenses in the consolidated and combined statements of income, and therefore is not included in stock-based compensation expense in the table below. The estimated costs allocated to QHC from CHS for stock-based compensation related to QHC’s employees were $2.3 million and $7.0 million for the years ended December 31, 2016 and 2015, respectively. The following table provides a summary of stock-based compensation expense for the periods subsequent to the Spin-off (in thousands): Year Ended December 31, 2017 2016 2015 Stock-based compensation resulting from the Spin-off $ 2,225 $ 3,089 $ — Stock-based compensation related to grants following the Spin-off 7,727 4,352 — Total stock-based compensation expense $ 9,952 $ 7,441 $ — As of December 31, 2017, the Company had unrecognized stock-based compensation expense of $0.4 million related to the outstanding unvested QHC and CHS restricted stock awards held by QHC employees as of the Spin-off date and $9.8 million of unrecognized stock-based compensation expense related to QHC restricted stock awards that were granted subsequent to the Spin-off.

Benefit Plans

Benefit Plans	12 Months Ended
	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Benefit Plans	NOTE 17 — BENEFIT PLANS The Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and deferred compensation plans, of which certain of the Company’s subsidiaries are the plan sponsors. The rights and obligations of certain of these plans were transferred from CHS in connection with the Spin-off, pursuant to the Separation and Distribution Agreement. Defined Contribution Plans The Quorum Health Retirement Savings Plan (the “Retirement Savings Plan”) is a defined contribution plan, which was established on January 1, 2016 by CHS in anticipation of the Spin-off. Prior to the Spin-off, the cumulative liability for these benefit costs was recorded in Due to Parent, net. The assets and liabilities under this plan were transferred to QHC in connection with the Spin-off. The Retirement Savings Plan covers the majority of the employees at the Company’s subsidiaries. The Company has other minor defined contribution plans at certain of its hospitals that cover employees under the terms of these individual plans. Total expenses to the Company under all defined contribution plans was $1.2 million, $13.6 million and $13.0 million for the years ended December 31, 2017, 2016 and 2015, respectively. The benefit costs associated with the Retirement Savings Plan are recorded as salaries and benefits expense in the consolidated and combined statements of income. Deferred Compensation Plans Prior to the Spin-off, certain of the Company’s employees participated in CHS’ unfunded deferred compensation plans. Under these CHS plans, participants were allowed to defer receipt of a portion of their compensation. The election period for those employees continued under the CHS plan through December 31, 2016. In January 2017, CHS transferred the assets and liabilities attributable to QHC employees under these plans to QHC and they were rolled into a new plan established by QHC, as described below. The assets and liabilities transferred in January 2017 were of $22.9 million and $23.9 million, respectively. On August 18, 2016, the Compensation Committee of the Board of Directors adopted the Executive Nonqualified Excess Plan Adoption Agreement (the “Adoption Agreement”) and the Executive Nonqualified Excess Plan Document (the “Plan Document”), that together, the Adoption Agreement names as the QHCCS, LLC Nonqualified Deferred Compensation Plan (the “NQDCP”). The NQDCP is an unfunded, nonqualified deferred compensation plan that provides deferred compensation benefits for a select group of management, highly compensated employees and independent contractors of the Company’s wholly-owned subsidiary, QHCCS, LLC, a Delaware limited liability company (“QHCCS”), including the Company’s named executive officers. The NQDCP permits participants to defer a portion of their annual base salary, service bonus and performance-based compensation, as well as up to 100% of their incentive compensation in any calendar year. In addition to participant deferrals, QHCCS, and/or its affiliates may make discretionary credits to participants’ accounts for any year. As of December 31 Supplemental Executive Retirement Plans On April 1, 2016, the Board adopted the Quorum Health Corporation Supplemental Executive Retirement Plan (the “Original SERP Plan”). Pursuant to the Employee Matters Agreement between the Company and CHS, the Company assumed the liabilities for all obligations under the Original SERP Plan as of April 29, 2016, the Spin-off date, which related to QHC employees, as defined in the Employee Matters Agreement. In addition, as defined by the Employee Matters Agreement, no additional benefits were to accrue under the Original SERP Plan following the Spin-off and no assets were transferred to the Company related to the Original SERP Plan. The accrued benefit liability transferred to the Company for the Original SERP Plan was $6.0 million. On May 24, 2016, the Board, upon recommendation of the Compensation Committee, approved the Company’s Amended and Restated Supplemental Executive Retirement Plan (the “Amended and Restated SERP”), in order to accrue additional benefits with respect to QHC employees who otherwise qualify as “Participants” under the Amended and Restated SERP. The Amended and Restated SERP is a noncontributory non-qualified deferred compensation plan under Section 409A of the Internal Revenue Code. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for the net periodic benefit costs of the Amended and Restated SERP. The benefit obligations under this plan were unfunded as of December 31, 2017. The following table provides a summary of the components of net periodic benefit costs (in thousands): Year Ended December 31, 2017 2016 2015 Service cost $ 1,347 $ 1,270 $ — Interest cost 299 237 — Amortizations: Prior service cost (credit) 396 268 — Net (gain) loss 3 12 — Total net periodic benefit cost $ 2,045 $ 1,787 $ — The following table provides a summary of the weighted-average assumptions used by the Company to determine its net periodic benefit costs: Year Ended December 31, 2017 2016 2015 Discount rate 3.6 % 3.2 % — % Rate of compensation increase 2.0 % 3.0 % — % The following table provides a summary of the c hanges recognized in other comprehensive income (loss) (in thousands): December 31, 2017 2016 2015 Prior service cost (credit) $ — $ 2,949 $ — Net loss (gain) arising during period (146 ) 14 — Amounts recognized as a component of net periodic benefit cost: Amortization or curtailment recognition of prior service (cost) credit (396 ) (264 ) — Amortization or settlement recognition of net gain (loss) (3 ) (3 ) — Total recognized in other comprehensive loss (income) $ (545 ) $ 2,696 $ — The estimated prior service cost that will be amortized from accumulated other comprehensive income (loss) into net periodic benefit cost for the year ended December 31, 2018 is $0.3 million. The estimated actuarial loss that will be amortized or recognized from accumulated other comprehensive income into net periodic benefit cost is minimal. The following table provides a summary of the changes in the benefit obligation (in thousands): December 31, 2017 2016 Benefit obligation at beginning of period $ 9,434 $ — Benefit obligation transferred from the Spin-off — 5,964 Service cost 1,347 1,270 Interest cost 299 190 Plan amendments — 2,921 Benefits paid (2,275 ) — Actuarial (gain) loss (146 ) (911 ) Benefit obligation at end of period $ 8,659 $ 9,434 As of December 31, 2017, the long-term portion of the Company’s benefit obligation liability was $8.7 million and there was no current portion of the benefit obligation liability. As of December 31, 2016, the current and long-term portions of the Company’s benefit obligation liability were $2.3 million and $7.1 million, respectively. The current portion is recognized as a component of accrued salaries and benefits and the long-term portion is recognized as a component of other long-term liabilities in the consolidated balance sheets. The accumulated benefit obligation at December 31, 2017 was $5.2 million. The following table provides a summary of the weighted-average assumptions used by the Company to determine its benefit obligation: December 31, 2017 2016 Discount rate 3.3 % 3.6 % Rate of compensation increase 2.0 % 2.0 % The following table provides a summary of the expected future benefit payments for each of the next five years and the five years thereafter (in thousands): 2018 $ — 2019 — 2020 — 2021 948 2022 — Five years thereafter 10,448 Total expected future benefit payments $ 11,396 Director’s Fees Deferral Plan On September 16, 2016, the Board adopted the Quorum Health Corporation Director’s Fees Deferral Plan (the “Director’s Plan”). Pursuant to the Director’s Plan, members of the Board may elect to defer and accumulate fees, including retainer fees and fees for attendance at Board meetings and Board committees. Under this plan, a director may elect that all or any specified portion of the director’s fees to be earned during a calendar year be credited to a director’s cash account and/or a director’s stock unit account maintained on the individual director’s behalf in lieu of payment. Payment of amounts credited to a director’s cash account and stock unit account will be made upon a payment commencement event, as defined in the Director’s Plan, in accordance with the payment method elected by each director, either in lump sum or in a number of annual installments, not to exceed 15 installments. The Director’s Plan covers directors of the Board not employed by the Company or any of its subsidiaries. Pursuant to the Director’s Plan, the Company registered and made available for issuance under the Director’s Plan a maximum of 150,000 shares of QHC common stock. Defined Benefit Pension Plan The Company provides benefits to employees at one of its hospitals through a defined benefit plan (the “Pension Plan”). The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan are made by the Company in accordance with the minimum funding requirements of ERISA. The Company expects to make contributions to the Pension Plan for the full year 2018 of $0.4 million. The Company uses a December 31 measurement date for the benefit obligations and a January 1 measurement date for the net periodic benefit costs of the Pension Plan. Variances from actuarially assumed rates result in increases or decreases in the benefit obligation, net periodic benefit cost and funding requirements in future periods. The weighted-average assumptions used for determining the net periodic benefit costs for the year ended December 31, 2017 were a discount rate of 3.6%, an annual salary increase of 3.5% and an expected long-term rate of return on assets of 6.25%. The weighted-average assumptions used for determining the net periodic benefit costs for the year ended December 31, 2016 were a discount rate of 3.75%, an annual salary increase of 3.0% and an expected long-term rate of return on assets of 7.0%. Net periodic benefits costs related to the Pension Plan were $0.1 million, $0.3 million and $0.3 million for the years ended December 31, 2017, 2016 and 2015, respectively. QHC recognizes

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 18 — RELATED PARTY TRANSACTIONS CHS was a related party to QHC prior to the Spin-off. The significant transactions and balances with CHS prior to the Spin-off and the agreements between QHC and CHS as of and subsequent to the Spin-off are described below. Carve-Out from Parent Prior to the Spin-off, QHC did not operate as a separate company and stand-alone financial statements were not prepared. Historically, QHC was managed and operated in the normal course of business with all other hospitals and affiliates of CHS. Accordingly, for the purposes of the carve-out financial statements related to the Spin-off, a combined opening balance sheet for the QHC hospitals and QHR was established. The combined opening balance sheet included the assets and liabilities of QHC hospitals and QHR, as reported by CHS, and a net liability to CHS, referred to as Due to Parent, net, for the net investment held by CHS related to its contribution of these net assets. The operating results of the QHC hospitals and QHR prior to the Spin-off were derived from the CHS operating results for these entities. In addition, certain corporate overhead costs were allocated to QHC from CHS during the carve-out period for the purpose of estimating QHC’s share of these expenses. Allocated Costs from CHS during the Carve-Out Period CHS allocated costs to QHC during the carve-out period for a portion of its corporate overhead costs and any other costs related to QHC hospitals and QHR that were paid by CHS or covered by an agreement, policy or contract owned by CHS. The following table provides a summary of the allocated costs to QHC from CHS for the periods prior to the Spin-off (in thousands): Year Ended December 31, 2016 2015 Insurance costs $ 44,246 $ 134,290 Management fees from Parent 11,792 36,466 All other allocated costs 25,021 72,262 Total related party operating costs and expenses $ 81,059 $ 243,018 The allocation of insurance costs from CHS primarily included costs for self-insurance estimates and third-party policies related to employee health benefits, professional and general liability and workers’ compensation liability coverage. Insurance costs were primarily allocated to QHC based on claims history of the QHC hospitals, as determined on an individual hospital level. Corporate management fees were allocated to QHC for certain corporate functions of CHS, including services such as, among others, executive and divisional management, treasury, accounting, risk management, legal, procurement, human resources, information technology support and other administrative support services. These corporate overhead costs were allocated to QHC using a ratio based on the number of licensed beds at each QHC hospital in proportion to CHS’ total licensed beds. This methodology used was comparable to how CHS allocated corporate overhead costs to all of its hospitals through a management fee charge that eliminates in consolidation. All other allocated costs in the table above include any other costs allocated to QHC hospitals or QHR that were not part of management fees. These costs were allocated to QHC using ratios based on revenues, expenses or licensed beds. If possible, allocations were made on a specific identification basis. Following the Spin-off, the Company began performing corporate functions using internal resources or purchased services, certain of which are being provided by CHS pursuant to the transition services agreements and other ancillary agreements. See the section “Agreements with CHS Related to the Spin-off” below. Due to Parent, Net Prior to the Spin-off, Due to Parent, net in the consolidated balance sheets represented the Company’s cumulative liability to CHS for the net assets of QHC hospitals and QHR, as well as an allocation of costs for corporate functions. See Note 1 — Description of the Business and Spin-off and Note 2 — Basis of Presentation and Significant Accounting Policies — Due to Parent, net for additional information on the types of transactions settled through Due to Parent, net during the carve-out period and the transactions that occurred to settle this liability in connection with the Spin-off. During the carve-out period, QHC was charged interest on a monthly basis by CHS on the amount of Due to Parent, net outstanding at the end of each month. Interest rates were variable and ranged from 4% to 7% during the carve-out period. Interest expense incurred on Due to Parent, net was recorded as an increase in the Due to Parent, net liability and was deemed settled each month. The total amount of related party interest expense arising from the liability with CHS was $35.8 million and $98.0 million for the years ended December 31, 2016 and 2015, respectively. Agreements with CHS Related to the Spin-off In connection with the Spin-off and effective as of April 29, 2016, the Company entered into certain agreements with CHS that allocated between the Company and CHS the various assets, employees, liabilities and obligations (including investments, property, employee benefits and tax-related assets and liabilities) that were previously part of CHS. In addition, these agreements govern certain relationships between, and activities of, the Company and CHS for a definitive period of time after the Spin-off, as specified by each individual agreement. The agreements were as follows: • Separation and Distribution Agreement. • Tax Matters Agreement • Employee Matters Agreement. In addition to the agreements referenced above, the Company entered into certain transition services agreements and other ancillary agreements with CHS defining agreed upon services to be provided by CHS to certain or all QHC hospitals, as determined by each agreement, commencing on the Spin-off date. The agreements generally have terms of five years. A summary of the major provisions of the transition services agreements follows: • Shared Services Centers Transition Services Agreement. • Computer and Data Processing Transition Services Agreement. • Receivables Collection Agreement (“PASI”). • Billing and Collection Agreement (“PPSI”). • Employee Service Center Agreement. • Eligibility Screening Services Agreement. The total expenses recorded by the Company under transition services agreements with CHS following the Spin-off were $63.5 million and $44.7 million for the years ended December 31, 2017 and 2016, respectively. The total expenses recorded by the Company under transition services agreements with CHS following the Spin-off combined with the allocations from CHS for these same services prior to the Spin-off were $63.5 million and $66.4 million for the year ended December 31, 2017 and 2016, respectively. Allocations from CHS for these services were $60.2 million for the year ended December 31, 2015. The Company is disputing in arbitration, among other issues and actions, certain charges and lack of performance of various obligations under the transition services agreements with CHS.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 19 — Legal Matters The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental proceedings, including the matters described herein, will have a material adverse effect on the operating results, financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in these matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could be material to the Company’s results of operations or cash flows for any particular reporting period. In connection with the Spin-off, CHS agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to the closing of the Spin-off, including (i) certain claims and proceedings known to be outstanding on or prior to the closing date of the Spin-off and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to the Company’s healthcare facilities prior to the closing date of the Spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by CHS, including professional and general liability and workers’ compensation liability. In this regard, CHS will continue to be responsible for certain Health Management Associates, Inc. legal matters covered by its contingent value rights agreement that relate to the portion of CHS’ business now held by QHC. Notwithstanding the foregoing, CHS is not indemnifying QHC in respect of any claims or proceedings arising out of, or related to, the business operations of QHR at any time or its compliance with the Corporate Integrity Agreement (“CIA”) . Subsequent to the Spin-off, the OIG entered into an “Assumption of CIA Liability Letter” with the Company reiterating the applicability of the CIA to certain of the Company’s hospitals, although the OIG declined to enter into a separate agreement with the Company. With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated amount of loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the amount of possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the amount of possible loss or range of loss. However, the Company is unable to estimate an amount of possible loss or range of loss in some instances based on the significant uncertainties involved in, or the preliminary nature of, certain legal, regulatory and governmental matters. Government Investigations • Tooele, Utah — Physician Compensation • Blue Island, Illinois — Patient Status Commercial Litigation and Other Lawsuits • Arbitration with Community Health Systems, Inc. • Zwick Partners LP and Aparna Rao, Individually and On Behalf of All Others Similarly Situated v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller and Michael J. Culotta • United Tort Claimants v. Quorum Health Resources, LLC (U.S. Bankruptcy Court for the District of New Mexico); Douthitt - Dugger, et al. v. Quorum Health Resources, LLC (Bernalillo County, New Mexico District Court). Plaintiffs in these cases underwent surgical procedures at Gerald Champion Regional Medical Center in New Mexico that they contend were experimental and performed by an unqualified doctor. Their lawsuits, originally filed starting on June 11, 2010 against the doctors, QHR and the hospital are pending in state court and in federal bankruptcy court in New Mexico. In 2012, QHR resolved plaintiffs’ claims for QHR’s liability exceeding insurance limits, and for liability not covered by insurance, for $5.1 million through a partial settlement agreement. Pursuant to this settlement agreement, the bankruptcy court has held that QHR is entitled to have language in any judgment entered in favor of the plaintiffs limiting enforcement to available insurance and not from QHR’s assets. Litigation of plaintiffs’ claims against QHR has continued, and the trial of the claims of most of the plaintiffs is proceeding in phases in a bankruptcy court bench trial. On December 23, 2016, during the liability phase, the bankruptcy court ruled that QHR was 16.5% at fault for plaintiffs’ injuries. The plaintiffs have made attempts to assert new allegations against QHR in an effort to increase the percentage of liability attributed to QHR, but the bankruptcy court has ruled against the plaintiffs as to each attempt. On January 24, 2018, the New Mexico state court ruled that collateral estoppel applies as to all rulings issued by the bankruptcy court in these matters, which includes the percentage of liability. As a result of the rulings in both courts, all that remains to be determined is the amount of damages sustained, if any, by the individual plaintiffs. The bankruptcy court has heard evidence regarding damages as to four of the plaintiffs and issued an opinion setting forth its findings January 30, 2018. Additional trials will be set in the bankruptcy court to hear evidence as to the remaining plaintiffs in that action. A jury will hear evidence as to the damages asserted by the plaintiffs in state court beginning November 26, 2018. QHR’s insurer, Lexington Insurance Company, is providing a defense in these cases, subject to a reservation of rights. Lexington has sued QHR in Williamson County, Tennessee seeking a declaration that plaintiffs’ claims and at least some portion of the cost of defending QHR are not covered by Lexington. ( Lexington Insurance Company v. Quorum Health Resources, LLC, et al. (Williamson County, Tennessee Chancery Court)). No trial date has been set for Lexington’s claim against QHR with respect to insurance coverage, which QHR also is vigorously defending. The Tennessee court has ruled that Lexington is not entitled to reimbursement of defense costs. Lexington is seeking appellate review of this ruling. • R2 Investments, LDC v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller, Michael J. Culotta, John A. Clerico, James S. Ely, III, John A. Fry, William Norris Jennings, Julia B. North, H. Mitchell Watson, Jr. and H. James Williams . On October 25, 2017, a shareholder filed an action in the Circuit Court of Williamson County, Tennessee against the Company and certain of its officers and directors and CHS and certain of its officers and directors. The complaint alleges that the defendants violated the Tennessee Securities Act and common law by, among other things, making alleged false and/or misleading statements and failing to disclose certain information regarding aspects of the Company’s business, operations and financial condition. Plaintiff is seeking rescissionary, compensatory and punitive damages. The Company filed a motion to dismiss the action on January 16, 2018. The Company is vigorously defending itself in this matter. Given the early stage of this matter, there are not sufficient facts available to reasonably assess the potential outcome of this matter or reasonably assess any estimate of the amount or range of any potential outcome. Insurance Reserves As part of the business of owning and operating hospitals, the Company is subject to potential professional and general liability and workers’ compensation liability claims or other legal actions alleging liability on its part. The Company is also subject to similar liabilities related to its QHR business. Prior to the Spin-off, CHS provided professional and general liability insurance and workers’ compensation liability insurance to QHC and indemnified QHC from losses under these insurance arrangements related to the hospital operations business assumed by QHC in the Spin-off. The liabilities for claims prior to the Spin-off and related to QHC’s hospital operations business are determined based on an actuarial study of QHC’s operations and historical claims experience at its hospitals, including during the period of ownership by CHS. Corresponding receivables from CHS are established to reflect the indemnification by CHS for each of these liabilities for claims that related to events and circumstances that occurred prior to the Spin-off date. After the Spin-off, QHC entered into its own professional and general liability insurance and workers’ compensation liability insurance arrangements to mitigate the risk for claims exceeding its self-insured retention levels. The Company maintains a self-insured retention level for professional and general liability claims of $5 million per claim and maintains a $0.5 million per claim, high deductible program for workers’ compensation liability claims. Due to the differing nature of its business, the Company maintains separate insurance arrangements for professional and general liability claims related to its subsidiary, QHR. The self-insured retention level for QHR is $6 million for professional and general liability claims. The following table provides a summary of the Company’s insurance reserves related to professional and general liability and workers’ compensation liability, distinguished between those indemnified by CHS and those related to the Company’s own risks (in thousands): December 31, 2017 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 21,465 $ 44,377 $ 21,465 $ 44,377 All other self-insurance reserves — — 2,883 32,616 Total insurance reserves for professional and general liability 21,465 44,377 24,348 76,993 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 3,032 14,545 3,032 14,545 All other self-insurance reserves — — 3,120 4,013 Total insurance reserves for workers' compensation liability 3,032 14,545 6,152 18,558 Total self-insurance reserves $ 24,497 $ 58,922 $ 30,500 $ 95,551 December 31, 2016 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 17,580 $ 59,652 $ 17,580 $ 59,652 All other self-insurance reserves — — 230 14,542 Total insurance reserves for professional and general liability 17,580 59,652 17,810 74,194 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 4,863 15,958 4,863 15,958 All other self-insurance reserves — — 1,736 1,458 Total insurance reserves for workers' compensation liability 4,863 15,958 6,599 17,416 Total self-insurance reserves $ 22,443 $ 75,610 $ 24,409 $ 91,610 For the years ended December 31, 2017 and 2016, the net present value of the projected payments for professional and general liability claims related to the Company’s self-insurance risks was discounted using a weighted-average risk-free rate of 2.0% in both years. The Company’s estimated liability for these claims was $35.5 million and $14.7 million as of December 31, 2017 and 2016, respectively. The estimated undiscounted claims liability was $39.2 million and $16.4 million as of December 31, 2017 and 2016, respectively. For the years ended December 31, 2017 and 2016, the net present value of the projected payments for professional and general liability claims indemnified by CHS was discounted using a weighted-average risk-free rate of 1.9% and 1.5%, respectively. The estimated undiscounted liability for these claims was $71.7 million and $86.6 million as of December 31, 2017 and 2016, respectively. For the years ended December 31, 2017 and 2016, the net present value of the projected payments for workers’ compensation liability claims related to the Company’s self-insurance risks was discounted using a weighted-average risk-free rate of 2.0%. The Company’s estimated liability for these claims was $7.1 million and $3.2 million as of December 31, 2017 and 2016, respectively. The estimated undiscounted liability for these claims was $7.4 million and $3.5 million as of December 31, 2017 and 2016, respectively. Physician Recruiting Commitments As part of its physician recruitment strategy, the Company provides income guarantee agreements to certain physicians who agree to relocate to its communities and commit to remain in practice there for a period of time. Under such agreements, the Company is required to make payments to a physician in excess of the amount earned as income by the physician in his or her practice, up to the amount of the income guarantee. The income guarantee period over which the Company agrees to subsidize a physician’s income is typically one year and the commitment period over which the physician agrees to practice in the designated community is typically three years. Under the terms of the agreements, such payments are recoverable by the Company from physicians who do not fulfill their commitment periods. As of December 31, 2017 and 2016, the Company had physician guarantee contract liabilities of $0.2 million and $1.6 million, respectively, which were included in other current liabilities in the consolidated balance sheets. At December 31, 2017, the maximum potential amount of future payments under these guarantees in excess of the liabilities recorded was $0.4 million. Construction and Capital Commitments McKenzie - Willamette Medical Center Project . The Company is building a new patient tower and expanding surgical capacity at McKenzie – Willamette Medical Center, its hospital in Springfield, Oregon. During the years ended December 31, 2017, 2016 and 2015, the Company incurred costs of $34.1 million, $38.5 million and $10.4 million, respectively, related to this project. As of December 31, 2017, the Company had incurred a total of $83.0 million of costs for this project, of which $76.1 million has been placed into service as of December 31, 2017. The total estimated cost of this project, including equipment costs, is estimated to be approximately $105 million. The project is expected to be completed in late 2018. Helena Regional Medical Center Master Lease . Pursuant to the lease agreement at the Company’s hospital in Helena, Arkansas, the Company has committed to make capital expenditures and improvements at this hospital averaging a specified percentage of the hospital’s annual net operating revenues. The Company estimates that it will make capital expenditures of approximately $1 million for each year of the remaining lease term, which extends through January 1, 2025. Other Renovation Projects. The Company has committed to certain other renovation projects at one of its hospitals that are expected to begin and be completed in 2018. The total estimated costs for these projects is approximately $4.7 million. Commitments Related to the Spin-off On April 29, 2016, the Company entered into certain agreements with CHS that allocated between QHC and CHS the various assets, employees, liabilities and obligations (including investments, property, employee benefits and tax-related assets and liabilities) that comprise the separate companies and governed or continue to govern certain relationships between, and activities of, QHC and CHS for a period of time after the Spin-off. In addition to these agreements, QHC entered into certain transition services agreements and other ancillary agreements with CHS defining agreed upon services to be provided by CHS to certain or all QHC hospitals, as determined by each agreement. The agreements generally have terms of five years. See Note 18 — Related Party Transactions for additional information on the Company’s agreements with CHS.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 20 — On March 14, 2018, the Company executed an agreement with its lenders pursuant to its Senior Credit Facility to amend the calculation of the Secured Net Leverage Ratio beginning July 1, 2017 through maturity, among other provisions. See Note 7 — Long-term Debt for additional information on the Company’s Senior Credit Facility and the terms of the amendment On March 1, 2018, the Company sold 70-bed Vista Medical Center West and its affiliated facilities (“Vista West”), located in Waukegan, Illinois, for proceeds of $1.2 million. For the years ended December 31, 2017, 2016 and 2015, the Company’s operating results included pre-tax gains (losses) of $(2.3) million, $4.9 million, and $5.7 million respectively, related to Vista West. In addition to the above, the Company recorded $11.1 million and $4.1 million of impairment to property, equipment and capitalized software costs of Vista West during the years ended December 31, 2017 and 2016, respectively. The Company does not expect the loss on sale of this hospital will be material, after consideration of the impairment recorded. On February 1, 2018, the Company announced that it had entered into a definitive agreement to sell 77-bed Clearview Regional Medical Center and its affiliated facilities (“Clearview”), located in Monroe, Georgia. The definitive agreement covers the hospital and its affiliated outpatient facilities. The Company currently anticipates completing the sale of this hospital by the end of the first quarter of 2018. The Company recorded $1.2 million of impairment to Medicare licenses of Clearview during the year ended December 31, 2016. On January 5, 2018, the Company announced plans to close Affinity Medical Center (“Affinity”) in Massillon, Ohio. Subsequent to January 5, 2018, the Company’s affiliates entered into an agreement with the City of Massillon related to the closure whereby all of the owned real property and a substantial majority of the related tangible assets located at the hospital will be transferred to the City of Massillon in exchange for nominal consideration and the assumption of certain ongoing real property lease obligations and equipment lease obligations. Operations ceased on February 11, 2018 and the Company currently anticipates the asset transfer to the City of Massillon will be completed by the end of the first quarter of 2018. The Company recorded $16.1 million and $20.2 million of impairment related to property, equipment and capitalized software costs of Affinity during the years ended December 31, 2017 and 2016 respectively. The Company expects to complete its assessment of the closure of Affinity by the end of the first quarter, including any potential impacts on the Company’s results of operations, financial position and cash flows.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Data (Unaudited)	NOTE 21 — QUARTERLY FINANCIAL DATA (UNAUDITED) The following table provides a summary of the Company’s quarterly operating results for the years ended December 31, 2017 and 2016 (in thousands, except earnings per share and shares): 2017 Quarters 1st 2nd 3rd 4th Net operating revenues $ 527,640 $ 530,146 $ 499,302 $ 515,082 Net income (loss) $ (27,205 ) (30,575 ) (28,554 ) (26,023 ) Less: Net income (loss) attributable to noncontrolling interests 356 55 637 785 Net income (loss) attributable to Quorum Health Corporation $ (27,561 ) $ (30,630 ) $ (29,191 ) $ (26,808 ) Earnings (loss) per share attributable to Quorum Health Corporation stockholders: Basic and diluted $ (0.99 ) $ (1.09 ) $ (1.03 ) $ (0.95 ) Weighted-average common shares outstanding: Basic and diluted 27,800,597 28,145,215 28,245,833 28,248,527 2016 Quarters 1st 2nd 3rd 4th Net operating revenues $ 549,551 $ 529,737 $ 543,939 $ 515,240 Net income (loss) (4,687 ) (243,966 ) (6,452 ) (90,092 ) Less: Net income (loss) attributable to noncontrolling interests 315 1,095 507 574 Net income (loss) attributable to Quorum Health Corporation $ (5,002 ) $ (245,061 ) $ (6,959 ) $ (90,666 ) Earnings (loss) per share attributable to Quorum Health Corporation stockholders: Basic and diluted $ (0.18 ) $ (8.63 ) $ (0.24 ) $ (3.19 ) Weighted-average common shares outstanding: Basic and diluted 28,412,054 28,412,720 28,413,532 28,416,801 Net income (loss) for each quarter in the year ended December 31, 2017 included the impact of impairment recorded for long-lived assets and goodwill. See Note 3 — Impairment of Long-lived Assets and Goodwill. Net income (loss) for the fourth quarter of 2017 additionally includes the impact of California HQAF of $22.0 million of operating revenues, net of provider taxes. The amount recognized in the fourth quarter included the impact for the entire year as the Company was unable to recognize the impact of the California HQAF program until the fourth quarter, after the program received regulatory approval. See Note 2 — Basis of Presentation and Significant Accounting Policies — Revenues and Accounts Receivable. Net income (loss) for the second and fourth quarters in the year ended December 31, 2016 included the impact of impairment recorded for long-lived assets and goodwill. See Note 3 — Impairment of Long-lived Assets and Goodwill. Net income (loss) for the fourth quarters of 2017 and 2016 additionally included the impact of the change in estimate related to collectability of patient accounts receivable. See Note 2 — Basis of Presentation and Significant Accounting Policies — Revenues and Accounts Receivable.

Guarantor and Non-Guarantor Sup

Guarantor and Non-Guarantor Supplemental Information	12 Months Ended
	Dec. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Guarantor and Non-Guarantor Supplemental Information	NOTE 22 — The Senior Notes are senior unsecured obligations of the Company guaranteed on a senior basis by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries (the “Guarantors”). The Senior Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or when a sale of all of the subsidiary guarantor’s assets used in operations occurs. The condensed consolidating and combining financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The accounting policies used in the preparation of this financial information are consistent with those elsewhere in these consolidated and combined financial statements of the Company, except as noted below: • Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. • Due to Parent and Due from Parent are presented gross in the supplemental condensed consolidating balance sheets. • Investments in consolidated subsidiaries, as well as guarantor subsidiaries’ investments in non-guarantor subsidiaries, are presented under the equity method of accounting with the related investments presented within the line items net investment in subsidiaries and other long-term liabilities in the supplemental condensed consolidating balance sheets. • The provision for (benefit from) income taxes is allocated from the parent issuer to the income producing operations (other guarantors and non-guarantors) through stockholders’ equity. As this approach represents an allocation, the provision for (benefit from) income tax allocation is considered non-cash for statement of cash flow purposes. Following the Spin-off, the Company’s intercompany activity consists primarily of daily cash transfers, the allocation of certain expenses and expenditures paid by the parent issuer on behalf of its subsidiaries, and the push down of investment in its subsidiaries. The parent issuer’s investment in its subsidiaries reflects the activity of the period beginning April 29, 2016 through December 31, 2017. Likewise, the parent issuer’s equity in earnings of unconsolidated affiliates represents the Company’s earnings for the same post-spin period. Condensed Consolidating and Combining Statement of Income (Loss) Year Ended December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 1,815,355 $ 512,300 $ — $ 2,327,655 Provision for bad debts — 215,021 40,464 — 255,485 Net operating revenues — 1,600,334 471,836 — 2,072,170 Operating costs and expenses: Salaries and benefits — 715,713 319,084 — 1,034,797 Supplies — 182,172 68,351 — 250,523 Other operating expenses 3,002 504,809 115,252 — 623,063 Depreciation and amortization — 68,770 13,385 — 82,155 Rent — 29,923 20,307 — 50,230 Electronic health records incentives earned — (3,681 ) (1,064 ) — (4,745 ) Legal, professional and settlement costs — 6,001 — — 6,001 Impairment of long-lived assets and goodwill — 47,281 — — 47,281 Loss (gain) on sale of hospitals, net — — (5,243 ) — (5,243 ) Transaction costs related to the Spin-off — 195 58 — 253 Total operating costs and expenses 3,002 1,551,183 530,130 — 2,084,315 Income (loss) from operations (3,002 ) 49,151 (58,294 ) — (12,145 ) Interest expense, net 124,060 (2,054 ) 71 — 122,077 Equity in earnings of affiliates 15,291 29,673 — (44,964 ) — Income (loss) before income taxes (142,353 ) 21,532 (58,365 ) 44,964 (134,222 ) Provision for (benefit from) income taxes (28,163 ) (3,508 ) 9,806 — (21,865 ) Net income (loss) (114,190 ) 25,040 (68,171 ) 44,964 (112,357 ) Less: Net income (loss) attributable to noncontrolling interests — — 1,833 — 1,833 Net income (loss) attributable to Quorum Health Corporation $ (114,190 ) $ 25,040 $ (70,004 ) $ 44,964 $ (114,190 ) Condensed Consolidating and Combining Statement of Income (Loss) Year Ended December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 1,811,586 $ 607,467 $ — $ 2,419,053 Provision for bad debts — 211,921 68,665 — 280,586 Net operating revenues — 1,599,665 538,802 — 2,138,467 Operating costs and expenses: Salaries and benefits — 715,925 341,194 — 1,057,119 Supplies — 180,098 78,541 — 258,639 Other operating expenses — 505,778 140,024 — 645,802 Depreciation and amortization — 97,318 19,970 — 117,288 Rent — 27,741 22,142 — 49,883 Electronic health records incentives earned — (8,948 ) (2,534 ) — (11,482 ) Legal, professional and settlement costs — 7,342 — — 7,342 Impairment of long-lived assets and goodwill — 242,685 49,185 — 291,870 Loss (gain) on sale of hospitals, net — — 2,150 — 2,150 Transaction costs related to the Spin-off — 4,105 1,383 — 5,488 Total operating costs and expenses — 1,772,044 652,055 — 2,424,099 Income (loss) from operations — (172,379 ) (113,253 ) — (285,632 ) Interest expense, net 78,266 32,541 2,633 — 113,440 Equity in earnings of affiliates 258,078 58,605 — (316,683 ) — Income (loss) before income taxes (336,344 ) (263,525 ) (115,886 ) 316,683 (399,072 ) Provision for (benefit from) income taxes (2,318 ) (35,576 ) (15,981 ) — (53,875 ) Net income (loss) (334,026 ) (227,949 ) (99,905 ) 316,683 (345,197 ) Less: Net income (loss) attributable to noncontrolling interests — — 2,491 — 2,491 Net income (loss) attributable to Quorum Health Corporation $ (334,026 ) $ (227,949 ) $ (102,396 ) $ 316,683 $ (347,688 ) Condensed Consolidating and Combining Statement of Income (Loss) Year Ended December 31, 2015 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 1,833,226 $ 612,632 $ — $ 2,445,858 Provision for bad debts — 204,968 53,552 — 258,520 Net operating revenues — 1,628,258 559,080 — 2,187,338 Operating costs and expenses: Salaries and benefits — 687,596 329,100 — 1,016,696 Supplies — 177,421 72,371 — 249,792 Other operating expenses — 507,514 126,719 — 634,233 Depreciation and amortization — 105,320 22,681 — 128,001 Rent — 27,871 20,858 — 48,729 Electronic health records incentives earned — (21,001 ) (4,778 ) — (25,779 ) Impairment of long-lived assets — 13,000 — — 13,000 Transaction costs related to the Spin-off — 12,161 4,176 — 16,337 Total operating costs and expenses — 1,509,882 571,127 — 2,081,009 Income (loss) from operations — 118,376 (12,047 ) — 106,329 Interest expense, net — 86,363 11,927 — 98,290 Equity in earnings of affiliates — (16,857 ) — 16,857 — Income (loss) before income taxes — 48,870 (23,974 ) (16,857 ) 8,039 Provision for (benefit from) income taxes — 16,904 (13,600 ) — 3,304 Net income (loss) — 31,966 (10,374 ) (16,857 ) 4,735 Less: Net income (loss) attributable to noncontrolling interests — (621 ) 4,019 — 3,398 Net income (loss) attributable to Quorum Health Corporation $ — $ 32,587 $ (14,393 ) $ (16,857 ) $ 1,337 Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Year Ended December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (114,190 ) $ 25,040 $ (68,171 ) $ 44,964 $ (112,357 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 804 804 — (804 ) 804 Comprehensive income (loss) (113,386 ) 25,844 (68,171 ) 44,160 (111,553 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 1,833 — 1,833 Comprehensive income (loss) attributable to Quorum Health Corporation $ (113,386 ) $ 25,844 $ (70,004 ) $ 44,160 $ (113,386 ) Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Year Ended December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (334,026 ) $ (227,949 ) $ (99,905 ) $ 316,683 $ (345,197 ) Amortization and recognition of unrecognized pension cost components, net of income taxes (2,760 ) (2,760 ) — 2,760 (2,760 ) Comprehensive income (loss) (336,786 ) (230,709 ) (99,905 ) 319,443 (347,957 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 2,491 — 2,491 Comprehensive income (loss) attributable to Quorum Health Corporation $ (336,786 ) $ (230,709 ) $ (102,396 ) $ 319,443 $ (350,448 ) Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Year Ended December 31, 2015 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ — $ 31,966 $ (10,374 ) $ (16,857 ) $ 4,735 Amortization and recognition of unrecognized pension cost components, net of income taxes — — — — — Comprehensive income (loss) — 31,966 (10,374 ) (16,857 ) 4,735 Less: Comprehensive income (loss) attributable to noncontrolling interests — (621 ) 4,019 — 3,398 Comprehensive income (loss) attributable to Quorum Health Corporation $ — $ 32,587 $ (14,393 ) $ (16,857 ) $ 1,337 Condensed Consolidating Balance Sheet December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 1,051 $ 4,222 $ 344 $ — $ 5,617 Patient accounts receivable, net of allowance for doubtful accounts — 262,690 80,455 — 343,145 Inventories — 43,276 10,183 — 53,459 Prepaid expenses 33 16,980 4,154 — 21,167 Due from third-party payors — 93,323 3,879 — 97,202 Current assets of hospitals held for sale — 8,112 — — 8,112 Other current assets — 32,867 14,573 — 47,440 Total current assets 1,084 461,470 113,588 — 576,142 Intercompany receivable 3 402,817 172,098 (574,918 ) — Property and equipment, net — 543,073 132,206 — 675,279 Goodwill — 243,618 165,611 — 409,229 Intangible assets, net — 58,240 6,610 — 64,850 Long-term assets of hospitals held for sale — 7,730 4 — 7,734 Other long-term assets — 74,918 20,689 — 95,607 Net investment in subsidiaries 1,488,021 — — (1,488,021 ) — Total assets $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,434 $ 421 $ — $ 1,855 Accounts payable 132 146,193 24,925 — 171,250 Accrued liabilities: Accrued salaries and benefits — 56,522 21,281 — 77,803 Accrued interest 10,466 — — — 10,466 Due to third-party payors — 46,381 1,324 — 47,705 Current liabilities of hospitals held for sale — 2,577 — — 2,577 Other current liabilities 516 30,664 12,507 — 43,687 Total current liabilities 11,114 283,771 60,458 — 355,343 Long-term debt 1,188,224 23,809 2 — 1,212,035 Intercompany payable 182,555 173,341 219,022 (574,918 ) — Deferred income tax liabilities, net 7,774 — — — 7,774 Other long-term liabilities — 195,132 31,100 (88,278 ) 137,954 Total liabilities 1,389,667 676,053 310,582 (663,196 ) 1,713,106 Redeemable noncontrolling interests — — 2,325 — 2,325 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 549,610 1,291,581 471,767 (1,763,348 ) 549,610 Accumulated other comprehensive income (loss) (1,956 ) (1,956 ) — 1,956 (1,956 ) Accumulated deficit (448,216 ) (173,812 ) (187,837 ) 361,649 (448,216 ) Total Quorum Health Corporation stockholders' equity 99,441 1,115,813 283,930 (1,399,743 ) 99,441 Nonredeemable noncontrolling interests — — 13,969 — 13,969 Total equity 99,441 1,115,813 297,899 (1,399,743 ) 113,410 Total liabilities and equity $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841 Condensed Consolidating Balance Sheet December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 21,609 $ 3,498 $ 348 $ — $ 25,455 Patient accounts receivable, net of allowance for doubtful accounts — 277,155 103,530 — 380,685 Inventories — 46,318 11,806 — 58,124 Prepaid expenses — 17,874 5,154 — 23,028 Due from third-party payors — 109,793 6,442 — 116,235 Current assets of hospitals held for sale — 1,502 — — 1,502 Other current assets — 41,673 16,269 — 57,942 Total current assets 21,609 497,813 143,549 — 662,971 Intercompany receivable 3 126,035 84,827 (210,865 ) — Property and equipment, net — 624,457 109,443 — 733,900 Goodwill — 252,433 164,400 — 416,833 Intangible assets, net — 73,404 11,578 — 84,982 Long-term assets of hospitals held for sale — 6,851 — — 6,851 Other long-term assets — 72,967 15,866 — 88,833 Net investment in subsidiaries 1,485,213 — — (1,485,213 ) — Total assets $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ 3,819 $ 1,560 $ 304 $ — $ 5,683 Accounts payable 158 147,521 22,005 — 169,684 Accrued liabilities: Accrued salaries and benefits — 69,896 28,907 — 98,803 Accrued interest 19,915 — — — 19,915 Due to third-party payors — 40,595 1,942 — 42,537 Current liabilities of hospitals held for sale — 492 — — 492 Other current liabilities — 46,002 7,266 — 53,268 Total current liabilities 23,892 306,066 60,424 — 390,382 Long-term debt 1,215,836 24,899 407 — 1,241,142 Intercompany payable 34,495 86,084 90,286 (210,865 ) — Deferred income tax liabilities, net 31,474 — — — 31,474 Other long-term liabilities — 144,950 22,651 (58,605 ) 108,996 Total liabilities 1,305,697 561,999 173,768 (269,470 ) 1,771,994 Redeemable noncontrolling interests — — 6,807 — 6,807 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 537,911 1,333,347 412,705 (1,746,052 ) 537,911 Accumulated other comprehensive income (loss) (2,760 ) (2,760 ) — 2,760 (2,760 ) Accumulated deficit (334,026 ) (238,626 ) (78,058 ) 316,684 (334,026 ) Total Quorum Health Corporation stockholders' equity 201,128 1,091,961 334,647 (1,426,608 ) 201,128 Nonredeemable noncontrolling interests — — 14,441 — 14,441 Total equity 201,128 1,091,961 349,088 (1,426,608 ) 215,569 Total liabilities and equity $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370 Condensed Consolidating and Combining Statement of Cash Flows Year Ended December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (121,079 ) $ 206,248 $ (18,199 ) $ — $ 66,970 Cash flows from investing activities: Capital expenditures for property and equipment — (24,777 ) (36,753 ) — (61,530 ) Capital expenditures for software — (6,090 ) (808 ) — (6,898 ) Acquisitions, net of cash acquired — (29 ) (1,891 ) — (1,920 ) Proceeds from the sale of hospitals — 11,925 20,156 — 32,081 Changes in intercompany balances with affiliates, net — (183,829 ) — 183,829 — Net cash provided by (used in) investing activities — (202,800 ) (19,296 ) 183,829 (38,267 ) Cash flows from financing activities: Borrowings under revolving credit facilities 508,000 — — — 508,000 Repayments under revolving credit facilities (508,000 ) — — — (508,000 ) Borrowings of long-term debt — 376 — — 376 Repayments of long-term debt (37,261 ) (1,592 ) (342 ) — (39,195 ) Payments of debt issuance costs (3,119 ) — — — (3,119 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,508 ) — — (1,508 ) Cash distributions to noncontrolling investors — — (3,851 ) — (3,851 ) Purchases of shares from noncontrolling investors — — (1,244 ) — (1,244 ) Changes in intercompany balances with affiliates, net 140,901 — 42,928 (183,829 ) — Net cash provided by (used in) financing activities 100,521 (2,724 ) 37,491 (183,829 ) (48,541 ) Net change in cash and cash equivalents (20,558 ) 724 (4 ) — (19,838 ) Cash and cash equivalents at beginning of period 21,609 3,498 348 — 25,455 Cash and cash equivalents at end of period $ 1,051 $ 4,222 $ 344 $ — $ 5,617 Condensed Consolidating and Combining Statement of Cash Flows Year Ended December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (66,266 ) $ 173,382 $ (26,030 ) $ — $ 81,086 Cash flows from investing activities: Capital expenditures for property and equipment — (73,327 ) (6,593 ) — (79,920 ) Capital expenditures for software — (3,854 ) (3,415 ) — (7,269 ) Acquisitions, net of cash acquired — (549 ) (236 ) — (785 ) Proceeds from the sale of hospitals — — 13,746 — 13,746 Proceeds from asset sales — 1,498 (416 ) — 1,082 Changes in intercompany balances with affiliates, net — (116,674 ) — 116,674 — Net cash provided by (used in) investing activities — (192,906 ) 3,086 116,674 (73,146 ) Cash flows from financing activities: Borrowings under revolving credit facilities 50,000 — — — 50,000 Repayments under revolving credit facilities (50,000 ) — — — (50,000 ) Borrowings of long-term debt 1,255,464 740 77 — 1,256,281 Repayments of long-term debt (11,581 ) (3,025 ) (616 ) — (15,222 ) Increase (decrease) in Due to Parent, net — 24,796 — — 24,796 Payments of debt issuance costs (29,146 ) — — — (29,146 ) Cash paid to Parent related to the Spin-off (1,217,336 ) — — — (1,217,336 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (13 ) — — (13 ) Cash distributions to noncontrolling investors — — (2,850 ) — (2,850 ) Purchases of shares from noncontrolling investors — — (101 ) — (101 ) Changes in intercompany balances with affiliates, net 90,474 — 26,200 (116,674 ) — Net cash provided by (used in) financing activities 87,875 22,498 22,710 (116,674 ) 16,409 Net change in cash and cash equivalents 21,609 2,974 (234 ) — 24,349 Cash and cash equivalents at beginning of period — 524 582 — 1,106 Cash and cash equivalents at end of period $ 21,609 $ 3,498 $ 348 $ — $ 25,455 Condensed Consolidating and Combining Statement of Cash Flows Year Ended December 31, 2015 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ — $ 87,313 $ (44,424 ) $ — $ 42,889 Cash flows from investing activities: Capital expenditures for property and equipment — (37,321 ) (22,134 ) — (59,455 ) Capital expenditures for software — (6,935 ) (1,910 ) — (8,845 ) Acquisitions, net of cash acquired — (3,467 ) (4,552 ) — (8,019 ) Proceeds from asset sales — 3,114 — — 3,114 Other investing activities — (1,416 ) (3,971 ) — (5,387 ) Net cash provided by (used in) investing activities — (46,025 ) (32,567 ) — (78,592 ) Cash flows from financing activities: Borrowings of long-term debt — 217 155 — 372 Repayments of long-term debt — (1,043 ) (520 ) — (1,563 ) Increase (decrease) in Due to Parent, net — 152,971 109,804 — 262,775 Increase (decrease) in receivables facility, net — (194,835 ) (29,939 ) — (224,774 ) Cash distributions to noncontrolling investors — — (1,623 ) — (1,623 ) Purchases of shares from noncontrolling investors — (526 ) (411 ) — (937 ) Net cash provided by (used in) financing activities — (43,216 ) 77,466 — 34,250 Net change in cash and cash equivalents — (1,928 ) 475 — (1,453 ) Cash and cash equivalents at beginning of period — 2,452 107 — 2,559 Cash and cash equivalents at end of period $ — $ 524 $ 582 $ — $ 1,106

Basis of Presentation and Sig30

Basis of Presentation and Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation (Policies)	Basis of Presentation The consolidated and combined financial statements and accompanying notes of the Company presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”). In the opinion of the Company’s management, the consolidated and combined financial information presented herein includes all adjustments necessary to present fairly the results of operations, financial position and cash flows of the Company for the periods presented. Prior to its separation from CHS on April 29, 2016, QHC did not operate as a separate company and stand-alone financial statements were not historically prepared; however, QHC was comprised of certain stand-alone legal entities for which discrete financial information was available under CHS’ ownership. The accompanying consolidated and combined financial statements include amounts and disclosures for QHC that have been derived from the consolidated financial statements and accounting records of CHS for the periods prior to the Spin-off in combination with the amounts and disclosures related to the stand-alone financial statements and accounting records of QHC after the Spin-off. The accompanying consolidated and combined financial statements may not necessarily be indicative of the results of operations, financial position and cash flows of QHC in the future or those that would have occurred had the Company operated on a stand-alone basis during the entirety of the periods presented herein. See Note 18 — Related Party Transactions for additional information on the carve-out of financial information from CHS.
Principles of Consolidation and Combination (Policies)	Principles of Consolidation and Combination The consolidated and combined financial statements include the accounts of the Company and its subsidiaries in which it holds either a direct or indirect ownership of a majority voting interest. Investments in less-than-wholly-owned consolidated subsidiaries of QHC are presented separately in the equity component of the Company’s consolidated balance sheets to distinguish between the interests of QHC and the interests of the noncontrolling investors. Revenues and expenses from these subsidiaries are included in the respective individual line items of the Company’s consolidated and combined statements of income, and net income is presented both in total and separately to distinguish the amounts attributable to the Company and the amounts attributable to the interests of the noncontrolling investors. Noncontrolling interests that are redeemable, or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company, are presented in mezzanine equity in the consolidated balance sheets. Intercompany transactions and accounts of the Company are eliminated in consolidation. Additionally, all significant transactions with CHS that occurred prior to the Spin-off have been included in the consolidated balance sheets within Due to Parent, net. This liability to CHS was settled in the Spin-off.
Use of Estimates (Policies)	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated and combined financial statements and accompanying notes. Actual results could differ from those estimates under different assumptions or conditions.
Reclassifications and Immaterial Restatements (Policies)	Reclassifications and Immaterial Restatements Certain revisions have been made to the prior period balances as follows: Beginning in 2017, the Company has reclassified and separately presented on the consolidated and combined statements of cash flows the borrowings and repayments of the revolving credit facilities. Both items are included in cash flows from financing activities. This restatement of the consolidated and combined statement of cash flows as of December 31, 2016 was considered immaterial and had no effect on the Company’s results of operations or financial position as of December 31, 2016. Beginning in 2017, the Company reclassified and separately presented in the notes to the consolidated and combined financial statements the components of deferred income tax assets and liabilities based on their type of asset and liability. Previously, deferred tax assets and liabilities were classified as either other current or other long-term assets or liabilities. The Company believes the current presentation helps distinguish the types of deferred tax assets and liabilities.
Revenue Recognition (Policies)	Revenue Recognition The Company recognizes revenues from patient services at its hospitals and affiliated facilities in the period services are performed and reports these revenues at the net realizable amount expected to be collected from patients and third-party payors. Billings and collections are outsourced to CHS under the transition services agreements that were entered into by CHS in connection with the Spin-off. See Note 18 — Related Party Transactions for additional information on these agreements. The amounts that are collected for patient services are generally less than established billing rates, or standard billing charges, due to contractual agreements with third-party payors, governmental programs that require reduced billing rates, discounts offered as incentives for payment, and a portion related to bad debts. The Company recognizes revenues related to its QHR business when management advisory and consulting services are provided and reports these revenues at the net realizable amount expected to be collected from the non-affiliated hospital clients of the Company’s QHR business. During the fourth quarter of 2017, the Company analyzed self-pay patient accounts receivable at a more comprehensive and disaggregated level and refined its estimate of the collectability of the portion of self-pay accounts receivable related to insured patients, primarily co-pays and deductibles. The Company’s analysis also included an evaluation of patient accounts receivable retained in the divestitures of six of the Company’s seven divested hospitals. As a result of these efforts, the Company recorded a change in estimate of $21.0 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the consolidated and combined statement of income for the year ended December 31, 2017. As of December 31, 2016, the Company recorded a change in estimate of $11.4 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the statement of income for the year ended December 31, 2016. This change in estimate related to an assessment of the collectability of managed care and commercial accounts receivable aged greater than one year based on the Company’s review of historical cash collections for these accounts. Payor Sources The primary sources of payment for patient healthcare services are third-party payors, including federal and state agencies administering the Medicare and Medicaid programs, other governmental agencies, managed care health plans, commercial insurance companies, workers’ compensation carriers and employers. Self-pay revenues are the portion of patient service revenues derived from patients who do not have health insurance coverage and the patient responsibility portion of services that are not covered by health insurance plans. Non-patient revenues primarily include revenues from QHR’s hospital management advisory and consulting services business, rental income and hospital cafeteria sales. The table above includes an $11.4 million change in estimate the Company recorded as of December 31, 2016 to reduce the net realizable value of patient accounts receivable due to increasing delays associated with collections on accounts receivable under the Illinois Medicaid program. This change in estimate impacted contractual allowances associated with Medicaid revenues. For the years ended December 31, 2017, 2016 and 2015, Medicare revenues related to Medicare Advantage Programs were $186.7 million, $170.4 million and $146.9 million, respectively. Contractual Allowances and Discounts The net realizable amount of patient service revenues due from third-party payors is subject to complexities and interpretations of payor-specific contractual agreements and governmental regulations that are frequently changing. The Medicare and Medicaid programs, which represent a large portion of the Company’s operating revenues, are highly complex programs to administer and are subject to interpretation of federal and state-specific reimbursement rates, new legislation and final cost report settlements. Contractual allowances, or differences in standard billing rates and the payments derived from contractual terms with governmental and non-governmental third-party payors, are recorded based on management’s best estimates in the period in which services are performed and a payment methodology is established with the patient. Recorded estimates for past contractual allowances are subject to change, in large part, due to ongoing contract negotiations and regulation changes, which are typical in the U.S. healthcare industry. Revisions to estimates are recorded as contractual allowance adjustments in the periods in which they become known and may be subject to further revisions. Billing and collections are outsourced to CHS under the transition services agreements that were put in place by CHS in connection with the Spin-off. The Company’s contractual allowances are impacted by the timing and ability of CHS to monitor the classification and collection of our patient accounts receivable. Self-pay and other payor discounts are incentives offered to uninsured or underinsured payors to reduce their costs of healthcare services. Third-Party Program Reimbursements Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans are estimated and recorded in the period the related services are performed and are adjusted in future periods, as needed, until the final cost report settlements are determined. ontractual allowance adjustments related to previous program reimbursements and final cost report settlements favorably (unfavorably) impacted net operating revenues by $2.0 million, $(5.8) million and $(15.1) million, respectively. Currently, several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of federal and state resources, including, in certain instances, taxes, fees or other program expenses (collectively, “provider taxes”) levied on the providers. The receivables and payables associated with these programs are included in due from and due to third-party payors in the consolidated balance sheets. After a state supplemental payment program is approved and fully authorized by the appropriate state legislative or governmental agency, the Company recognizes the revenues and related expenses based on the terms of each program in the period in which amounts are estimable and revenue collection is reasonably assured. The revenues earned by the Company under these programs are included in net operating revenues and the expenses associated with these programs are included in other operating expenses in the consolidated and combined statements of income. The California Department of Health Care Services implemented the HQAF Program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California’s Medi-Cal and uninsured patients. Under Phase IV of the program, covering the period from January 2014 through December 2016, and Phase V of the program, covering the period from January 2017 through June 2019, the Company recognized $22.0 million, $34.4 million and $31.5 million of operating revenues, net of provider taxes, for the years ended December 31, 2017, 2016 and 2015, respectively. Charity Care In the ordinary course of business, the Company provides services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the poverty level guidelines established by the federal government. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at the standard billing rates and fully offset in contractual allowances. The Company’s gross amounts of charity care revenues were $34.0 million, $34.6 million and $30.4 million for the years ended December 31, 2017, 2016 and 2015, respectively. The Company estimates the cost of providing charity care services utilizing a ratio of cost to gross charges and applying this ratio to the gross charges associated with providing care to charity patients for the period. The estimated costs of providing charity care services was $5.6 million, $5.7 million and $5.0 million for the years ended December 31, 2017, 2106 and 2015, respectively. To the extent the Company receives reimbursement from any of the various governmental assistance programs to subsidize its care of indigent patients, the Company excludes the charges for such patients from the cost of care provided under its charity care program.
Accounts Receivable and Allowance for Doubtful Accounts (Policies)	Accounts Receivable and Allowance for Doubtful Accounts Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated outpatient facilities. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. Receivables from third-parties include the non-self-pay receivables due to the Company from providers of governmental and non-governmental programs and plans. For insured receivables, the Company estimates the allowance for doubtful accounts based on a model that considers the uncontractualized portion of all accounts aging over 365 days from the date of patient discharge, reduced by an estimate of recoveries. For self-pay receivables, the Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category. The allowance percentage is based on a model that considers historical write-off activity and is adjusted for expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the allowance for doubtful accounts is not significantly impacted by the aging of accounts receivable, as management believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. Collections are impacted by the economic ability of patients to pay, the effectiveness of CHS’ billing and collection efforts, including their current policies on collections, and the ability of the Company to further attempt collection efforts. Billings and collections are outsourced to CHS under the transition services agreements that were established with the Spin-off. See Note 18 — Related Party Transactions for additional information on these agreements. Significant changes in payor mix, CHS’s business office operations, including the CHS shared services centers’ efforts in collecting the Company’s accounts receivables, economic conditions, or trends in federal and state governmental healthcare coverage, among others, could affect the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall allowance adequacy by monitoring historical cash collections as a percentage of trailing net operating revenues after the provision for bad debts, as well as by analyzing current period net operating revenues and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, and the impact of recent divestitures. During the fourth quarter of 2017, the Company analyzed self-pay patient accounts receivable at a more comprehensive and disaggregated level and refined its estimate of the collectability of the portion of self-pay accounts receivable related to insured patients, primarily co-payments and deductibles. The Company’s analysis also included an evaluation of patient accounts receivable retained in the divestitures of six of the Company’s seven divested hospitals. As a result of these efforts, the Company recorded a change in estimate of $21.0 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the consolidated and combined statement of income for the year ended December 31, 2017. As of December 31, 2016, the Company recorded a change in estimate of $11.4 million to reduce the net realizable value of patient accounts receivable, which negatively impacted the provision for bad debts in the consolidated and combined statement of income for the year ended December 31, 2016. This change in estimate related to the Company’s assessment of the collectability of managed care and commercial accounts receivable aged greater than one year based on the Company’s review of historical cash collections for these accounts.
Concentration of Credit Risk (Policies)	Concentration of Credit Risk The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s hospitals and affiliated facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s markets and non-governmental third-party payors, Medicare receivables are a significant concentration of credit risk. Accounts receivable, net of contractual allowances, from Medicare were $70.4 million and $72.6 million, or 10.0% and 9.8% of total patient accounts receivable, net as of December 31, 2017 and 2016, respectively. Additionally, the Company believes Illinois Medicaid represents a concentration of credit risk to the Company due to the fiscal problems in the state of Illinois that affect the timing and extent of payments due to providers which are administered by the state of Illinois under the Medicaid program. The Company’s accounts receivable, net of contractual allowances, from Illinois Medicaid were $29.6 million and $34.8 million, or 4.2% and 4.7% of total patient accounts receivable, net as of December 31, 2017 and 2016, respectively. The Company’s state supplemental program receivables from Illinois Medicaid were $22.9 million and $16.6 million, or 23.5% and 14.3% of total due from third-party payors, as of December 31, 2017 and 2016, respectively. The Company’s state supplemental program receivables from California Medicaid were $48.4 million and $66.2 million, or 49.8% and 57.0% of total due from third-party payors, as of December 31, 2017 and 2016, respectively. The Company’s revenues are particularly sensitive to regulatory and economic changes in certain states where the Company generates significant revenues. Accordingly, any changes in the current demographic, economic, competitive or regulatory conditions in certain states in which revenues are significant could have an adverse effect on the Company’s results of operations, financial condition or cash flows. Changes to the Medicaid and other government-managed payor programs in these states, including reductions in reimbursement rates or delays in reimbursement payments under state supplemental payment or other programs, could also have a similar adverse effect.
Other Operating Expenses (Policies)	Other Operating Expenses Following the Spin-off, the Company began recording costs associated with the transition services agreements and other ancillary agreements with CHS in accordance with the terms of these agreements. These costs, which primarily include the costs of providing information technology, patient billing and collections and payroll services, are included in “Transition services agreements and allocations from Parent” in the table above. Amounts allocated to the Company by CHS for periods prior to the Spin-off are also included in “Transition services agreements and allocations from Parent” in the table above. Prior to the Spin-off, QHC recorded a monthly corporate management fee from CHS that represented a portion of CHS’ corporate office costs, and this fee was included in other operating expenses. Following the Spin-off, the costs for corporate office functions are primarily included in salaries and benefits expenses in the consolidated and combined statements of income. See Note 18 — Related Party Transactions for additional information on the allocated costs from CHS.
General and Administrative Costs (Policies)	General and Administrative Costs Substantially all of the Company’s operating costs and expenses are “cost of revenues” items. Operating expenses that could be classified as general and administrative by the Company are costs related to corporate office functions, including, but not limited to tax, treasury, audit, risk management, legal, investor relations and human resources. These costs are primarily salaries and benefits expenses associated with these corporate office functions. General and administrative costs of the Company were $52.7 million, $55.2 million and $43.5 million during the years ended December 31, 2017, 2016 and 2015, respectively. Prior to the Spin-off, the majority of these costs were allocations from CHS. See Note 18 — Related Party Transactions for additional information on the allocated costs from CHS.
Electronic Health Records Incentives Earned (Policies)	Electronic Health Records Incentives Earned Pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”) and other laws, HHS has established Medicare and Medicaid incentive programs to encourage adoption of Electronic Health Records (“EHR”) technology. The Company is eligible to receive incentive payments under these programs for its eligible hospitals and physician clinics that demonstrate meaningful use of certified EHR technology. EHR incentive payments paid to the Company are subject to audit and potential recoupment if it is determined that the applicable meaningful use standards were not met. EHR incentive payments are also subject to retrospective adjustment because the cost report data upon which the incentive payments are based are further subject to audit. The Company utilizes a gain contingency model to recognize EHR incentive payments. When the recognition criteria have been fully met, the Company recognizes the income from EHR incentives payments as a part of operating costs and expenses in the consolidated and combined statements of income. Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals demonstrate meaningful use of certified EHR technology. Medicare EHR incentive payments are calculated when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year used to determine the final incentive payment is available. In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the income from EHR incentive payments is deferred until all recognition criteria are met. The Company recognizes r eceivables for EHR incentive payments that have been earned, but are uncollected at period end, as other current assets in the consolidated balance sheets. The receivables are adjusted for any known audit or retrospective adjustments related to prior periods. Deferred revenue from EHR incentive payments is recorded in other current liabilities in the consolidated balance sheets. The Company incurs both capital expenditures and operating expenses in connection with the implementation of EHR technology initiatives. The amounts and timing of these expenditures does not directly correlate with the timing of the Company’s receipt or recognition of EHR incentive payments as earned. As the Company completes its full implementation of certified EHR technology in accordance with all three phases of the program, its EHR incentive payments will decline and ultimately end.
Legal, Professional and Settlement Costs (Policies)	Legal, Professional and Settlement Costs Legal, professional and settlement costs in the consolidated and combined statements of income primarily include legal costs and related settlements, if any, associated with regulatory claims, government investigations into reimbursement payments, claims associated with QHR’s hospital management contracts and professional costs of projects approved by the Company’s Board of Directors (the “Board”).
Loss (Gain) on Sale of Hospitals, Net (Policies)	Loss (Gain) on Sale of Hospitals, Net Loss (gain) on sale of hospitals, net is the loss (gain) incurred by the Company’s divestiture of hospitals and their related outpatient facilities. It is calculated as the difference between the cash proceeds from the sale and the carrying values of the associated net assets sold at the date of sale, less certain incremental direct selling costs.
Transaction Costs Related to the Spin-off (Policies)	Transaction Costs Related to the Spin-off Transaction costs related to the Spin-off consists of QHC’s portion of the costs to effect the Spin-off and the costs associated with forming a new company. These costs include audit, management advisory and consulting costs, investment advisory costs, legal expenses and other miscellaneous costs.
Income Taxes (Policies)	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the provision for (benefit from) income taxes in the consolidated and combined statements of income in the period that includes the enactment date. The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income. To the extent the Company believes that recovery is not likely, a valuation allowance is established. To the extent the Company establishes a valuation allowance or increases this allowance, the related expense is included in the provision for (benefit from) income taxes in the consolidated and combined statements of income. The Company classifies interest and penalties, if any, related to its tax positions as a component of provision for (benefit from) income taxes. See Note 12 — Income Taxes for information on the separate return method of accounting for income taxes that was used by the Company during the carve-out period.
Comprehensive Income (Loss) (Policies)	Comprehensive Income (Loss) The Company’s other comprehensive income (loss) consists of pension costs related to the Company’s defined benefit pension plan at one of its hospitals and the Company’s supplemental employee retirement plan.
Cash and Cash Equivalents (Policies)	Cash and Cash Equivalents Cash includes cash on hand and cash with banks. Cash equivalents are short-term, highly liquid investments with a maturity of three months or less from the date acquired that are subject to an insignificant risk of change in value.
Inventories (Policies)	Inventories Inventories, primarily consisting of medical supplies and drugs, are stated at the lower of cost or market on a first-in, first-out basis.
Property and Equipment (Policies)	Property and Equipment Purchases of property and equipment are recorded at cost. Property and equipment acquired in a business combination are recorded at estimated fair value. Routine maintenance and repairs are expensed as incurred. Expenditures that increase capacities or extend useful lives are capitalized. The Company capitalizes interest related to financing of major capital additions with the respective asset. Depreciation is recognized using the straight-line method over the estimated useful life of an asset. The Company depreciates land improvements over 3 to 20 years, buildings and improvements over 5 to 40 years, and equipment and fixtures over 3 to 18 years. The Company also leases certain facilities and equipment under capital lease obligations. These assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the asset. Property and equipment assets that are held for sale are not depreciated.
Goodwill (Policies)	Goodwill The Company’s hospital operations and QHR’s management advisory and healthcare consulting services operations meet the criteria for classification as separate reporting units for goodwill. Goodwill was initially determined for QHC’s hospital operations reporting unit based on a relative fair value approach as of September 30, 2013 (CHS’ goodwill impairment testing date). Additional goodwill was allocated on a similar basis for four hospitals acquired by CHS in 2014 that were included in the group of hospitals spun-off to QHC. For the QHR reporting unit, goodwill was allocated based on the amount recorded by CHS at the time of its acquisition in 2007. All subsequent goodwill generated from hospital, physician practice or other ancillary business acquisitions is recorded at fair value at the time of acquisition.
Intangible Assets (Policies)	Intangible Assets The Company’s intangible assets primarily consist of purchase and development costs of software for internal use and contract-based intangible assets, including physician guarantee contracts, medical licenses, hospital management contracts, non-compete agreements and certificates of need. There are no expected residual values related to the Company’s intangible assets. Capitalized software costs are generally amortized over three years, except for software costs for significant system conversions, which are amortized over 8 to 10 years. Costs incurred to renew certain contract-based intangibles, such as hospital management contracts and certificates of need, are recognized as intangible assets and amortized over the respective renewal contract periods. Capitalized software costs that are in the development stage are not amortized until the related projects are complete. Assets related to physician guarantee contracts, hospital management contracts, non-compete agreements and certificates of need are amortized over the life of the individual contracts. Intangible assets held for sale are not amortized.
Impairment of Long-Lived Assets and Goodwill (Policies)	Impairment of Long-Lived Assets and Goodwill Whenever an event occurs or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, the Company projects the undiscounted cash flows expected to be generated by these assets. If the projections indicate that the carrying values are not expected to be recovered, such amounts are reduced to their estimated fair value based on a quoted market price, if available, or an estimated fair value based on valuation techniques available in the circumstances. Goodwill arising from business combinations is not amortized. Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying value, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performs its annual testing for impairment of goodwill in the fourth quarter of each year. The fair value of the Company’s reporting units is estimated using both a discounted cash flow model as well as a multiple model based on earnings before interest, taxes, depreciation and amortization. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s best estimate of a market participant’s weighted-average cost of capital. Both models are based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions of the Company. See Note 3 — Impairment of Long-Lived Assets and Goodwill for additional information related to impairment recorded in the consolidated and combined statements of income for the years ended December 31, 2017, 2016 and 2015.
Professional and General Liability and Workers’ Compensation Liability Insurance Reserves (Policies)	Professional and General Liability and Workers’ Compensation Liability Insurance Reserves As part of the business of owning and operating hospitals, the Company is subject to legal actions alleging liability on its part. To mitigate a portion of these risks, the Company maintains insurance exceeding a self-insured retention level for these types of claims. The Company’s self-insurance reserves reflect the current estimate of all outstanding losses, including incurred but not reported losses, based on actuarial calculations as of period end. The loss estimates included in the actuarial calculations may change in the future based on updated facts and circumstances. The Company’s insurance expense includes the actuarially determined estimates of losses for the current year, including claims incurred but not reported, the change in the estimates of losses for prior years based upon actual claims development experience as compared to prior actuarial projections, the insurance premiums for losses in excess of the Company’s self-insured retention levels, the administrative costs of the insurance programs, and interest expense related to the discounted portion of the liability. The Company’s reserves for professional and general liability and workers’ compensation liability claims are based on semi-annual actuarial calculations, which are discounted to present value and consider historical claims data, demographic factors, severity factors and other actuarial assumptions. The reserves for self-insured claims are discounted based on the Company’s risk-free interest rate that corresponds to the period when the self-insured claims are incurred and projected to be paid. See Note 19 — Commitments and Contingencies for information related to the portion of the Company’s insurance reserves for professional and general liability and workers’ compensation liability and that are indemnified by CHS and the related accounting treatment and presentation in the consolidated and combined financial statements. Self-Insured Employee Health Benefits The Company is self-insured for substantially all of the medical benefits of its employees. The Company maintains a liability for its current estimate of incurred but not reported employee health claims based on historical claims data provided by third-party administrators. The undiscounted reserve for self-insured employee health benefits was $8.8 million and $11.0 million as of December 31, 2017 and 2016, respectively, and is included in accrued salaries and benefits in the consolidated balance sheets. Expense each period is based on the actual claims received during the period plus the impact of any adjustment to the liability for incurred but not reported employee health claims. Prior to the Spin-off, QHC was allocated employee health benefit expense as part of the monthly corporate overhead charges allocated from CHS. The allocation was determined by CHS based on claims made by QHC employees during the period plus an estimate for the change in liability related to QHC employee health claims incurred but not reported. The liability was included in Due to Parent, net in the consolidated balance sheets, as the related employee health insurance policy was owned by CHS. Employee health benefit expense is included in salaries and benefits expenses in the consolidated and combined statements of income for all periods. See Note 18 — Related Party Transactions for additional information on corporate overhead costs allocated from CHS prior to the Spin-off.
Debt Issuance Costs and Discounts (Policies)	Debt Issuance Costs and Discounts The Company recognizes debt issuance costs as a reduction to the related debt liability on the consolidated balance sheet, consistent with the accounting treatment for debt discounts. Amortization of debt issuance costs and debt discounts are each recorded as non-cash interest expense over the life of the respective debt instrument.
Due to Parent, Net (Policies)	Due to Parent, Net Prior to the Spin-off, Due to Parent, net in the consolidated balance sheets represented the Company’s liability to CHS for the accumulation of (1) CHS’ historical investment in QHC, (2) liabilities related to the cost allocations from CHS to QHC, (3) interest charged by CHS on the monthly outstanding Due to Parent, net balance, (4) the net effect of transactions between CHS and QHC, and (5) the net effect of cash transfers from QHC to CHS under CHS’ centralized cash management program. In connection with the Spin-off, certain liabilities were transferred through Due to Parent, net to the Company, pursuant to the Separation and Distribution Agreement, and the remaining balance was settled with cash and in the form of a non-cash capital contribution to the Company. See Note 1 — Description of the Business and Spin-off and Note 18 — Related Party Transactions for additional information on the Spin-off and related party transactions with CHS.
Redeemable and Non-Redeemable Noncontrolling Interests (Policies)	Redeemable and Non-Redeemable Noncontrolling Interests The Company’s consolidated and combined financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that it controls. Certain of the Company’s consolidated subsidiaries have noncontrolling physician ownership interests with redemption features that require the Company to deliver cash upon the occurrence of certain events outside its control, such as the retirement, death, or disability of a physician-owner. The carrying amount of redeemable noncontrolling interests is recognized in the Company’s consolidated balance sheets at the greater of: (1) the initial carrying amount of these investments, increased or decreased for the noncontrolling interests' share of cumulative net income (loss), net of cumulative amounts distributed to the noncontrolling interest partners, if any, or (2) the redemption value of the investments held by the noncontrolling interest partners.
Assets and Liabilities of Hospitals Held for Sale (Policies)	Assets and Liabilities of Hospitals Held for Sale The Company reports separately from other assets in the consolidated balance sheets those assets that meet the criteria for classification as held for sale. Generally, assets that meet the criteria include those for which the carrying amount will be settled principally through a sale transaction rather than through continuing use. The asset must be available for immediate sale in its present condition, subject to usual or customary terms, and the sale must be probable to occur in the next 12 months. Similarly, the liabilities of a disposal group are classified as held for sale upon meeting these criteria. Immediately following classification as held for sale, the Company remeasures these assets and liabilities and adjusts the value to the lesser of the carrying amount or fair value less costs to sell. The assets and liabilities classified as held for sale are no longer depreciated or amortized into expense. The carrying values of assets classified as held for sale are reported net of impairment in the consolidated balance sheets. See Note 3 — Impairment of Long-Lived Assets and Goodwill for additional information on impairment recorded during the years ended December 31, 2017, 2016 and 2015.
Stock-Based Compensation (Policies)	Stock-Based Compensation In connection with the Spin-off, the Company issued QHC restricted stock awards to all CHS restricted stock award holders as of the Record Date. Each holder of CHS restricted stock awards received one QHC restricted stock award for every four CHS restricted stock awards held. In addition, QHC employees that held CHS restricted stock awards were allowed to continue to hold the CHS awards under the same terms and conditions that existed prior to the Spin-off, excluding certain shares granted on March 1, 2016 that were canceled in connection with the Spin-off. The unrecognized compensation expense related to the vesting of the CHS restricted stock awards held by QHC employees was transferred to QHC with the Spin-off. As a result, the Company is responsible for recording stock-based compensation expense attributable to the unvested portion of CHS restricted stock awards held by QHC employees and the unvested portion of all QHC restricted stock awards held by its employees, consisting of both QHC awards issued on the Record Date and additional awards granted under the Quorum Health Corporation 2016 Stock Award Plan (the “2016 Stock Award Plan”) following the Spin-off. See Note 16 — Stock-Based Compensation for additional information related to stock-based compensation.
Benefit Plans (Policies)	Benefit Plans The Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and a deferred compensation plan, for which certain of the Company’s subsidiaries are the plan sponsors. The rights and obligations of these plans were transferred from CHS to the Company, pursuant to the Separation and Distribution Agreement. Prior to the Spin-off, QHC was allocated a portion of CHS’ benefit costs under its defined contribution plans. The allocation was based on specific identification for plans associated exclusively with QHC hospitals and on QHC’s proportional share of employees covered under all other applicable plans. Benefits costs are recorded as salaries and benefits in the consolidated and combined statements of income for prior to and subsequent to the Spin-off. The cumulative liability for these benefit costs, which were transferred to the Company in connection with the Spin-off, is recorded in other long-term liabilities on the consolidated balance sheets. Prior to the Spin-off the cumulative liability was recorded in Due to Parent, net in the consolidated balance sheets. QHC recognizes the unfunded liability of its defined benefit plan in other long-term liabilities in the consolidated balance sheets. Unrecognized gains (losses) and prior service credits (costs) are recorded as changes in other comprehensive income (loss). The measurement date of the plan’s assets and liabilities coincides with the Company’s year end. The Company’s pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases and expected long-term returns on plan assets. The calculations additionally consider expectations related to the retirement age and mortality of plan participants. The Company records pension benefit costs related to all of its plans as salaries and benefits expenses in the consolidated and combined statements of income. See Note 17 — Benefit Plans for additional information on the Company’s individual plans.
Fair Value of Financial Instruments (Policies)	Fair Value of Financial Instruments The Company utilizes the U.S. GAAP fair value hierarchy to measure the fair value of its financial instruments. The fair value hierarchy distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumption about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy). The inputs used to measure fair value are classified into the following fair value hierarchy: • Level 1 • Level 2 • Level 3
Segment Reporting (Policies)	Segment Reporting The principal business of the Company is to provide healthcare services at its hospitals and outpatient service facilities. The Company’s only other line of business is the hospital management advisory and consulting services it provides through QHR. The Company has determined that its hospital operations business and for QHR’s business meets the criteria for separate segment reporting. The Company’s corporate functions have been reported in the all other reportable segment. See Note 15 — Segments.
New Accounting Pronouncements (Policies)	New Accounting Pronouncements In January 2017, the FASB issued ASU No. 2017-04, Intangibles — In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation, In February 2016, the FASB issued ASU No. 2016-02, Leases, which amends the accounting for leases and requires the rights and obligations arising from lease contracts, including existing and new arrangements, to be recognized as assets and labilities on the balance sheet. Recognition of these assets and liabilities will have a material impact to the Company’s consolidated balance sheets upon adoption Under ASU 2016-02, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach, which includes a number of optional practical expedients. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which provides for a single comprehensive principles-based model for the recognition of revenue across all industries using a five-step model to recognize revenue from customer contracts. The new standard significantly expands disclosures about the nature, amount, timing, and uncertainty of revenues and cash flows, as well as certain additional quantitative and qualitative disclosures. The standard is effective for fiscal years beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016, and permits the use of either a full or modified retrospective approach upon adoption. The Company adopted this ASU on January 1, 2018 using the modified retrospective approach and during the fourth quarter of 2017 completed its evaluation of the resulting impact on its consolidated results of operations, financial position and cash flows. A significant portion of the adoption of this ASU was the process of evaluating the characteristics of patient accounts receivable portfolios to ensure that when evaluated under the new standard it would result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. A component of this evaluation was the estimation of what portion of an insured patient’s account will ultimately be due from the patient as a co-payment or deductible and of that amount what will ultimately be collectible. The Company updated its processes to accommodate this estimate and has recorded a change in estimate to increase the Company’s allowance for doubtful accounts at December 31, 2017, which is further discussed above with respect to the Company’s accounting policies on accounts receivable and allowance for doubtful accounts. The Company completed its evaluation of the impact on its results of operations as of the fourth quarter 2017 and the Company does not expect the adoption of this ASU to have a material impact on its consolidated results of operations on a prospective basis, other than the impact of the presentation of the income statement, as the provision for bad debts will be recorded as a direct reduction to revenues and will not be presented as a separate line item.
Legal Matters (Policies)	With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated amount of loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the amount of possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the amount of possible loss or range of loss. However, the Company is unable to estimate an amount of possible loss or range of loss in some instances based on the significant uncertainties involved in, or the preliminary nature of, certain legal, regulatory and governmental matters
Guarantor and Non Guarantor Supplemental Information (Policies)	The condensed consolidating and combining financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The accounting policies used in the preparation of this financial information are consistent with those elsewhere in these consolidated and combined financial statements of the Company, except as noted below: • Intercompany receivables and payables are presented gross in the supplemental condensed consolidating balance sheets. • Due to Parent and Due from Parent are presented gross in the supplemental condensed consolidating balance sheets. • Investments in consolidated subsidiaries, as well as guarantor subsidiaries’ investments in non-guarantor subsidiaries, are presented under the equity method of accounting with the related investments presented within the line items net investment in subsidiaries and other long-term liabilities in the supplemental condensed consolidating balance sheets. • The provision for (benefit from) income taxes is allocated from the parent issuer to the income producing operations (other guarantors and non-guarantors) through stockholders’ equity. As this approach represents an allocation, the provision for (benefit from) income tax allocation is considered non-cash for statement of cash flow purposes.

Description of the Business a31

Description of the Business and the Spin-Off (Tables)	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Transactions to Effect the Spin-Off	The following table provides a summary of the major transactions to effect the Spin-off of QHC as a newly formed, independent company (dollars in thousands): Additional Long-Term Due to Common Stock Paid-in Parent's Debt Parent, Net Shares Amount Capital Equity Balances at April 29, 2016 (prior to the Spin-off) $ 24,179 $ 1,813,836 — $ — $ — $ 3,137 Borrowings of long-term debt, net of debt issuance discounts 1,255,464 — — — — — Payments of debt issuance costs (29,146 ) — — — — — Cash proceeds paid to Parent — (1,217,336 ) — — — — Transfer of liabilities from Parent — (22,292 ) — — — — Net deferred income tax liability resulting from the Spin-off — (46,783 ) — — — — Non-cash capital contribution from Parent — (527,425 ) — — 530,562 (3,137 ) Distribution of common stock — — 27,719,645 3 (3 ) — Distribution of restricted stock awards — — 692,409 — — — Balances at April 29, 2016 (after the Spin-off) $ 1,250,497 $ — 28,412,054 $ 3 $ 530,559 $ —

Basis of Presentation and Sig32

Basis of Presentation and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Summary of Components of Net Operating Revenues Before Provision for Bad Debts	The following table provides a summary of the components of net operating revenues, before the provision for bad debts (in thousands): Year Ended December 31, 2017 2016 2015 Operating revenues $ 11,930,145 $ 12,104,580 $ 11,613,826 Less: Contractual allowances (9,173,711 ) (9,247,789 ) (8,795,674 ) Less: Discounts (428,779 ) (437,738 ) (372,294 ) Total net operating revenues, before the provision for bad debts $ 2,327,655 $ 2,419,053 $ 2,445,858
Summary of Net Operating Revenues, Before the Provision for Bad Debts, by Payor Source	The following table provides a summary of net operating revenues, before the provision for bad debts, by payor source (dollars in thousands): Year Ended December 31, 2017 2016 2015 $ Amount % of Total $ Amount % of Total $ Amount % of Total Medicare $ 656,843 28.2 % $ 673,074 27.8 % $ 656,799 26.9 % Medicaid 425,943 18.3 % 446,273 18.4 % 443,479 18.1 % Managed care and commercial plans 921,503 39.6 % 952,535 39.4 % 984,480 40.3 % Self-pay 226,043 9.7 % 242,095 10.1 % 247,234 10.0 % Non-patient 97,323 4.2 % 105,076 4.3 % 113,866 4.7 % Total net operating revenues, before the provision for bad debts $ 2,327,655 100.0 % $ 2,419,053 100.0 % $ 2,445,858 100.0 %
Summary of Components of Amounts Due from and Due to Third-Party Payors	The following table provides a summary of the components of amounts due from and due to third-party payors, as presented in the consolidated balance sheets (in thousands): December 31, 2017 2016 Amounts due from third-party payors: Previous program reimbursements and final cost report settlements $ 17,383 $ 23,876 State supplemental payment programs 79,819 92,359 Total amounts due from third-party payors $ 97,202 $ 116,235 Amounts due to third-party payors: Previous program reimbursements and final cost report settlements $ 33,163 $ 33,366 State supplemental payment programs 14,542 9,171 Total amounts due to third-party payors $ 47,705 $ 42,537
Summary of Portion of Medicaid Reimbursements Included in Statement of Income that are Attributable to State Supplemental Payment Programs	The following table provides a summary of the portion of Medicaid reimbursements included in the consolidated and combined statements of income that are attributable to state supplemental payment programs (in thousands): Year Ended December 31, 2017 2016 2015 Medicaid revenues $ 211,448 $ 220,389 $ 211,696 Provider taxes and other expenses 75,388 76,616 75,929 Reimbursements attributable to state supplemental payment programs, net of expenses $ 136,060 $ 143,773 $ 135,767
Summary of Components of Accounts Receivable Before Contractual Allowances Discounts and Allowance for Doubtful Accounts	The following table provides a summary of the components of patient accounts receivable before contractual allowances, discounts and allowance for doubtful accounts (dollars in thousands): December 31, 2017 2016 $ Amount % of Total $ Amount % of Total Third-parties $ 1,796,852 75.1 % $ 1,930,103 74.6 % Self-pay 596,863 24.9 % 656,373 25.4 % Total patient accounts receivable, gross $ 2,393,715 100.0 % $ 2,586,476 100.0 %
Summary of Changes in Allowance for Doubtful Accounts	The following table provides a summary of the changes in the allowance for doubtful accounts (in thousands): December 31, 2017 2016 2015 Balance at beginning of period $ 360,796 $ 346,507 $ 341,527 Provision for bad debts 255,485 280,586 258,520 Amounts written off, net of recoveries (263,772 ) (266,297 ) (253,540 ) Balance at end of period $ 352,509 $ 360,796 $ 346,507
Summary of States in Which Company Generates More Than 5% of its Total Revenues	The following table provides a summary of the states in which the Company generates more than 5% of total net patient revenues, before the provision for bad debts, as determined in each year (dollars in thousands): Number of Year Ended December 31, Hospitals at 2017 2016 2015 December 31, 2017 $ Amount % of Total $ Amount % of Total $ Amount % of Total Illinois 9 $ 829,473 37.2 % $ 811,565 35.1 % $ 822,501 35.3 % Oregon 1 218,653 9.8 % 210,818 9.1 % 201,610 8.6 % California 2 195,725 8.8 % 199,743 8.6 % 209,500 9.0 % Georgia 2 148,353 6.7 % 216,745 9.4 % 224,330 9.6 % Kentucky 3 124,317 5.6 % 121,988 5.3 % 131,077 5.6 %
Summary of Major Components of Other Operating Expenses	The following table provides a summary of the major components of other operating expenses (in thousands): Year Ended December 31, 2017 2016 2015 Purchased services $ 168,711 $ 180,672 $ 176,758 Taxes and insurance 131,734 129,775 124,635 Medical specialist fees 111,840 106,803 85,042 Transition services agreements and allocations from Parent 63,470 66,441 60,166 Repairs and maintenance 41,048 42,986 45,945 Utilities 27,324 29,833 29,856 Management fees from Parent — 11,792 36,466 Other miscellaneous operating expenses 78,936 77,500 75,365 Total other operating expenses $ 623,063 $ 645,802 $ 634,233
Summary of Activity Related to Electronic Health Records Incentives	The following table provides a summary of activity related to EHR incentives (in thousands): Year Ended December 31, 2017 2016 2015 Electronic health records incentives receivable at beginning of period $ 4,189 $ 11,227 $ 12,204 Electronic health records incentives earned 4,489 7,843 11,428 Cash incentive payments received (5,796 ) (13,808 ) (10,084 ) Adjustments to receivable based on final cost report settlement or audit (1,103 ) (1,073 ) (2,321 ) Electronic health records incentives receivable at end of period $ 1,779 $ 4,189 $ 11,227 Deferred revenue related to electronic health records incentives at beginning of period $ — $ — $ (14,351 ) Cash received and deferred during period (256 ) (3,639 ) — Recognition of deferred incentives as earned 256 3,639 14,351 Deferred revenue related to electronic health records incentives at end of period $ — $ — $ — Total electronic health records incentives earned during period $ 4,745 $ 11,482 $ 25,779 Total cash incentive payments received during period 6,052 17,447 10,084

Acquisitions and Divestitures (

Acquisitions and Divestitures (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Summary of Purchase Price Allocation	The following table provides a summary of the combined purchase price allocation by year for the Company’s acquisitions (in thousands): Year Ended December 31, 2017 2016 2015 Current assets $ 142 $ (343 ) $ 422 Property and equipment 695 851 3,190 Goodwill 1,211 129 6,788 Other long-term assets — — 564 Liabilities (128 ) 16 (1,229 ) Noncontrolling interests — 132 (1,716 ) Total consideration paid or allocated from CHS $ 1,920 $ 785 $ 8,019

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Summary of Components of Property and Equipment	The following table provides a summary of the components of property and equipment (in thousands): December 31, 2017 2016 Property and equipment, at cost: Land and improvements $ 70,731 $ 84,474 Building and improvements 790,619 782,892 Equipment and fixtures 529,150 592,463 Construction in progress 14,684 60,146 Total property and equipment, at cost 1,405,184 1,519,975 Less: Accumulated depreciation and amortization (729,905 ) (786,075 ) Total property and equipment, net $ 675,279 $ 733,900

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Changes in Goodwill	The following table provides a summary of the changes in goodwill (in thousands): December 31, 2017 2016 Balance at beginning of period $ 416,833 $ 541,704 Acquisitions 1,211 129 Divestitures (5,293 ) — Reclass to held for sale (1,593 ) — Impairment (1,929 ) (125,000 ) Balance at end of period $ 409,229 $ 416,833
Summary of the Components of Intangible Assets	The following table provides a summary of the components of intangible assets (in thousands): December 31, 2017 2016 Finite-lived intangible assets: Capitalized software costs: Cost $ 159,449 $ 180,855 Accumulated amortization (111,661 ) (118,391 ) Capitalized software costs, net 47,788 62,464 Physician guarantee contracts: Cost 7,489 11,355 Accumulated amortization (4,290 ) (6,329 ) Physician guarantee contracts, net 3,199 5,026 Other finite-lived intangible assets: Cost 43,376 44,342 Accumulated amortization (34,668 ) (33,059 ) Other finite-lived intangible assets, net 8,708 11,283 Total finite-lived intangible assets Cost 210,314 236,552 Accumulated amortization (150,618 ) (157,779 ) Total finite-lived intangible assets, net $ 59,696 $ 78,773 Indefinite-lived intangible assets: Tradenames $ 4,000 $ 4,000 Medical licenses and other indefinite-lived intangible assets 1,154 2,209 Total indefinite-lived intangible assets $ 5,154 $ 6,209 Total intangible assets: Cost $ 215,468 $ 242,761 Accumulated amortization (150,618 ) (157,779 ) Total intangible assets, net $ 64,850 $ 84,982
Summary of the Components of Amortization Expense	The following table provides a summary of the components of amortization expense (in thousands): Year Ended December 31, 2017 2016 2015 Amortization of finite-lived intangible assets: Capitalized software costs $ 15,879 $ 25,193 $ 27,317 Physician guarantee contracts 2,032 3,108 3,951 Other finite-lived intangible assets 2,594 2,866 3,334 Total amortization expense related to finite-lived intangible assets 20,505 31,167 34,602 Amortization of leasehold improvements and property and equipment assets held under capital lease obligations 3,038 3,111 2,496 Total amortization expense $ 23,543 $ 34,278 $ 37,098
Summary of Future Estimated Amortization Expense	The following table provides a summary of estimated future amortization expense for the next five years and thereafter related to intangible assets (in thousands): 2018 $ 18,898 2019 14,475 2020 11,791 2021 9,378 2022 3,900 Thereafter 1,254 Total estimated future amortization expense $ 59,696

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Summary of Components of Long-Term Debt	The following table provides a summary of the components of long-term debt (in thousands): December 31, 2017 2016 Senior Credit Facility: Revolving Credit Facility, maturing 2021 $ — $ — Term Loan Facility, maturing 2022 831,158 868,419 ABL Credit Facility, maturing 2021 — — Senior Notes, maturing 2023 400,000 400,000 Unamortized debt issuance costs and discounts (42,934 ) (48,764 ) Capital lease obligations 24,411 25,588 Other miscellaneous debt 1,255 1,582 Total debt 1,213,890 1,246,825 Less: Current maturities of long-term debt (1,855 ) (5,683 ) Total long-term debt $ 1,212,035 $ 1,241,142
Summary of Maximum Secured Net Leverage Ratio Permitted Under Credit Facility	After giving effect to the CS Amendment and the CS Second Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA, which is defined in the CS Agreement, follows: Maximum Secured Net Period Leverage Ratio Period from January 1, 2017 to June 30, 2017 4.50 to 1.00 Period from July 1, 2017 to June 30, 2018 4.75 to 1.00 Period from July 1, 2018 to December 31, 2019 5.00 to 1.00 Period from January 1, 2020 and thereafter 4.50 to 1.00
Summary of Redemption Dates and Prices of Senior Notes	The following table provides a summary of the redemption periods and prices related to the Senior Notes: Redemption Period Prices Period from April 15, 2019 to April 14, 2020 108.719 % Period from April 15, 2020 to April 14, 2021 105.813 % Period from April 15, 2021 to April 14, 2022 102.906 % Period from April 15, 2022 to April 14, 2023 100.000 %
Summary of Unamortized Debt Issuance Costs and Discounts	The following table provides a summary of unamortized debt issuance costs and discounts (in thousands): December 31, 2017 2016 Debt issuance costs $ 32,265 $ 29,146 Debt discounts 24,536 24,536 Total debt issuance costs and discounts at origination 56,801 53,682 Less: Amortization of debt issuance costs and discounts (13,867 ) (4,918 ) Total unamortized debt issuance costs and discounts $ 42,934 $ 48,764
Summary of Debt Maturities for Each of the Next Five Years and Thereafter	The following table provides a summary of debt maturities for each of the next five years and thereafter (in thousands): 2018 $ 1,855 2019 1,486 2020 1,517 2021 3,329 2022 830,796 Thereafter 417,841 Total debt, excluding unamortized debt issuance costs and discounts $ 1,256,824
Summary of Components of Interest Expense, Net	The following table provides a summary of the components of interest expense, net (in thousands): Year Ended December 31, 2017 2016 2015 Senior Credit Facility: Revolving Credit Facility $ 528 $ 330 $ — Term Loan Facility 66,111 40,719 — ABL Credit Facility 1,854 342 — Senior Notes 46,516 32,166 — Amortization of debt issuance costs and discounts 8,949 4,918 — All other interest expense (income), net (1,881 ) (849 ) 283 Total interest expense, net, from long-term debt 122,077 77,626 283 Due to Parent, net — 35,814 98,007 Total interest expense, net $ 122,077 $ 113,440 $ 98,290

Other Long-Term Assets and Ot37

Other Long-Term Assets and Other Long-Term Liabilities (Tables)	12 Months Ended
	Dec. 31, 2017
Other Noncurrent Assets And Other Noncurrent Liabilities Disclosure [Abstract]
Summary of Major Components of Other Long-Term Assets	The following table provides a summary of the major components of other long-term assets (in thousands): December 31, 2017 2016 Receivable for professional and general liability insurance reserves indemnified by CHS $ 44,377 $ 59,652 Receivable for workers' compensation liability insurance reserves indemnified by CHS 14,545 15,958 Assets of Nonqualified Deferred Compensation Plan 23,052 69 Other miscellaneous long-term assets 13,633 13,154 Total other long-term assets $ 95,607 $ 88,833
Summary of Components of Other Long-Term Liabilities	The following table provides a summary of the components of other long-term liabilities (in thousands): December 31, 2017 2016 Professional and general liability insurance reserves $ 76,993 $ 74,194 Workers' compensation liability insurance reserves 18,558 17,416 Benefit plan liabilities 36,103 10,722 Deferred rent 4,268 4,001 Other miscellaneous long-term liabilities 2,032 2,663 Total other long-term liabilities $ 137,954 $ 108,996

Fair Value of Financial Instr38

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Summary of Carrying Values and Estimated Fair Values of Long-Term Debt	The following table provides a summary of the carrying values and estimated fair values of the Company’s long-term debt (in thousands): December 31, 2017 2016 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Revolving Credit Facility $ — $ — $ — $ — Term Loan Facility 831,158 838,954 868,419 849,427 ABL Credit Facility — — — — Senior Notes 400,000 393,396 400,000 334,720 Other debt 25,666 25,666 27,170 27,170 Total long-term debt, excluding debt issuance costs and discounts $ 1,256,824 $ 1,258,016 $ 1,295,589 $ 1,211,317

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2017
Leases [Abstract]
Summary of Commitments Relating to Non-Cancellable Operating and Capital Leases	The following table provides a summary of the Company’s commitments relating to non-cancellable operating and capital leases for each of the next five years and thereafter (in thousands): Year Ending December 31, Operating (1) Capital 2018 $ 32,253 $ 2,531 2019 25,568 2,552 2020 19,673 2,590 2021 12,722 2,628 2022 8,294 2,332 Thereafter 17,236 20,707 Total minimum future payments obligations $ 115,746 33,340 Less: Imputed interest (8,929 ) Total capital lease obligations 24,411 Less: Current portion of capital lease obligations (1,140 ) Total long-term capital lease obligations $ 23,271 (1) Minimum lease payments obligations have not been reduced by minimum sublease rentals due in the future of $5.2 million.

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Summary of Components of Provision for (Benefit from) Income Taxes	The following table provides a summary of the components of the provision for (benefit from) income taxes (in thousands): Year Ended December 31, 2017 2016 2015 Current: Federal $ — $ — $ — State 271 530 762 Total provision for (benefit from) current income taxes 271 530 762 Deferred: Federal (22,540 ) (51,177 ) 1,749 State 404 (3,228 ) 793 Total provision for (benefit from) deferred income taxes (22,136 ) (54,405 ) 2,542 Total provision for (benefit from) income taxes $ (21,865 ) $ (53,875 ) $ 3,304
Schedule of Reconciliation of Provision for (Benefit from) Income Taxes Utilizing Statutory Federal Income Tax Rate to Effective Income Tax Rate	On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) was signed into law. The Tax Act includes a number of changes to existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate tax rate from 35% to 21% for tax years after December 31, 2017. As a direct result of changes in tax law due to the passage of the Tax Act, the Company recorded a total tax benefit of $24.0 million during 2017 which is composed of two amounts: a tax benefit of $10.9 million in deferred income tax expense for the net change in its deferred tax liabilities at the new 21% tax rate, and a $13.1 million tax benefit in deferred income tax expense for the reduction in valuation allowance attributable to the change in net realizability of deferred tax assets. The Tax Act also provides for acceleration of depreciation for certain assets placed into service after September 27, 2017, as well as prospective changes beginning in 2018. These prospective changes include an increased limitation on the deductibility of executive compensation, a limitation on the deductibility of interest expense, new rules surrounding meals and entertainment expense and fines and penalties. Also, while net operating losses generated in the future may by carried forward indefinitely under the new law, there is a limitation on the amount that may be used in any given year. The Tax Act may also have an impact on projected future taxable income that could further affect valuation allowance considerations. In addition to the federal law, the Company awaits guidance from the states in which it files on how components of the Tax Act may be treated in these jurisdictions. The $24.0 million tax benefit represents what the Company believes is the impact of the Tax Act, the key components being the re-measurement of deferred tax balances to the new corporate rate and reduction in valuation allowance as a result of anticipated realizability of deferred tax assets due to the change in tax law. As the benefit is based on currently available information and interpretations, which are continuing to evolve, the benefit should be considered provisional. The Company will continue to analyze additional information and guidance related to the Tax Act as supplemental legislation, regulatory federal or state guidance, or evolving technical interpretations become available. The final impacts may differ from the recorded amounts as of December 31, 2017, and the Company will continue to refine such amounts within the measurement period provided by Staff Accounting Bulletin No. 118. The Company expects to complete the analysis by the end of 2018. The following table reconciles the provision for (benefit from) income taxes utilizing the statutory federal income tax rate to the Company’s effective income tax rate (dollars in thousands): Year Ended December 31, 2017 2016 2015 Amount % Amount % Amount % Provision for (benefit from) income taxes at statutory federal tax rate $ (46,978 ) 35.0 % $ (139,685 ) 35.0 % $ 2,814 35.0 % State income taxes, net of federal income tax benefit (6,137 ) 4.6 % (47,749 ) 12.0 % (171 ) (2.1 )% Net (income) loss attributable to noncontrolling interests (641 ) 0.5 % (872 ) 0.2 % (1,189 ) (14.8 )% Non-deductible goodwill and Spin-off costs 535 (0.4 )% 36,009 (9.0 )% — — % Change in valuation allowance (pre Tax Act) 53,470 (39.8 )% 94,745 (23.7 )% 1,459 18.2 % Change in rate due to Tax Act (10,934 ) 8.1 % — — % — — % Change in valuation allowance due to Tax Act (13,121 ) 9.8 % — — % — — % All other items 1,941 (1.5 )% 3,677 (1.0 )% 391 4.8 % Total provision for (benefit from) income taxes and effective tax rate $ (21,865 ) 16.3 % $ (53,875 ) 13.5 % $ 3,304 41.1 %
Summary of Components of Deferred Income Tax Assets and Liabilities	The following table provides a summary of the components of deferred income tax assets and liabilities (in thousands): December 31, 2017 2016 Assets Liabilities Assets Liabilities Net operating loss and credit carryforwards $ 83,879 $ — $ 72,195 $ — Property and equipment 2,039 1,416 — 10,447 Prepaid expenses — 2,836 — 6,874 Goodwill and intangible assets — 18,544 — 27,193 Investments in unconsolidated affiliates 140 — 298 — Accounts receivable 4,928 — 1,532 10,290 Accrued compensation and recruiting accruals 8,743 828 14,968 965 Other accruals 175 — 251 — Deferred compensation 9,160 — 10,208 — Debt issuance costs — 7,756 — 53 Insurance and settlement reserves 31,322 — 39,112 — Total deferred income tax assets and liabilities, before valuation allowance 140,386 31,380 138,564 55,822 Valuation allowance (116,780 ) — (114,216 ) — Total deferred income tax assets and liabilities $ 23,606 $ 31,380 $ 24,348 $ 55,822 Total deferred income tax liabilities, net $ 7,774 $ 31,474

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Earnings (Loss) Per Share	The following table provides a summary of the computation of basic and diluted earnings (loss) per share (in thousands, except earnings per share and shares): Year Ended December 31, 2017 2016 2015 Numerator: Net income (loss) $ (112,357 ) $ (345,197 ) $ 4,735 Less: Net income (loss) attributable to noncontrolling interests 1,833 2,491 3,398 Net income (loss) attributable to Quorum Health Corporation $ (114,190 ) $ (347,688 ) $ 1,337 Denominator: Weighted-average shares outstanding - basic and diluted 28,113,566 28,413,247 28,412,054 Earnings (loss) per share attributable to Quorum Health Corporation stockholders - basic and diluted $ (4.06 ) $ (12.24 ) $ 0.05

Segments (Tables)

Segments (Tables)	12 Months Ended
	Dec. 31, 2017
Segment Reporting [Abstract]
Summary of Financial Information Related to Segments	The following tables provide a summary of financial information related to the Company’s reportable segments (in thousands): Year Ended December 31, 2017 2016 2015 Net operating revenues: Hospital operations $ 1,987,973 $ 2,052,751 $ 2,096,831 QHR operations 80,863 85,533 90,507 All other 3,334 183 — Total net operating revenues $ 2,072,170 $ 2,138,467 $ 2,187,338 Adjusted EBITDA: Hospital operations $ 175,597 $ 184,000 $ 249,375 QHR operations 20,599 16,980 14,246 All other (54,351 ) (38,058 ) 46 Total Adjusted EBITDA $ 141,845 $ 162,922 $ 263,667 December 31, 2017 2016 Assets: Hospital operations $ 1,687,576 $ 1,802,121 QHR operations 61,752 75,113 All other 79,513 117,136 Total assets $ 1,828,841 $ 1,994,370
Summary of Reconciliation of Adjusted EBITDA to Net Income (Loss)	The following table provides a reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable U.S. GAAP financial measure (in thousands): Year Ended December 31, 2017 2016 2015 Adjusted EBITDA $ 141,845 $ 162,922 $ 263,667 Interest expense, net (122,077 ) (113,440 ) (98,290 ) (Provision for) benefit from income taxes 21,865 53,875 (3,304 ) Depreciation and amortization (82,155 ) (117,288 ) (128,001 ) Legal, professional and settlement costs (6,001 ) (7,342 ) — Impairment of long-lived assets and goodwill (47,281 ) (291,870 ) (13,000 ) Loss (gain) on sale of hospitals, net 5,243 (2,150 ) — Transaction costs related to the Spin-off (253 ) (5,488 ) (16,337 ) Post-spin headcount reductions (2,543 ) (1,617 ) — Change in estimate related to collectability of patient accounts receivable (21,000 ) (22,799 ) — Net income (loss) $ (112,357 ) $ (345,197 ) $ 4,735

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Summary of Stock-Based Compensation Expense for Periods Subsequent to Spin-Off	The following table provides a summary of stock-based compensation expense for the periods subsequent to the Spin-off (in thousands): Year Ended December 31, 2017 2016 2015 Stock-based compensation resulting from the Spin-off $ 2,225 $ 3,089 $ — Stock-based compensation related to grants following the Spin-off 7,727 4,352 — Total stock-based compensation expense $ 9,952 $ 7,441 $ —
QHC Awards Distributed in Spin-off [Member]
Summary of Activity Related to Unvested Restricted Stock Awards	The following table provides a summary of the activity related to unvested QHC restricted stock awards held by QHC and CHS employees from the Spin-off date through December 31, 2017 (in shares): QHC Awards Distributed in Spin-off QHC Employees CHS Employees Total Unvested restricted stock awards at Spin-off date 54,321 638,088 692,409 Vested (1,317 ) (6,098 ) (7,415 ) Forfeited (542 ) (10,465 ) (11,007 ) Unvested restricted stock awards at December 31, 2016 52,462 621,525 673,987 Vested (34,131 ) (204,858 ) (238,989 ) Forfeited (14,174 ) (153,944 ) (168,118 ) Unvested restricted stock awards at December 31, 2017 4,157 262,723 266,880
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Summary of Activity Related to Unvested Restricted Stock Awards	The following table provides a summary of the activity related to unvested restricted stock awards granted subsequent to the Spin-off: QHC Awards Granted Subsequent to Spin-off Weighted- Average Grant Date Fair Value Shares Per Share Unvested restricted stock awards at Spin-off date — $ — Granted 1,081,005 12.77 Vested — — Forfeited — — Unvested restricted stock awards at December 31, 2016 1,081,005 12.77 Granted 1,142,571 7.54 Vested (282,582 ) 12.77 Forfeited (161,506 ) 10.90 Unvested restricted stock awards at December 31, 2017 1,779,488 $ 9.58

Benefit Plans (Tables)

Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Net Periodic Benefit Costs	The following table provides a summary of the components of net periodic benefit costs (in thousands): Year Ended December 31, 2017 2016 2015 Service cost $ 1,347 $ 1,270 $ — Interest cost 299 237 — Amortizations: Prior service cost (credit) 396 268 — Net (gain) loss 3 12 — Total net periodic benefit cost $ 2,045 $ 1,787 $ —
Summary of Weighted-Average Assumptions Used	The following table provides a summary of the weighted-average assumptions used by the Company to determine its net periodic benefit costs: Year Ended December 31, 2017 2016 2015 Discount rate 3.6 % 3.2 % — % Rate of compensation increase 2.0 % 3.0 % — % The following table provides a summary of the weighted-average assumptions used by the Company to determine its benefit obligation: December 31, 2017 2016 Discount rate 3.3 % 3.6 % Rate of compensation increase 2.0 % 2.0 %
Summary of Changes Recognized in Other Comprehensive Income (Loss)	The following table provides a summary of the c hanges recognized in other comprehensive income (loss) (in thousands): December 31, 2017 2016 2015 Prior service cost (credit) $ — $ 2,949 $ — Net loss (gain) arising during period (146 ) 14 — Amounts recognized as a component of net periodic benefit cost: Amortization or curtailment recognition of prior service (cost) credit (396 ) (264 ) — Amortization or settlement recognition of net gain (loss) (3 ) (3 ) — Total recognized in other comprehensive loss (income) $ (545 ) $ 2,696 $ —
Summary of Changes in Benefit Obligation	The following table provides a summary of the changes in the benefit obligation (in thousands): December 31, 2017 2016 Benefit obligation at beginning of period $ 9,434 $ — Benefit obligation transferred from the Spin-off — 5,964 Service cost 1,347 1,270 Interest cost 299 190 Plan amendments — 2,921 Benefits paid (2,275 ) — Actuarial (gain) loss (146 ) (911 ) Benefit obligation at end of period $ 8,659 $ 9,434
Summary of Expected Future Benefit Payments	The following table provides a summary of the expected future benefit payments for each of the next five years and the five years thereafter (in thousands): 2018 $ — 2019 — 2020 — 2021 948 2022 — Five years thereafter 10,448 Total expected future benefit payments $ 11,396

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Summary of Allocated Costs from Parent Prior to Spin-off	The following table provides a summary of the allocated costs to QHC from CHS for the periods prior to the Spin-off (in thousands): Year Ended December 31, 2016 2015 Insurance costs $ 44,246 $ 134,290 Management fees from Parent 11,792 36,466 All other allocated costs 25,021 72,262 Total related party operating costs and expenses $ 81,059 $ 243,018

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Summary of Insurance Reserves Related to Professional and General Liability Claims and Workers' Compensation Claims	The following table provides a summary of the Company’s insurance reserves related to professional and general liability and workers’ compensation liability, distinguished between those indemnified by CHS and those related to the Company’s own risks (in thousands): December 31, 2017 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 21,465 $ 44,377 $ 21,465 $ 44,377 All other self-insurance reserves — — 2,883 32,616 Total insurance reserves for professional and general liability 21,465 44,377 24,348 76,993 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 3,032 14,545 3,032 14,545 All other self-insurance reserves — — 3,120 4,013 Total insurance reserves for workers' compensation liability 3,032 14,545 6,152 18,558 Total self-insurance reserves $ 24,497 $ 58,922 $ 30,500 $ 95,551 December 31, 2016 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 17,580 $ 59,652 $ 17,580 $ 59,652 All other self-insurance reserves — — 230 14,542 Total insurance reserves for professional and general liability 17,580 59,652 17,810 74,194 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 4,863 15,958 4,863 15,958 All other self-insurance reserves — — 1,736 1,458 Total insurance reserves for workers' compensation liability 4,863 15,958 6,599 17,416 Total self-insurance reserves $ 22,443 $ 75,610 $ 24,409 $ 91,610

Quarterly Financial Data (Una47

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Quarterly Financial Information Disclosure [Abstract]
Summary of Company's Quarterly Operating Results	The following table provides a summary of the Company’s quarterly operating results for the years ended December 31, 2017 and 2016 (in thousands, except earnings per share and shares): 2017 Quarters 1st 2nd 3rd 4th Net operating revenues $ 527,640 $ 530,146 $ 499,302 $ 515,082 Net income (loss) $ (27,205 ) (30,575 ) (28,554 ) (26,023 ) Less: Net income (loss) attributable to noncontrolling interests 356 55 637 785 Net income (loss) attributable to Quorum Health Corporation $ (27,561 ) $ (30,630 ) $ (29,191 ) $ (26,808 ) Earnings (loss) per share attributable to Quorum Health Corporation stockholders: Basic and diluted $ (0.99 ) $ (1.09 ) $ (1.03 ) $ (0.95 ) Weighted-average common shares outstanding: Basic and diluted 27,800,597 28,145,215 28,245,833 28,248,527 2016 Quarters 1st 2nd 3rd 4th Net operating revenues $ 549,551 $ 529,737 $ 543,939 $ 515,240 Net income (loss) (4,687 ) (243,966 ) (6,452 ) (90,092 ) Less: Net income (loss) attributable to noncontrolling interests 315 1,095 507 574 Net income (loss) attributable to Quorum Health Corporation $ (5,002 ) $ (245,061 ) $ (6,959 ) $ (90,666 ) Earnings (loss) per share attributable to Quorum Health Corporation stockholders: Basic and diluted $ (0.18 ) $ (8.63 ) $ (0.24 ) $ (3.19 ) Weighted-average common shares outstanding: Basic and diluted 28,412,054 28,412,720 28,413,532 28,416,801

Guarantor and Non-Guarantor S48

Guarantor and Non-Guarantor Supplemental Information (Tables)	12 Months Ended
	Dec. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Schedule of Condensed Consolidating and Combining Statement of Income (Loss)	Condensed Consolidating and Combining Statement of Income (Loss) Year Ended December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 1,815,355 $ 512,300 $ — $ 2,327,655 Provision for bad debts — 215,021 40,464 — 255,485 Net operating revenues — 1,600,334 471,836 — 2,072,170 Operating costs and expenses: Salaries and benefits — 715,713 319,084 — 1,034,797 Supplies — 182,172 68,351 — 250,523 Other operating expenses 3,002 504,809 115,252 — 623,063 Depreciation and amortization — 68,770 13,385 — 82,155 Rent — 29,923 20,307 — 50,230 Electronic health records incentives earned — (3,681 ) (1,064 ) — (4,745 ) Legal, professional and settlement costs — 6,001 — — 6,001 Impairment of long-lived assets and goodwill — 47,281 — — 47,281 Loss (gain) on sale of hospitals, net — — (5,243 ) — (5,243 ) Transaction costs related to the Spin-off — 195 58 — 253 Total operating costs and expenses 3,002 1,551,183 530,130 — 2,084,315 Income (loss) from operations (3,002 ) 49,151 (58,294 ) — (12,145 ) Interest expense, net 124,060 (2,054 ) 71 — 122,077 Equity in earnings of affiliates 15,291 29,673 — (44,964 ) — Income (loss) before income taxes (142,353 ) 21,532 (58,365 ) 44,964 (134,222 ) Provision for (benefit from) income taxes (28,163 ) (3,508 ) 9,806 — (21,865 ) Net income (loss) (114,190 ) 25,040 (68,171 ) 44,964 (112,357 ) Less: Net income (loss) attributable to noncontrolling interests — — 1,833 — 1,833 Net income (loss) attributable to Quorum Health Corporation $ (114,190 ) $ 25,040 $ (70,004 ) $ 44,964 $ (114,190 ) Condensed Consolidating and Combining Statement of Income (Loss) Year Ended December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 1,811,586 $ 607,467 $ — $ 2,419,053 Provision for bad debts — 211,921 68,665 — 280,586 Net operating revenues — 1,599,665 538,802 — 2,138,467 Operating costs and expenses: Salaries and benefits — 715,925 341,194 — 1,057,119 Supplies — 180,098 78,541 — 258,639 Other operating expenses — 505,778 140,024 — 645,802 Depreciation and amortization — 97,318 19,970 — 117,288 Rent — 27,741 22,142 — 49,883 Electronic health records incentives earned — (8,948 ) (2,534 ) — (11,482 ) Legal, professional and settlement costs — 7,342 — — 7,342 Impairment of long-lived assets and goodwill — 242,685 49,185 — 291,870 Loss (gain) on sale of hospitals, net — — 2,150 — 2,150 Transaction costs related to the Spin-off — 4,105 1,383 — 5,488 Total operating costs and expenses — 1,772,044 652,055 — 2,424,099 Income (loss) from operations — (172,379 ) (113,253 ) — (285,632 ) Interest expense, net 78,266 32,541 2,633 — 113,440 Equity in earnings of affiliates 258,078 58,605 — (316,683 ) — Income (loss) before income taxes (336,344 ) (263,525 ) (115,886 ) 316,683 (399,072 ) Provision for (benefit from) income taxes (2,318 ) (35,576 ) (15,981 ) — (53,875 ) Net income (loss) (334,026 ) (227,949 ) (99,905 ) 316,683 (345,197 ) Less: Net income (loss) attributable to noncontrolling interests — — 2,491 — 2,491 Net income (loss) attributable to Quorum Health Corporation $ (334,026 ) $ (227,949 ) $ (102,396 ) $ 316,683 $ (347,688 ) Condensed Consolidating and Combining Statement of Income (Loss) Year Ended December 31, 2015 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 1,833,226 $ 612,632 $ — $ 2,445,858 Provision for bad debts — 204,968 53,552 — 258,520 Net operating revenues — 1,628,258 559,080 — 2,187,338 Operating costs and expenses: Salaries and benefits — 687,596 329,100 — 1,016,696 Supplies — 177,421 72,371 — 249,792 Other operating expenses — 507,514 126,719 — 634,233 Depreciation and amortization — 105,320 22,681 — 128,001 Rent — 27,871 20,858 — 48,729 Electronic health records incentives earned — (21,001 ) (4,778 ) — (25,779 ) Impairment of long-lived assets — 13,000 — — 13,000 Transaction costs related to the Spin-off — 12,161 4,176 — 16,337 Total operating costs and expenses — 1,509,882 571,127 — 2,081,009 Income (loss) from operations — 118,376 (12,047 ) — 106,329 Interest expense, net — 86,363 11,927 — 98,290 Equity in earnings of affiliates — (16,857 ) — 16,857 — Income (loss) before income taxes — 48,870 (23,974 ) (16,857 ) 8,039 Provision for (benefit from) income taxes — 16,904 (13,600 ) — 3,304 Net income (loss) — 31,966 (10,374 ) (16,857 ) 4,735 Less: Net income (loss) attributable to noncontrolling interests — (621 ) 4,019 — 3,398 Net income (loss) attributable to Quorum Health Corporation $ — $ 32,587 $ (14,393 ) $ (16,857 ) $ 1,337
Schedule of Condensed Consolidating and Combining Statement of Comprehensive Income (Loss)	Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Year Ended December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (114,190 ) $ 25,040 $ (68,171 ) $ 44,964 $ (112,357 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 804 804 — (804 ) 804 Comprehensive income (loss) (113,386 ) 25,844 (68,171 ) 44,160 (111,553 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 1,833 — 1,833 Comprehensive income (loss) attributable to Quorum Health Corporation $ (113,386 ) $ 25,844 $ (70,004 ) $ 44,160 $ (113,386 ) Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Year Ended December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ (334,026 ) $ (227,949 ) $ (99,905 ) $ 316,683 $ (345,197 ) Amortization and recognition of unrecognized pension cost components, net of income taxes (2,760 ) (2,760 ) — 2,760 (2,760 ) Comprehensive income (loss) (336,786 ) (230,709 ) (99,905 ) 319,443 (347,957 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 2,491 — 2,491 Comprehensive income (loss) attributable to Quorum Health Corporation $ (336,786 ) $ (230,709 ) $ (102,396 ) $ 319,443 $ (350,448 ) Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Year Ended December 31, 2015 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net income (loss) $ — $ 31,966 $ (10,374 ) $ (16,857 ) $ 4,735 Amortization and recognition of unrecognized pension cost components, net of income taxes — — — — — Comprehensive income (loss) — 31,966 (10,374 ) (16,857 ) 4,735 Less: Comprehensive income (loss) attributable to noncontrolling interests — (621 ) 4,019 — 3,398 Comprehensive income (loss) attributable to Quorum Health Corporation $ — $ 32,587 $ (14,393 ) $ (16,857 ) $ 1,337
Schedule of Condensed Consolidating and Combining Balance Sheet	Condensed Consolidating Balance Sheet December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 1,051 $ 4,222 $ 344 $ — $ 5,617 Patient accounts receivable, net of allowance for doubtful accounts — 262,690 80,455 — 343,145 Inventories — 43,276 10,183 — 53,459 Prepaid expenses 33 16,980 4,154 — 21,167 Due from third-party payors — 93,323 3,879 — 97,202 Current assets of hospitals held for sale — 8,112 — — 8,112 Other current assets — 32,867 14,573 — 47,440 Total current assets 1,084 461,470 113,588 — 576,142 Intercompany receivable 3 402,817 172,098 (574,918 ) — Property and equipment, net — 543,073 132,206 — 675,279 Goodwill — 243,618 165,611 — 409,229 Intangible assets, net — 58,240 6,610 — 64,850 Long-term assets of hospitals held for sale — 7,730 4 — 7,734 Other long-term assets — 74,918 20,689 — 95,607 Net investment in subsidiaries 1,488,021 — — (1,488,021 ) — Total assets $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,434 $ 421 $ — $ 1,855 Accounts payable 132 146,193 24,925 — 171,250 Accrued liabilities: Accrued salaries and benefits — 56,522 21,281 — 77,803 Accrued interest 10,466 — — — 10,466 Due to third-party payors — 46,381 1,324 — 47,705 Current liabilities of hospitals held for sale — 2,577 — — 2,577 Other current liabilities 516 30,664 12,507 — 43,687 Total current liabilities 11,114 283,771 60,458 — 355,343 Long-term debt 1,188,224 23,809 2 — 1,212,035 Intercompany payable 182,555 173,341 219,022 (574,918 ) — Deferred income tax liabilities, net 7,774 — — — 7,774 Other long-term liabilities — 195,132 31,100 (88,278 ) 137,954 Total liabilities 1,389,667 676,053 310,582 (663,196 ) 1,713,106 Redeemable noncontrolling interests — — 2,325 — 2,325 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 549,610 1,291,581 471,767 (1,763,348 ) 549,610 Accumulated other comprehensive income (loss) (1,956 ) (1,956 ) — 1,956 (1,956 ) Accumulated deficit (448,216 ) (173,812 ) (187,837 ) 361,649 (448,216 ) Total Quorum Health Corporation stockholders' equity 99,441 1,115,813 283,930 (1,399,743 ) 99,441 Nonredeemable noncontrolling interests — — 13,969 — 13,969 Total equity 99,441 1,115,813 297,899 (1,399,743 ) 113,410 Total liabilities and equity $ 1,489,108 $ 1,791,866 $ 610,806 $ (2,062,939 ) $ 1,828,841 Condensed Consolidating Balance Sheet December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 21,609 $ 3,498 $ 348 $ — $ 25,455 Patient accounts receivable, net of allowance for doubtful accounts — 277,155 103,530 — 380,685 Inventories — 46,318 11,806 — 58,124 Prepaid expenses — 17,874 5,154 — 23,028 Due from third-party payors — 109,793 6,442 — 116,235 Current assets of hospitals held for sale — 1,502 — — 1,502 Other current assets — 41,673 16,269 — 57,942 Total current assets 21,609 497,813 143,549 — 662,971 Intercompany receivable 3 126,035 84,827 (210,865 ) — Property and equipment, net — 624,457 109,443 — 733,900 Goodwill — 252,433 164,400 — 416,833 Intangible assets, net — 73,404 11,578 — 84,982 Long-term assets of hospitals held for sale — 6,851 — — 6,851 Other long-term assets — 72,967 15,866 — 88,833 Net investment in subsidiaries 1,485,213 — — (1,485,213 ) — Total assets $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ 3,819 $ 1,560 $ 304 $ — $ 5,683 Accounts payable 158 147,521 22,005 — 169,684 Accrued liabilities: Accrued salaries and benefits — 69,896 28,907 — 98,803 Accrued interest 19,915 — — — 19,915 Due to third-party payors — 40,595 1,942 — 42,537 Current liabilities of hospitals held for sale — 492 — — 492 Other current liabilities — 46,002 7,266 — 53,268 Total current liabilities 23,892 306,066 60,424 — 390,382 Long-term debt 1,215,836 24,899 407 — 1,241,142 Intercompany payable 34,495 86,084 90,286 (210,865 ) — Deferred income tax liabilities, net 31,474 — — — 31,474 Other long-term liabilities — 144,950 22,651 (58,605 ) 108,996 Total liabilities 1,305,697 561,999 173,768 (269,470 ) 1,771,994 Redeemable noncontrolling interests — — 6,807 — 6,807 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 537,911 1,333,347 412,705 (1,746,052 ) 537,911 Accumulated other comprehensive income (loss) (2,760 ) (2,760 ) — 2,760 (2,760 ) Accumulated deficit (334,026 ) (238,626 ) (78,058 ) 316,684 (334,026 ) Total Quorum Health Corporation stockholders' equity 201,128 1,091,961 334,647 (1,426,608 ) 201,128 Nonredeemable noncontrolling interests — — 14,441 — 14,441 Total equity 201,128 1,091,961 349,088 (1,426,608 ) 215,569 Total liabilities and equity $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370
Schedule of Condensed Consolidating and Combining Statement of Cash Flows	Condensed Consolidating and Combining Statement of Cash Flows Year Ended December 31, 2017 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (121,079 ) $ 206,248 $ (18,199 ) $ — $ 66,970 Cash flows from investing activities: Capital expenditures for property and equipment — (24,777 ) (36,753 ) — (61,530 ) Capital expenditures for software — (6,090 ) (808 ) — (6,898 ) Acquisitions, net of cash acquired — (29 ) (1,891 ) — (1,920 ) Proceeds from the sale of hospitals — 11,925 20,156 — 32,081 Changes in intercompany balances with affiliates, net — (183,829 ) — 183,829 — Net cash provided by (used in) investing activities — (202,800 ) (19,296 ) 183,829 (38,267 ) Cash flows from financing activities: Borrowings under revolving credit facilities 508,000 — — — 508,000 Repayments under revolving credit facilities (508,000 ) — — — (508,000 ) Borrowings of long-term debt — 376 — — 376 Repayments of long-term debt (37,261 ) (1,592 ) (342 ) — (39,195 ) Payments of debt issuance costs (3,119 ) — — — (3,119 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,508 ) — — (1,508 ) Cash distributions to noncontrolling investors — — (3,851 ) — (3,851 ) Purchases of shares from noncontrolling investors — — (1,244 ) — (1,244 ) Changes in intercompany balances with affiliates, net 140,901 — 42,928 (183,829 ) — Net cash provided by (used in) financing activities 100,521 (2,724 ) 37,491 (183,829 ) (48,541 ) Net change in cash and cash equivalents (20,558 ) 724 (4 ) — (19,838 ) Cash and cash equivalents at beginning of period 21,609 3,498 348 — 25,455 Cash and cash equivalents at end of period $ 1,051 $ 4,222 $ 344 $ — $ 5,617 Condensed Consolidating and Combining Statement of Cash Flows Year Ended December 31, 2016 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (66,266 ) $ 173,382 $ (26,030 ) $ — $ 81,086 Cash flows from investing activities: Capital expenditures for property and equipment — (73,327 ) (6,593 ) — (79,920 ) Capital expenditures for software — (3,854 ) (3,415 ) — (7,269 ) Acquisitions, net of cash acquired — (549 ) (236 ) — (785 ) Proceeds from the sale of hospitals — — 13,746 — 13,746 Proceeds from asset sales — 1,498 (416 ) — 1,082 Changes in intercompany balances with affiliates, net — (116,674 ) — 116,674 — Net cash provided by (used in) investing activities — (192,906 ) 3,086 116,674 (73,146 ) Cash flows from financing activities: Borrowings under revolving credit facilities 50,000 — — — 50,000 Repayments under revolving credit facilities (50,000 ) — — — (50,000 ) Borrowings of long-term debt 1,255,464 740 77 — 1,256,281 Repayments of long-term debt (11,581 ) (3,025 ) (616 ) — (15,222 ) Increase (decrease) in Due to Parent, net — 24,796 — — 24,796 Payments of debt issuance costs (29,146 ) — — — (29,146 ) Cash paid to Parent related to the Spin-off (1,217,336 ) — — — (1,217,336 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (13 ) — — (13 ) Cash distributions to noncontrolling investors — — (2,850 ) — (2,850 ) Purchases of shares from noncontrolling investors — — (101 ) — (101 ) Changes in intercompany balances with affiliates, net 90,474 — 26,200 (116,674 ) — Net cash provided by (used in) financing activities 87,875 22,498 22,710 (116,674 ) 16,409 Net change in cash and cash equivalents 21,609 2,974 (234 ) — 24,349 Cash and cash equivalents at beginning of period — 524 582 — 1,106 Cash and cash equivalents at end of period $ 21,609 $ 3,498 $ 348 $ — $ 25,455 Condensed Consolidating and Combining Statement of Cash Flows Year Ended December 31, 2015 (In Thousands) Parent Issuer Other Guarantors Non- Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ — $ 87,313 $ (44,424 ) $ — $ 42,889 Cash flows from investing activities: Capital expenditures for property and equipment — (37,321 ) (22,134 ) — (59,455 ) Capital expenditures for software — (6,935 ) (1,910 ) — (8,845 ) Acquisitions, net of cash acquired — (3,467 ) (4,552 ) — (8,019 ) Proceeds from asset sales — 3,114 — — 3,114 Other investing activities — (1,416 ) (3,971 ) — (5,387 ) Net cash provided by (used in) investing activities — (46,025 ) (32,567 ) — (78,592 ) Cash flows from financing activities: Borrowings of long-term debt — 217 155 — 372 Repayments of long-term debt — (1,043 ) (520 ) — (1,563 ) Increase (decrease) in Due to Parent, net — 152,971 109,804 — 262,775 Increase (decrease) in receivables facility, net — (194,835 ) (29,939 ) — (224,774 ) Cash distributions to noncontrolling investors — — (1,623 ) — (1,623 ) Purchases of shares from noncontrolling investors — (526 ) (411 ) — (937 ) Net cash provided by (used in) financing activities — (43,216 ) 77,466 — 34,250 Net change in cash and cash equivalents — (1,928 ) 475 — (1,453 ) Cash and cash equivalents at beginning of period — 2,452 107 — 2,559 Cash and cash equivalents at end of period $ — $ 524 $ 582 $ — $ 1,106

Description of the Business a49

Description of the Business and the Spin-Off (Narrative) (Details)	Apr. 29, 2016USD ($)Hospital$ / sharesshares	Apr. 22, 2016USD ($)	Dec. 31, 2017USD ($)Hospitalbedstate$ / shares	Dec. 31, 2016USD ($)$ / shares	Dec. 31, 2015
Description Of Business And Spin Off [Line Items]
Number of hospitals owned or leased | Hospital			31
Number of licensed beds | bed			2,979
Number of States in which Entity Operates | state			15
Common stock, par value | $ / shares			$ 0.0001	$ 0.0001
Cash proceeds paid to Parent	$ 1,217,336,000
Debt Instrument, Unamortized Discount			$ 24,536,000	$ 24,536,000
Senior Notes, maturing 2023 [Member]
Description Of Business And Spin Off [Line Items]
Debt Instrument, Face Amount		$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt Instrument, Unamortized Discount		$ 6,900,000
Debt instrument issue discount percentage		1.734%
ABL Credit Facility, maturing 2021 [Member]
Description Of Business And Spin Off [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	125,000,000		124,000,000
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Description Of Business And Spin Off [Line Items]
Debt Instrument, Face Amount	880,000,000
Debt Instrument, Unamortized Discount	$ 17,600,000
Term Facility Issued Percentage on Par Value	98.00%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Description Of Business And Spin Off [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000,000		$ 87,500,000
Spin-off from CHS [Member]
Description Of Business And Spin Off [Line Items]
Number of hospitals owned or leased | Hospital	38
Percentage ownership of number of stock shares held by the parent	100.00%
Common stock, par value | $ / shares	$ 0.0001
Record date for stockholders of the parent to be eligible to receive share distribution in spin-off	Apr. 22, 2016
Number of shares distributed to each stockholder in spin-off | shares	1
Number of shares held by each stockholder of the parent used to determine share distribution in spin-off | shares	4
Contributed capital, in excess of par value of common stock	$ 530,600,000
Cash contribution from parent	13,500,000
Cash contribution from parent for initial working capital	20,000,000
Differences in estimated and actual financing transaction fees for the Spin-off	$ 6,500,000
Sales Revenue, Segment [Member] | Segment Concentration Risk [Member] | Hospital Operations Reporting Unit [Member]
Description Of Business And Spin Off [Line Items]
Concentration risk, percentage			95.00%	95.00%	95.00%

Description of the Business a50

Description of the Business and the Spin-Off - Summary of Transactions to Effect the Spin-Off (Details) - USD ($) $ in Thousands	Apr. 29, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Description Of Business And Spin Off [Line Items]
Long-Term Debt, balance at April 29, 2016 (prior to the spin-off)	$ 24,179	$ 1,241,142
Borrowings of long-term debt, net of debt issuance discounts	1,255,464
Payments of debt issuance costs	(29,146)	(3,119)	$ (29,146)	$ 0
Long-Term Debt, balance at April 29, 2016 (after the spin-off)	1,250,497	1,212,035	1,241,142
Due to Parent, Net, balance at April 29, 2016 (prior to the spin-off)	1,813,836
Cash proceeds paid to Parent	(1,217,336)
Transfer of liabilities from Parent	(22,292)
Net deferred income tax liability resulting from the Spin-off	(46,783)
Non-cash capital contribution from Parent	(527,425)
Due to Parent, Net, balance at April 29, 2016 (after the spin-off)	$ 0
Stockholders' equity, beginning balance		$ 215,569	15,943	7,918
Stockholders' equity, beginning balance, shares		29,482,050
Stockholders' equity, ending balance		$ 113,410	$ 215,569	15,943
Stockholders' equity, ending balance, shares	28,412,054	30,294,895	29,482,050
Common Stock [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	$ 0	$ 3
Stockholders' equity, beginning balance, shares	0	29,482,050
Distribution of common stock	$ 3
Distribution of common stock, shares	27,719,645
Distribution of restricted stock awards	$ 0
Distribution of restricted stock awards, shares	692,409
Stockholders' equity, ending balance	$ 3	$ 3	$ 3
Stockholders' equity, ending balance, shares	28,412,054	30,294,895	29,482,050
Additional Paid-In Capital [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	$ 0	$ 537,911
Non-cash capital contribution from Parent	530,562
Distribution of common stock	(3)
Stockholders' equity, ending balance	530,559	$ 549,610	$ 537,911
Parent [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	3,137		$ 3,184	3,109
Non-cash capital contribution from Parent	(3,137)
Stockholders' equity, ending balance	$ 0			$ 3,184

Basis of Presentation and Sig51

Basis of Presentation and Significant Accounting Policies (Summary of Components of Net Operating Revenues Before Provision for Bad Debts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Health Care Organizations [Abstract]
Operating revenues	$ 11,930,145	$ 12,104,580	$ 11,613,826
Less: Contractual allowances	(9,173,711)	(9,247,789)	(8,795,674)
Less: Discounts	(428,779)	(437,738)	(372,294)
Total net operating revenues, before the provision for bad debts	$ 2,327,655	$ 2,419,053	$ 2,445,858

Basis of Presentation and Sig52

Basis of Presentation and Significant Accounting Policies (Narrative) (Details)	3 Months Ended		12 Months Ended
	Dec. 31, 2017USD ($)Hospital	Jun. 30, 2015USD ($)	Dec. 31, 2017USD ($)Hospital	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014Hospital	Apr. 29, 2016shares
Basis Of Presentation And Significant Accounting Policies [Line Items]
Provision for bad debts			$ 255,485,000	$ 280,586,000	$ 258,520,000
Operating revenues, net of contractual allowances and discounts			2,327,655,000	2,419,053,000	2,445,858,000
Increase (decrease) in net operating revenues during period for contractual allowance adjustments related to final cost report settlements on previous program reimbursements			2,000,000	(5,800,000)	(15,100,000)
Increase (decrease) in net operating revenues during period for all other contractual allowance adjustments related to final cost report settlements on previous program reimbursements					4,000,000
Operating revenues			11,930,145,000	12,104,580,000	11,613,826,000
Charity care service costs			5,600,000	5,700,000	5,000,000
Accounts receivable, net of contractual allowances	$ 343,145,000		343,145,000	380,685,000
Due from third-party payors	97,202,000		97,202,000	116,235,000
General and administrative costs			$ 52,700,000	55,200,000	43,500,000
Acquired finite-lived intangible asset, residual value				0
New date of annual goodwill impairment test			The Company performs its annual testing for impairment of goodwill in the fourth quarter of each year.
Redeemable and non-redeemable noncontrolling interests			The Company’s consolidated and combined financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that it controls.
Maximum period during which assets held for sale sold			12 months
Spin-off from CHS [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of shares distributed to each stockholder in spin-off | shares							1
Number of shares held by each stockholder of the parent used to determine share distribution in spin-off | shares							4
Restricted Stock [Member] | Spin-off from CHS [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of shares distributed to each stockholder in spin-off | shares							1
Number of shares held by each stockholder of the parent used to determine share distribution in spin-off | shares							4
Accrued Salaries and Benefits [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Undiscounted reserve for self-insured employee health benefits	8,800,000		$ 8,800,000	$ 11,000,000
Capitalized Internal Use Software, Except Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life			3 years
Community Health Systems, Inc [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of Hospitals | Hospital						4
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			100.00%	100.00%
Minimum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of days from date of discharge in which company establishes doubtful accounts reserve on non-self pay payor receivables				365 days
Minimum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life			8 years
Minimum [Member] | Land Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			3 years
Minimum [Member] | Buildings and Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			5 years
Minimum [Member] | Equipment and Fixtures [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			3 years
Maximum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life			10 years
Maximum [Member] | Land Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			20 years
Maximum [Member] | Buildings and Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			40 years
Maximum [Member] | Equipment and Fixtures [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset			18 years
Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Increase (decrease) in net operating revenues during period for contractual allowance adjustments related to final cost report settlements on previous program reimbursements		$ (11,100,000)
Medicare Advantage Program Revenues [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of contractual allowances and discounts			$ 186,700,000	$ 170,400,000	146,900,000
California Hospital Quality Assurance Fee [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of provider taxes	22,000,000		22,000,000	34,400,000	31,500,000
Charity Care [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues			34,000,000	34,600,000	30,400,000
Medicare [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of contractual allowances and discounts			656,843,000	673,074,000	656,799,000
Accounts receivable, net of contractual allowances	70,400,000		$ 70,400,000	$ 72,600,000
Medicare [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			10.00%	9.80%
Medicaid [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of contractual allowances and discounts			$ 425,943,000	$ 446,273,000	$ 443,479,000
Medicaid [Member] | Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Accounts receivable, net of contractual allowances	29,600,000		29,600,000	34,800,000
Due from third-party payors	22,900,000		$ 22,900,000	$ 16,600,000
Medicaid [Member] | Illinois [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			4.20%	4.70%
Medicaid [Member] | Illinois [Member] | Supplemental Program Receivables [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			23.50%	14.30%
Medicaid [Member] | California [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Due from third-party payors	$ 48,400,000		$ 48,400,000	$ 66,200,000
Medicaid [Member] | California [Member] | Supplemental Program Receivables [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage			49.80%	57.00%
Uncollectible Receivables [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of hospitals divested | Hospital	7		7
Provision for bad debts			$ 21,000,000	$ 11,400,000

Basis of Presentation and Sig53

Basis of Presentation and Significant Accounting Policies (Summary of Net Operating Revenues, Before the Provision for Bad Debts, by Payor Source) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 2,327,655	$ 2,419,053	$ 2,445,858
Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	100.00%	100.00%	100.00%
Medicare [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 656,843	$ 673,074	$ 656,799
Medicare [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	28.20%	27.80%	26.90%
Medicaid [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 425,943	$ 446,273	$ 443,479
Medicaid [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	18.30%	18.40%	18.10%
Managed Care and Commercial Plans [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 921,503	$ 952,535	$ 984,480
Managed Care and Commercial Plans [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	39.60%	39.40%	40.30%
Self-Pay [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 226,043	$ 242,095	$ 247,234
Self-Pay [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	9.70%	10.10%	10.00%
Non-Patient [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 97,323	$ 105,076	$ 113,866
Non-Patient [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	4.20%	4.30%	4.70%

Basis of Presentation and Sig54

Basis of Presentation and Significant Accounting Policies (Summary of Components of Amounts Due from and Due to Third-Party Payors) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	$ 97,202	$ 116,235
Due to third-party payors	47,705	42,537
Previous Program Reimbursements and Final Cost Report Settlements [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	17,383	23,876
Due to third-party payors	33,163	33,366
State Supplemental Payment Programs [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	79,819	92,359
Due to third-party payors	$ 14,542	$ 9,171

Basis of Presentation and Sig55

Basis of Presentation and Significant Accounting Policies (Summary of Portion of Medicaid Reimbursements Included in Statement of Income that are Attributable to State Supplemental Payment Programs) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Medicaid revenues	$ 11,930,145	$ 12,104,580	$ 11,613,826
Provider taxes and other expenses	131,734	129,775	124,635
State Supplemental Payment Programs [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Medicaid revenues	211,448	220,389	211,696
Provider taxes and other expenses	75,388	76,616	75,929
Reimbursements attributable to state supplemental payment programs, net of expenses	$ 136,060	$ 143,773	$ 135,767

Basis of Presentation and Sig56

Basis of Presentation and Significant Accounting Policies (Summary of Components of Patient Accounts Receivable Before Contractual Allowances Discounts and Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounts Notes And Loans Receivable [Line Items]
Total patient accounts receivable gross, Amount	$ 2,393,715	$ 2,586,476
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Accounts Notes And Loans Receivable [Line Items]
Concentration risk, percentage	100.00%	100.00%
Third-Parties [Member]
Accounts Notes And Loans Receivable [Line Items]
Total patient accounts receivable gross, Amount	$ 1,796,852	$ 1,930,103
Third-Parties [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Accounts Notes And Loans Receivable [Line Items]
Concentration risk, percentage	75.10%	74.60%
Self-Pay [Member]
Accounts Notes And Loans Receivable [Line Items]
Total patient accounts receivable gross, Amount	$ 596,863	$ 656,373
Self-Pay [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Accounts Notes And Loans Receivable [Line Items]
Concentration risk, percentage	24.90%	25.40%

Basis of Presentation and Sig57

Basis of Presentation and Significant Accounting Policies (Summary of Changes in Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Accounting Policies [Abstract]
Balance at beginning of period	$ 360,796	$ 346,507	$ 341,527
Provision for bad debts	255,485	280,586	258,520
Amounts written off, net of recoveries	(263,772)	(266,297)	(253,540)
Balance at end of period	$ 352,509	$ 360,796	$ 346,507

Basis of Presentation and Sig58

Basis of Presentation and Significant Accounting Policies (Summary of States in Which Company Generates More Than 5% of its Total Revenues) (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017USD ($)Hospital	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2017USD ($)Hospital	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	31								31
Total net operating revenues before the provision for bad debts, Amount | $	$ 515,082	$ 499,302	$ 530,146	$ 527,640	$ 515,240	$ 543,939	$ 529,737	$ 549,551	$ 2,072,170	$ 2,138,467	$ 2,187,338
Illinois [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	9								9
Total net operating revenues before the provision for bad debts, Amount | $									$ 829,473	$ 811,565	$ 822,501
Illinois [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage									37.20%	35.10%	35.30%
Oregon [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	1								1
Total net operating revenues before the provision for bad debts, Amount | $									$ 218,653	$ 210,818	$ 201,610
Oregon [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage									9.80%	9.10%	8.60%
Georgia [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	2								2
Total net operating revenues before the provision for bad debts, Amount | $									$ 148,353	$ 216,745	$ 224,330
Georgia [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage									6.70%	9.40%	9.60%
California [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	2								2
Total net operating revenues before the provision for bad debts, Amount | $									$ 195,725	$ 199,743	$ 209,500
California [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage									8.80%	8.60%	9.00%
Kentucky [Member]
Concentration Risk [Line Items]
Number of hospitals owned or leased | Hospital	3								3
Total net operating revenues before the provision for bad debts, Amount | $									$ 124,317	$ 121,988	$ 131,077
Kentucky [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage									5.60%	5.30%	5.60%

Basis of Presentation and Sig59

Basis of Presentation and Significant Accounting Policies (Summary of Major Components of Other Operating Expenses) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Other Operating Expenses [Line Items]
Taxes and insurance	$ 131,734	$ 129,775	$ 124,635
Transition services agreements and allocations from Parent	63,470	66,441	60,166
Repairs and maintenance	41,048	42,986	45,945
Utilities	27,324	29,833	29,856
Other miscellaneous operating expenses	78,936	77,500	75,365
Total other operating expenses	623,063	645,802	634,233
Purchased Services [Member]
Other Operating Expenses [Line Items]
Professional fees	168,711	180,672	176,758
Medical Specialist Fees [Member]
Other Operating Expenses [Line Items]
Professional fees	$ 111,840	106,803	85,042
Community Health Systems, Inc [Member] | Management Fees From Parent [Member]
Other Operating Expenses [Line Items]
Other operating expenses		$ 11,792	$ 36,466

Basis of Presentation and Sig60

Basis of Presentation and Significant Accounting Policies (Summary of Activity Related to Electronic Health Records Incentives) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Electronic Health Records Incentives Earned [Abstract]
Electronic health records incentives receivable at beginning of period	$ 4,189	$ 11,227	$ 12,204
Electronic health records incentives earned	4,489	7,843	11,428
Cash incentive payments received	(5,796)	(13,808)	(10,084)
Adjustments to receivable based on final cost report settlement or audit	(1,103)	(1,073)	(2,321)
Electronic health records incentives receivable at end of period	1,779	4,189	11,227
Deferred revenue related to electronic health records incentives at beginning of period	0	0	(14,351)
Cash received and deferred during period	(256)	(3,639)	0
Recognition of deferred incentives as earned	256	3,639	14,351
Deferred revenue related to electronic health records incentives at end of period	0	0	0
Total electronic health records incentives earned during period	4,745	11,482	25,779
Total cash incentive payments received during period	$ 6,052	$ 17,447	$ 10,084

Impairment of Long-Lived Asse61

Impairment of Long-Lived Assets and Goodwill (Narrative) (Details) $ in Thousands	3 Months Ended						12 Months Ended
	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)Hospital
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets and goodwill							$ 47,281	$ 291,870	$ 13,000
Impairment of long-lived assets						$ 45,400
Goodwill impairment charge							$ 1,929	$ 125,000
Number of hospitals long lived assets impaired | Hospital									7
Hospital Operations Reporting Unit [Member]
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets					$ 82,700
Goodwill impairment charge					2,700	200,000
Goodwill impaired adjustment to initial estimate amount					80,000
Additional recorded impairment of long-lived assets					$ 38,800
Hospitals Held for Sale [Member]
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets and goodwill	$ 25,800	$ 5,300	$ 12,900	$ 3,300
Impairment of long-lived assets	23,700	3,700		1,100
Impairment of intangible assets	$ 2,100	1,000		800
Goodwill impairment charge		$ 600		$ 1,400		$ 5,000

Acquisitions and Divestitures62

Acquisitions and Divestitures (Summary of Purchase Price Allocation) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Acquisition [Line Items]
Goodwill	$ 409,229	$ 416,833	$ 541,704
All Other Acquisitions [Member]
Business Acquisition [Line Items]
Current assets	142		422
Current assets		(343)
Property and equipment	695	851	3,190
Goodwill	1,211	129	6,788
Other long-term assets			564
Liabilities	(128)		(1,229)
Liabilities		16
Noncontrolling interests			(1,716)
Noncontrolling interests		132
Total consideration paid or allocated from CHS	$ 1,920	$ 785	$ 8,019

Acquisitions and Divestitures63

Acquisitions and Divestitures (Narrative) (Details)	Mar. 01, 2018USD ($)bed	Oct. 31, 2017USD ($)bed	Sep. 30, 2017USD ($)bed	Jun. 30, 2017USD ($)bed	Mar. 31, 2017USD ($)bed	Dec. 31, 2016USD ($)bed	Dec. 31, 2017USD ($)bed	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)
Business Acquisition [Line Items]
Proceeds from the sale of hospitals							$ 32,081,000	$ 13,746,000	$ 0
Impairment of long-lived assets and goodwill							47,281,000	291,870,000	13,000,000
Gain (loss) on sale of business							5,243,000	(2,150,000)	0
Redemption of shares from noncontrolling interests							2,158,000		5,586,000
Cash distributions to noncontrolling investors							$ 3,809,000	2,464,000	1,124,000
Sunbury Community Hospital and Lock Haven Hospital [Member]
Business Acquisition [Line Items]
Disposal date							Sep. 30, 2017
Proceeds from the sale of hospitals			$ 9,100,000
Pre-tax gain (loss) from discontinued operation							$ (8,800,000)	(9,400,000)	(8,700,000)
Gain (loss) on sale of business							(100,000)
Sunbury Community Hospital and Lock Haven Hospital [Member] | Property, Equipment and Capitalized Software [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill							1,900,000	12,700,000	3,000,000
Sunbury Community Hospital and Lock Haven Hospital [Member] | Property and Equipment [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill										$ 3,000,000	$ 6,000,000
Waukegan, Illinois [Member] | Vista Medical Center West [Member]
Business Acquisition [Line Items]
Pre-tax gain (loss) from discontinued operation							(2,300,000)	4,900,000	5,700,000
Waukegan, Illinois [Member] | Vista Medical Center West [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Disposal date	Mar. 1, 2018
Number of beds in hospital sold | bed	70
Proceeds from the sale of hospitals	$ 1,200,000
Waukegan, Illinois [Member] | Vista Medical Center West [Member] | Property, Equipment and Capitalized Software [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill							$ 11,100,000	4,100,000
Greenville, Alabama [Member] | L.V. Stabler Memorial Hospital [Member}
Business Acquisition [Line Items]
Disposal date							Oct. 31, 2017
Proceeds from the sale of hospitals		$ 2,800,000
Pre-tax gain (loss) from discontinued operation							$ (5,300,000)	(4,000,000)	(700,000)
Number of beds in hospital sold | bed		72
Greenville, Alabama [Member] | L.V. Stabler Memorial Hospital [Member} | Maximum [Member]
Business Acquisition [Line Items]
Gain (loss) on sale of business							(100,000)
Greenville, Alabama [Member] | L.V. Stabler Memorial Hospital [Member} | Property, Equipment and Capitalized Software [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill							$ 2,500,000	2,900,000
Sunbury, Pennsylvania [Member] | Sunbury Community Hospital and Lock Haven Hospital [Member]
Business Acquisition [Line Items]
Number of beds in hospital sold | bed			70
Lock Haven, Pennsylvania [Member] | Sunbury Community Hospital and Lock Haven Hospital [Member]
Business Acquisition [Line Items]
Number of beds in hospital sold | bed			47
Augusta, Georgia [Member] | Trinity Hospital of Augusta [Member]
Business Acquisition [Line Items]
Disposal date							Jun. 30, 2017
Proceeds from the sale of hospitals				$ 15,900,000
Pre-tax gain (loss) from discontinued operation							$ (9,700,000)	(9,500,000)	(2,800,000)
Number of beds in hospital sold | bed				231
Gain (loss) on sale of business							5,300,000
Redemption of shares from noncontrolling interests				$ 3,500,000
Cash distributions to noncontrolling investors				$ 1,200,000
Augusta, Georgia [Member] | Trinity Hospital of Augusta [Member] | Property, Equipment and Capitalized Software [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill							$ 33,900,000
Centre, Alabama [Member] | Cherokee Medical Center [Member]
Business Acquisition [Line Items]
Disposal date							Mar. 31, 2017
Proceeds from the sale of hospitals					$ 4,300,000
Pre-tax gain (loss) from discontinued operation							$ (1,000,000)	(3,700,000)	(1,600,000)
Number of beds in hospital sold | bed					60
Gain (loss) on sale of business							200,000
Centre, Alabama [Member] | Cherokee Medical Center [Member] | Property, Equipment and Capitalized Software [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill							$ 3,900,000	2,000,000
Centre, Alabama [Member] | Cherokee Medical Center [Member] | Property and Equipment [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill											$ 1,000,000
Georgia [Member] | Barrow Regional Medical Center [Member]
Business Acquisition [Line Items]
Disposal date							Dec. 31, 2016
Proceeds from the sale of hospitals						$ 6,600,000
Pre-tax gain (loss) from discontinued operation							$ (2,400,000)	(14,500,000)	(6,200,000)
Number of beds in hospital sold | bed						56
Gain (loss) on sale of business							$ 1,200,000
Georgia [Member] | Barrow Regional Medical Center [Member] | Property, Equipment and Capitalized Software [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill								4,000,000
Hamlet, North Carolina [Member] | Sandhills Regional Medical Center
Business Acquisition [Line Items]
Disposal date							Dec. 1, 2016
Proceeds from the sale of hospitals							$ 7,200,000
Pre-tax gain (loss) from discontinued operation							$ 200,000	(6,900,000)	$ (2,000,000)
Number of beds in hospital sold | bed							64
Gain (loss) on sale of business								1,000,000
Hamlet, North Carolina [Member] | Sandhills Regional Medical Center | Property, Equipment and Capitalized Software [Member]
Business Acquisition [Line Items]
Impairment of long-lived assets and goodwill								$ 4,800,000

Property and Equipment (Summary

Property and Equipment (Summary of Components of Property and Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 1,405,184	$ 1,519,975
Less: Accumulated depreciation and amortization	(729,905)	(786,075)
Total property and equipment, net	675,279	733,900
Land and Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	70,731	84,474
Building and improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	790,619	782,892
Equipment and Fixtures [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	529,150	592,463
Construction in progress [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 14,684	$ 60,146

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Property Plant And Equipment [Abstract]
Depreciation expense	$ 58.6	$ 83	$ 90.9
Assets held under capital lease obligations, at cost	29.2	30.2
Assets held under capital lease obligations, net of accumulated amortization	25.6	27.5
Purchases of property and equipment accrued in accounts payable	$ 6.8	$ 15.7

Goodwill and Intangible Asset66

Goodwill and Intangible Assets (Summary of Changes in Goodwill) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, beginning balance	$ 416,833	$ 541,704
Acquisitions	1,211	129
Divestitures	(5,293)	0
Reclass to held for sale	(1,593)	0
Impairment	(1,929)	(125,000)
Goodwill, ending balance	$ 409,229	$ 416,833

Goodwill and Intangible Asset67

Goodwill and Intangible Assets (Goodwill Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Goodwill [Line Items]
Goodwill	$ 409,229	$ 416,833	$ 541,704
Hospital Operations Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	375,900	383,500
Hospital Management Advisory and Consulting Services Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	$ 33,300	$ 33,300

Goodwill and Intangible Asset68

Goodwill and Intangible Assets (Summary of the Components of Intangible Assets ) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	$ 210,314	$ 236,552
Accumulated amortization	(150,618)	(157,779)
Total finite-lived intangible assets, net	59,696	78,773
Total indefinite-lived intangible assets	5,154	6,209
Total intangible assets, gross	215,468	242,761
Total intangible assets, net	64,850	84,982
Trade Names [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	4,000	4,000
Medical Licenses and Other Indefinite-Lived Intangible Assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	1,154	2,209
Capitalized Software Costs [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	159,449	180,855
Accumulated amortization	(111,661)	(118,391)
Total finite-lived intangible assets, net	47,788	62,464
Physician Income Guarantee Contracts [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	7,489	11,355
Accumulated amortization	(4,290)	(6,329)
Total finite-lived intangible assets, net	3,199	5,026
Other Finite-Lived Intangible Assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	43,376	44,342
Accumulated amortization	(34,668)	(33,059)
Total finite-lived intangible assets, net	$ 8,708	$ 11,283

Goodwill and Intangible Asset69

Goodwill and Intangible Assets (Intangible Assets Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets	$ 45,400
Finite-lived intangible assets, gross		$ 210,314	$ 236,552
Capitalized Software Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of long-lived assets		3,400	18,900
Finite-lived intangible assets, gross		159,449	$ 180,855
Capitalized Software Costs in Development Stage [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross		$ 700

Goodwill and Intangible Asset70

Goodwill and Intangible Assets (Summary of the Components of Amortization Expense) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 20,505	$ 31,167	$ 34,602
Amortization of leasehold improvements and property and equipment assets held under capital lease obligations	3,038	3,111	2,496
Total amortization expense	23,543	34,278	37,098
Capitalized Software Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	15,879	25,193	27,317
Physician Income Guarantee Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	2,032	3,108	3,951
Other Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 2,594	$ 2,866	$ 3,334

Goodwill and Intangible Asset71

Goodwill and Intangible Assets (Amortization Expense Narrative) (Details)	12 Months Ended
	Dec. 31, 2016
Intangible Assets Except Software Costs and Physician Income Guarantee Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, weighted-average useful life	4 years 7 months 6 days

Goodwill and Intangible Asset72

Goodwill and Intangible Assets (Summary of Future Estimated Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Goodwill And Intangible Assets Disclosure [Abstract]
2,018	$ 18,898
2,019	14,475
2,020	11,791
2,021	9,378
2,022	3,900
Thereafter	1,254
Total finite-lived intangible assets, net	$ 59,696	$ 78,773

Long-Term Debt (Summary of Comp

Long-Term Debt (Summary of Components of Long-Term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Apr. 29, 2016	Apr. 27, 2016
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	$ 1,256,824	$ 1,295,589
Unamortized debt issuance costs and discounts	(42,934)	(48,764)
Capital lease obligations	24,411	25,588
Other miscellaneous debt	1,255	1,582
Total debt	1,213,890	1,246,825
Less: Current maturities of long-term debt	(1,855)	(5,683)
Long-term debt	1,212,035	1,241,142	$ 1,250,497	$ 24,179
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	400,000	400,000
ABL Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	0	0
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	0	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	$ 831,158	$ 868,419

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details)	Apr. 29, 2016Agreement
Debt Disclosure [Abstract]
Number of credit agreement	2

Long-Term Debt (Senior Credit F

Long-Term Debt (Senior Credit Facility Narrative) (Details) - USD ($)	Apr. 29, 2016	Dec. 31, 2017	Mar. 14, 2018	Jan. 01, 2018	Dec. 31, 2016
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount		$ 24,536,000			$ 24,536,000
Senior Credit Facility [Member]
Debt Instrument [Line Items]
Secured net leverage ratio		387.00%			393.00%
Line of credit, additional borrowing capacity		$ 193,300,000
Secured net leverage ratio to exercise incremental term loan commitments description		Through December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments for the greater of $100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00.
Secured net leverage ratio after December 31, 2018		335.00%
Leverage ratio to incur permitted additional debt description		Through December 31, 2018, the Company is allowed to incur Permitted Additional Debt, as defined in the CS Agreement, only Total Leverage Ratio, adjustment for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, the Company may incur Permitted Additional Debt so long as the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00.
Letters of credit outstanding		$ 10,200,000
Senior Credit Facility [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio through December 31, 2018		335.00%
Leverage ratio to incur permitted additional debt through December 31, 2018		450.00%
Leverage ratio to incur permitted additional debt after December 31, 2018		550.00%
Senior Credit Facility [Member] | Minimum [Member]
Debt Instrument [Line Items]
Incremental term loan commitments		$ 100,000,000
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 880,000,000
Debt Instrument, Unamortized Discount	$ 17,600,000
Term Facility Issued Percentage on Par Value	98.00%
Debt Instrument, Maturity Date		Apr. 29, 2022
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	5.75%
Derivative, Floor Interest Rate	1.00%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	4.75%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		8.77%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		6.75%
Derivative, Floor Interest Rate		1.00%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		5.75%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000,000	$ 87,500,000
Debt Instrument, Maturity Date		Apr. 29, 2021
Line of credit, outstanding balance		$ 0
Line of credit, borrowing capacity		$ 77,300,000
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | CS Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.75%
Derivative, Floor Interest Rate		0.00%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | CS Amendment [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.75%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 62,500,000	$ 75,000,000

Long-Term Debt (Maximum Secured

Long-Term Debt (Maximum Secured Net Leverage Ratio Permitted) (Details) - Senior Credit Facility [Member]	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Secured net leverage ratio	387.00%	393.00%
Period from January 1, 2017 to June 30, 2017 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	450.00%
Period from July 1, 2017 to June 30, 2018 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	475.00%
Period from July 1, 2018 to December 31, 2019 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	500.00%
Period from January 1, 2020 and thereafter [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	450.00%

Long-Term Debt (ABL Credit Faci

Long-Term Debt (ABL Credit Facility Narrative) (Details) - USD ($)	Apr. 29, 2016	Dec. 31, 2017
UBS Agreement [Member]
Debt Instrument [Line Items]
Amended agreement date		Apr. 11, 2017
ABL Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 125,000,000	$ 124,000,000
Line of credit, outstanding balance		0
Line of Credit Facility, Maturity Date	Apr. 29, 2021
Covenant Trigger Event, minimum required excess availability amount		$ 12,500,000
Covenant Trigger Event, minimum required excess availability as percentage of aggregate commitments		10.00%
Minimum Consolidated Fixed Charge Ratio required to be maintained if covenant trigger event occurs		110.00%
Cash Dominion Trigger Event, minimum required excess availability as percentage of aggregate commitments		12.50%
Cash Dominion Trigger Event, minimum required excess availability amount		$ 15,000,000
ABL Credit Facility, maturing 2021 [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	0.00%
ABL Credit Facility, maturing 2021 [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
ABL Credit Facility, maturing 2021 [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.25%
ABL Credit Facility, maturing 2021 [Member] | Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.75%
ABL Credit Facility, maturing 2021 [Member] | Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.25%

Long-Term Debt (Senior Notes Na

Long-Term Debt (Senior Notes Narrative) (Details) - USD ($)	May 17, 2017	Apr. 22, 2016	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount			$ 24,536,000	$ 24,536,000
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt Instrument, Unamortized Discount		$ 6,900,000
Debt instrument issue discount percentage		1.734%
Debt Instrument, Maturity Date		Apr. 15, 2023
Debt Instrument, Payment Terms			Payable semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2016.
Debt Instrument, Frequency of Periodic Payment			semi-annually
Debt Instrument, Date of First Required Payment		Oct. 15, 2016
Debt Instrument, Interest Rate, Effective Percentage			12.49%
Debt Instrument, Redemption Price Percentage		100.00%
Senior Notes, maturing 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price Percentage		35.00%
Debt Instrument, Redemption Notice Period			60 days
Senior Notes, maturing 2023 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Notice Period			30 days
Senior Notes, maturing 2023 [Member] | Initial Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage	11.625%
Debt instrument due date	2,023
Senior Notes, maturing 2023 [Member] | Exchange Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	11.625%
Debt instrument due date	2,023

Long-Term Debt (Summary of Rede

Long-Term Debt (Summary of Redemption Dates and Prices of Senior Notes) (Details) - Senior Notes, maturing 2023 [Member]	Apr. 22, 2016	Dec. 31, 2017
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage	100.00%
Period from April 15, 2019 to April 14, 2020 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		108.719%
Period from April 15, 2020 to April 14, 2021 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		105.813%
Period from April 15, 2021 to April 14, 2022 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		102.906%
Period from April 15, 2022 to April 14, 2023 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		100.00%

Long-Term Debt (Summary of Re80

Long-Term Debt (Summary of Redemption Dates and Prices of Senior Notes) (Parenthetical) (Details) - Senior Notes, maturing 2023 [Member]	12 Months Ended
	Dec. 31, 2017
Period from April 15, 2019 to April 14, 2020 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2019
Debt Instrument, Redemption Period, End Date	Apr. 14, 2020
Period from April 15, 2020 to April 14, 2021 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2020
Debt Instrument, Redemption Period, End Date	Apr. 14, 2021
Period from April 15, 2021 to April 14, 2022 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2021
Debt Instrument, Redemption Period, End Date	Apr. 14, 2022
Period from April 15, 2022 to April 14, 2023 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2022
Debt Instrument, Redemption Period, End Date	Apr. 14, 2023

Long-Term Debt (Summary of Unam

Long-Term Debt (Summary of Unamortized Debt Issuance Costs and Discounts) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt issuance costs	$ 32,265	$ 29,146
Debt discounts	24,536	24,536
Total debt issuance costs and discounts at origination	56,801	53,682
Less: Amortization of debt issuance costs and discounts	(13,867)	(4,918)
Total unamortized debt issuance costs and discounts	$ 42,934	$ 48,764

Long-Term Debt (Capital Lease O

Long-Term Debt (Capital Lease Obligations and Other Debt Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Capital lease obligations	$ 24,411	$ 25,588
New Corporate Office [Member] | Brentwood, Tennessee [Member]
Debt Instrument [Line Items]
Capital lease obligations	$ 17,900	$ 18,700

Long-Term Debt (Summary of Debt

Long-Term Debt (Summary of Debt Maturities for Each of the Next Five Years and Thereafter) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
2,018	$ 1,855
2,019	1,486
2,020	1,517
2,021	3,329
2,022	830,796
Thereafter	417,841
Total debt, excluding unamortized debt issuance costs and discounts	$ 1,256,824	$ 1,295,589

Long-Term Debt (Summary of Co84

Long-Term Debt (Summary of Components of Interest Expense, Net) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Amortization of debt issuance costs and discounts	$ 8,949	$ 4,918	$ 0
All other interest expense (income), net	(1,881)	(849)	283
Total interest expense, net	122,077	113,440	98,290
Due to Parent, net	0	35,814	98,007
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Interest expense	46,516	32,166	0
ABL Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Interest expense	1,854	342	0
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Interest expense	528	330	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Interest expense	66,111	40,719	0
Interest Expense Portion From Long Term Debt [Member]
Debt Instrument [Line Items]
Total interest expense, net	$ 122,077	$ 77,626	$ 283

Other Long-Term Assets and Ot85

Other Long-Term Assets and Other Long-Term Liabilities (Summary of Major Components of Other Long-Term Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Assets Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term receivable	$ 44,377	$ 59,652
Insurance reserve for workers' compensation liability, long-term receivable	14,545	15,958
Other miscellaneous long-term assets	13,633	13,154
Total other long-term assets	95,607	88,833
Nonqualified Plan [Member]
Other Assets Noncurrent [Line Items]
Assets of Nonqualified Deferred Compensation Plan	23,052	69
Insurance Reserves Indemnified By CHS [Member]
Other Assets Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term receivable	44,377	59,652
Insurance reserve for workers' compensation liability, long-term receivable	$ 14,545	$ 15,958

Other Long-Term Assets and Ot86

Other Long-Term Assets and Other Long-Term Liabilities (Summary of Components of Other Long-Term Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Other Liabilities Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term liability	$ 76,993	$ 74,194
Insurance reserve for workers' compensation liability, long-term liability	18,558	17,416
Benefit plan liabilities	36,103	10,722
Deferred rent	4,268	4,001
Other miscellaneous long-term liabilities	2,032	2,663
Total other long-term liabilities	137,954	108,996
Professional and General Liability Insurance [Member]
Other Liabilities Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term liability	$ 76,993	$ 74,194

Fair Value Of Financial Instr87

Fair Value Of Financial Instruments (Summary of Carrying Values and Estimated Fair Values of Long-Term Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total long-term debt, excluding debt issuance costs and discounts, Carrying Amount	$ 1,256,824	$ 1,295,589
Total long-term debt, excluding debt issuance costs and discounts, Estimated Fair Value	1,258,016	1,211,317
ABL Credit Facility, maturing 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total long-term debt, excluding debt issuance costs and discounts, Carrying Amount	0	0
Total long-term debt, excluding debt issuance costs and discounts, Estimated Fair Value	0	0
Senior Notes, maturing 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total long-term debt, excluding debt issuance costs and discounts, Carrying Amount	400,000	400,000
Total long-term debt, excluding debt issuance costs and discounts, Estimated Fair Value	393,396	334,720
Other debt [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total long-term debt, excluding debt issuance costs and discounts, Carrying Amount	25,666	27,170
Total long-term debt, excluding debt issuance costs and discounts, Estimated Fair Value	25,666	27,170
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total long-term debt, excluding debt issuance costs and discounts, Carrying Amount	0	0
Total long-term debt, excluding debt issuance costs and discounts, Estimated Fair Value	0	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total long-term debt, excluding debt issuance costs and discounts, Carrying Amount	831,158	868,419
Total long-term debt, excluding debt issuance costs and discounts, Estimated Fair Value	$ 838,954	$ 849,427

Leases (Summary of Commitments

Leases (Summary of Commitments Relating to Non-Cancellable Operating and Capital Leases) (Details) - USD ($) $ in Thousands		Dec. 31, 2017	Dec. 31, 2016
Leases [Abstract]
Operating leases - 2018	[1]	$ 32,253
Operating leases - 2019	[1]	25,568
Operating leases - 2020	[1]	19,673
Operating leases - 2021	[1]	12,722
Operating leases - 2022	[1]	8,294
Operating leases - Thereafter	[1]	17,236
Total minimum future payments obligations	[1]	115,746
Capital leases - 2018		2,531
Capital leases - 2019		2,552
Capital leases - 2020		2,590
Capital leases - 2021		2,628
Capital leases - 2022		2,332
Capital leases - Thereafter		20,707
Total minimum future payments obligations		33,340
Less: Imputed interest		(8,929)
Total capital lease obligations		24,411	$ 25,588
Less: Current portion of capital lease obligations		(1,140)
Total long-term capital lease obligations		$ 23,271
[1]	Minimum lease payments obligations have not been reduced by minimum sublease rentals due in the future of $5.2 million.

Leases (Summary of Commitment89

Leases (Summary of Commitments Relating to Non-Cancellable Operating and Capital Leases) (Parenthetical) (Details) $ in Millions	Dec. 31, 2017USD ($)
Leases [Abstract]
Operating leases, future minimum sublease rentals due	$ 5.2

Equity (Narrative) (Details)

Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Apr. 29, 2016USD ($)vote / shares$ / sharesshares
Class Of Stock [Line Items]
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, par value | $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	30,294,895	29,482,050
Common stock, shares outstanding	30,294,895	29,482,050	28,412,054
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Contributed capital | $	$ 549,610	$ 537,911
Spin-off from CHS [Member]
Class Of Stock [Line Items]
Preferred stock, shares authorized			100,000,000
Preferred stock, par value | $ / shares			$ 0.0001
Common stock, shares authorized			300,000,000
Common stock, shares issued			28,412,054
Common stock, par value | $ / shares			$ 0.0001
Common stock voting description	Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters for which stockholders may vote. Holders of the Company’s common stock do not have cumulative voting rights in the election of directors.
Number of vote | vote / shares			1
Contributed capital | $			$ 530,600

Income Taxes (Summary of Compon

Income Taxes (Summary of Components of Provision for (Benefit from) Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current:
Federal	$ 0	$ 0	$ 0
State	271	530	762
Total provision for (benefit from) current income taxes	271	530	762
Deferred:
Federal	(22,540)	(51,177)	1,749
State	404	(3,228)	793
Total provision for (benefit from) deferred income taxes	(22,136)	(54,405)	2,542
Total provision for (benefit from) income taxes	$ (21,865)	$ (53,875)	$ 3,304

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Income tax rate, percent		35.00%	35.00%	35.00%
Tax Cuts and Jobs Act of 2017, incomplete accounting, provisional income tax benefit		$ 24,000
Tax Cuts and Jobs Act of 2017, incomplete accounting, change in tax rate, deferred tax liability, income tax benefit		10,900
Tax Cuts and Job Acts of 2017, change in deferred Tax assets valuation allowance, income tax benefit		$ 13,121	$ 0	$ 0
Scenario Plan [Member]
Income Taxes [Line Items]
Income tax rate, percent	21.00%

Income Taxes (Schedule of Recon

Income Taxes (Schedule of Reconciliation of Provision for (Benefit from) Income Taxes Utilizing Statutory Federal Income Tax Rate to Effective Income Tax Rate) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Provision for (benefit from) income taxes at statutory federal tax rate, Amount	$ (46,978)	$ (139,685)	$ 2,814
State income taxes, net of federal income tax benefit, Amount	(6,137)	(47,749)	(171)
Net (income) loss attributable to noncontrolling interests, Amount	(641)	(872)	(1,189)
Non-deductible goodwill and Spin-off costs, Amount	535	36,009	0
Change in valuation allowance (pre Tax Act), Amount	53,470	94,745	1,459
Change in rate due to Tax Act, Amount	(10,934)	0	0
Change in valuation allowance due to Tax Act, Amount	(13,121)	0	0
All other items, Amount	1,941	3,677	391
Total provision for (benefit from) income taxes	$ (21,865)	$ (53,875)	$ 3,304
Income tax rate, percent	35.00%	35.00%	35.00%
State income taxes, net of federal income tax benefit, Percentage	4.60%	12.00%	(2.10%)
Net (income) loss attributable to noncontrolling interests, Percentage	0.50%	0.20%	(14.80%)
Non-deductible goodwill and Spin-off costs, Percentage	(0.40%)	(9.00%)	0.00%
Change in valuation allowance (pre Tax Act), Percentage	(39.80%)	(23.70%)	18.20%
Change in rate due to Tax Act, Percentage	8.10%	0.00%	0.00%
Change in valuation allowance due to Tax Act, Percentage	9.80%	0.00%	0.00%
All other items, Percentage	(1.50%)	(1.00%)	4.80%
Total effective tax rate	16.30%	13.50%	41.10%

Income Taxes - (Summary of Comp

Income Taxes - (Summary of Components of Deferred Income Tax Assets and Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Assets
Net operating loss and credit carryforwards	$ 83,879	$ 72,195
Property and equipment	2,039	0
Prepaid expenses	0	0
Goodwill and intangible assets	0	0
Investments in unconsolidated affiliates	140	298
Accounts receivable	4,928	1,532
Accrued compensation and recruiting accruals	8,743	14,968
Other accruals	175	251
Deferred compensation	9,160	10,208
Debt issuance costs	0	0
Insurance and settlement reserves	31,322	39,112
Total deferred income tax assets before valuation allowance	140,386	138,564
Valuation allowance	(116,780)	(114,216)
Total deferred income tax assets	23,606	24,348
Liabilities
Net operating loss and credit carryforwards	0	0
Property and equipment	1,416	10,447
Prepaid expenses	2,836	6,874
Goodwill and intangible assets	18,544	27,193
Investments in unconsolidated affiliates	0	0
Accounts receivable	0	10,290
Accrued compensation and recruiting accruals	828	965
Other accruals	0	0
Deferred compensation	0	0
Debt issuance costs	7,756	53
Insurance and settlement reserves	0	0
Total deferred income tax liabilities, before valuation allowance	31,380	55,822
Valuation allowance	0	0
Total deferred income tax liabilities, net	$ 7,774	$ 31,474

Income Taxes (Operating Loss Ca

Income Taxes (Operating Loss Carryforwards Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Refundable alternative minimum tax credit carryforwards		$ 500
Valuation allowance		116,780	$ 114,216
Effect of Increase in valuation allowance post tax act		2,600
Increase in valuation allowance prior to tax act		53,470	$ 94,745	$ 1,459
Tax Cuts and Job Acts of 2017, decrease in valuation allowance		$ 37,700
Income tax rate, percent		35.00%	35.00%	35.00%
Tax Cuts and Job Acts of 2017, change in deferred Tax assets valuation allowance, income tax benefit		$ 13,121	$ 0	$ 0
Percentage of net operating loss usage to taxable income		80.00%
Scenario Plan [Member]
Income Taxes [Line Items]
Income tax rate, percent	21.00%
Texas [Member]
Income Taxes [Line Items]
Tax credit carryforwards		$ 400
Operating loss carryforwards expiration year		2,027
Federal [Member]
Income Taxes [Line Items]
Net operating loss carryforwards		$ 125,000
Operating loss carryforwards expiration start year		2,035
State [Member]
Income Taxes [Line Items]
Net operating loss carryforwards		$ 668,000
Operating loss carryforwards expiration start year		2,018
Operating loss carryforwards expiration end year		2,037

Earnings Per Share (Summary of

Earnings Per Share (Summary of Computation of Basic and Diluted Earnings (Loss) Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Numerator:
Net income (loss)	$ (26,023)	$ (28,554)	$ (30,575)	$ (27,205)	$ (90,092)	$ (6,452)	$ (243,966)	$ (4,687)	$ (112,357)	$ (345,197)	$ 4,735
Less: Net income (loss) attributable to noncontrolling interests	785	637	55	356	574	507	1,095	315	1,833	2,491	3,398
Net income (loss) attributable to Quorum Health Corporation	$ (26,808)	$ (29,191)	$ (30,630)	$ (27,561)	$ (90,666)	$ (6,959)	$ (245,061)	$ (5,002)	$ (114,190)	$ (347,688)	$ 1,337
Denominator:
Weighted-average shares outstanding - basic and diluted	28,248,527	28,245,833	28,145,215	27,800,597	28,416,801	28,413,532	28,412,720	28,412,054	28,113,566	28,413,247	28,412,054
Earnings (loss) per share attributable to Quorum Health Corporation stockholders - basic and diluted	$ (0.95)	$ (1.03)	$ (1.09)	$ (0.99)	$ (3.19)	$ (0.24)	$ (8.63)	$ (0.18)	$ (4.06)	$ (12.24)	$ 0.05

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	Apr. 27, 2016	Dec. 31, 2017	Dec. 31, 2016	Apr. 29, 2016
Earnings Per Share [Abstract]
Common stock, shares outstanding		30,294,895	29,482,050	28,412,054
Dilutive Shares	0	0	0

Segments (Narrative) (Details)

Segments (Narrative) (Details)	12 Months Ended
	Dec. 31, 2017segment
Segment Reporting [Abstract]
Number of operating segments	2

Segments (Summary of Financial

Segments (Summary of Financial Information Related to the Company`s Segments) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting Information [Line Items]
Total net operating revenues	$ 515,082	$ 499,302	$ 530,146	$ 527,640	$ 515,240	$ 543,939	$ 529,737	$ 549,551	$ 2,072,170	$ 2,138,467	$ 2,187,338
Total adjusted EBITDA									141,845	162,922	263,667
Total assets	1,828,841				1,994,370				1,828,841	1,994,370
Hospital Operations Reporting Unit [Member]
Segment Reporting Information [Line Items]
Total net operating revenues									1,987,973	2,052,751	2,096,831
Total adjusted EBITDA									175,597	184,000	249,375
Total assets	1,687,576				1,802,121				1,687,576	1,802,121
Quorum Health Resources [Member]
Segment Reporting Information [Line Items]
Total net operating revenues									80,863	85,533	90,507
Total adjusted EBITDA									20,599	16,980	14,246
Total assets	61,752				75,113				61,752	75,113
All Other Operations [Member]
Segment Reporting Information [Line Items]
Total net operating revenues									3,334	183	0
Total adjusted EBITDA									(54,351)	(38,058)	$ 46
Total assets	$ 79,513				$ 117,136				$ 79,513	$ 117,136

Segments (Summary of Reconcilia

Segments (Summary of Reconciliation of Adjusted EBITDA to Net Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Segment Reporting [Abstract]
Total adjusted EBITDA									$ 141,845	$ 162,922	$ 263,667
Interest expense, net									(122,077)	(113,440)	(98,290)
(Provision for) benefit from income taxes									21,865	53,875	(3,304)
Depreciation and amortization									(82,155)	(117,288)	(128,001)
Legal, professional and settlement costs									(6,001)	(7,342)	0
Impairment of long-lived assets and goodwill									(47,281)	(291,870)	(13,000)
Loss (gain) on sale of hospitals, net									5,243	(2,150)	0
Transaction costs related to the Spin-off									(253)	(5,488)	(16,337)
Post-spin headcount reductions									(2,543)	(1,617)	0
Change in estimate related to collectability of patient accounts receivable									(21,000)	(22,799)	0
Net income (loss)	$ (26,023)	$ (28,554)	$ (30,575)	$ (27,205)	$ (90,092)	$ (6,452)	$ (243,966)	$ (4,687)	$ (112,357)	$ (345,197)	$ 4,735

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($) $ in Thousands	8 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Apr. 29, 2016
Restricted Stock [Member] | Performance-Based Vesting [Member] | Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted		230,000	460,000
Share-based compensation, vesting period			3 years
Share-based compensation, vesting description		the restrictions on the restricted stock awards will lapse on the second anniversary of the grant date.
Restricted Stock [Member] | Time-Based Vesting [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted			551,005
Share-based compensation, vesting description		lapse on the first anniversary of the grant date
Restrictions lapsing date on time-vested restricted stock awards		Feb. 22, 2018
Restricted Stock [Member] | Time-Based Vesting [Member] | Non-Employee Director, Individual [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted		192,571	70,000
Restricted Stock [Member] | Time Based Vesting Lapse in Equal Installments on Each of First Three Anniversaries [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted		720,000	445,000
Share-based compensation, vesting period		3 years	3 years
Restricted Stock [Member] | Time Based Vesting Lapse in Equal Installments on Second and Third Anniversaries [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted			106,005
Share-based compensation, vesting description		lapse in equal installments on the second and third anniversaries of the grant date.
QHC and CHS Restricted Stock Awards Held By QHC Employees as of Spin-off Date [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense		$ 400
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted	1,081,005	1,142,571
Unrecognized stock-based compensation expense		$ 9,800
Community Health Systems, Inc [Member] | Corporate Allocations [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation expense included in corporate management fee			$ 81,059	$ 243,018
Community Health Systems, Inc [Member] | Corporate Allocations [Member] | Share-based Compensation Expense Included in Corporate Management Fee [Member] | QHC Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation expense included in corporate management fee			$ 2,300	$ 7,000
2016 Stock Award Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock that may be issued under stock award plan					4,700,000

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Activity Related to Unvested Restricted Stock Awards) (Details) - $ / shares	8 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017
QHC Awards Distributed in Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	692,409	673,987
Vested, Shares	(7,415)	(238,989)
Forfeited, Shares	(11,007)	(168,118)
Unvested restricted stock awards at end of period, Shares	673,987	266,880
QHC Awards Distributed in Spin-off [Member] | QHC Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	54,321	52,462
Vested, Shares	(1,317)	(34,131)
Forfeited, Shares	(542)	(14,174)
Unvested restricted stock awards at end of period, Shares	52,462	4,157
QHC Awards Distributed in Spin-off [Member] | CHS Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	638,088	621,525
Vested, Shares	(6,098)	(204,858)
Forfeited, Shares	(10,465)	(153,944)
Unvested restricted stock awards at end of period, Shares	621,525	262,723
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	0	1,081,005
Granted, Shares	1,081,005	1,142,571
Vested, Shares	0	(282,582)
Forfeited, Shares	0	(161,506)
Unvested restricted stock awards at end of period, Shares	1,081,005	1,779,488
Unvested restricted stock awards at beginning of period, Weighted Average Grant Date Fair Value Per Share	$ 0	$ 12.77
Granted, Weighted Average Grant Date Fair Value Per Share	12.77	7.54
Vested, Weighted Average Grant Date Fair Value Per Share	0	12.77
Forfeited, Weighted Average Grant Date Fair Value Per Share	0	10.90
Unvested restricted stock awards at end of period, Weighted Average Grant Date Fair Value Per Share	$ 12.77	$ 9.58

Stock-Based Compensation (Su103

Stock-Based Compensation (Summary of Stock-Based Compensation Expense for Periods Subsequent to Spin-Off) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 9,952	$ 7,441	$ 0
Resulting from Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	2,225	3,089	0
Related to Grants Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 7,727	$ 4,352	$ 0

Benefit Plans (Narrative) (Deta

Benefit Plans (Narrative) (Details)	Sep. 16, 2016Installmentshares	Aug. 18, 2016	Apr. 29, 2016USD ($)	Jan. 31, 2017USD ($)	Dec. 31, 2017USD ($)Hospital	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, total expense					$ 1,200,000	$ 13,600,000	$ 13,000,000
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of Hospitals | Hospital					1
Defined benefit plan, expected contributions by employer					$ 400,000
Weighted- average assumptions used in determining net periodic cost, discount rate					3.60%	3.75%
Weighted- average assumptions used in determining net periodic cost, annual compensation increase					3.50%	3.00%
Weighted- average assumptions used in determining net periodic cost, expected long-term rate on return on assets					6.25%	7.00%
Defined benefit plan net periodic benefit cost					$ 100,000	$ 300,000	$ 300,000
Accrued benefit obligation liability					800,000	$ 1,100,000
Original SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, assets transferred			$ 0
Accrued benefit liability			$ 6,000,000
Amended and Restated SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Estimated prior service costs that will be amortized from accumulated other comprehensive income into net periodic benefit costs for year ended December 31, 2018					300,000
Accumulated benefit obligation					$ 5,200,000
Weighted- average assumptions used in determining net periodic cost, discount rate					3.60%	3.20%	0.00%
Weighted- average assumptions used in determining net periodic cost, annual compensation increase					2.00%	3.00%	0.00%
Defined benefit plan net periodic benefit cost					$ 2,045,000	$ 1,787,000	$ 0
Maximum [Member] | Director's Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of annual installments | Installment	15
Common stock shares available for issuance | shares	150,000
Other long-term liabilities [Member] | Amended and Restated SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability					8,700,000	7,100,000
Accrued Salaries and Benefits [Member] | Amended and Restated SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Current portion of benefit obligation liability					0	$ 2,300,000
CHS Unfunded Deferred Compensation Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, assets transferred				$ 22,900,000
Defined benefit plan, liabilities transferred				$ 23,900,000
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Percentage of incentive compensation participants are permitted to defer		100.00%
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Other long-term liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability					24,300,000
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Other long-term Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term portion of benefit Asset					$ 23,100,000

Benefit Plans (Summary of Compo

Benefit Plans (Summary of Components of Net Periodic Benefit Costs) (Details) - Amended and Restated SERP Plan [Member] - USD ($) $ in Thousands	8 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 1,270	$ 1,347	$ 1,270	$ 0
Interest cost	$ 190	299	237	0
Prior service cost (credit)		396	268	0
Net (gain) loss		3	12	0
Total net periodic benefit cost		$ 2,045	$ 1,787	$ 0

Benefit Plans (Summary of Weigh

Benefit Plans (Summary of Weighted-Average Assumptions Used to Determine Net Periodic Benefit Costs) (Details) - Amended and Restated SERP Plan [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.60%	3.20%	0.00%
Rate of compensation increase	2.00%	3.00%	0.00%

Benefit Plans (Summary of Chang

Benefit Plans (Summary of Changes Recognized in Other Comprehensive Income (Loss) (Details) - Amended and Restated SERP Plan [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Prior service cost (credit)	$ 0	$ 2,949	$ 0
Net loss (gain) arising during period	(146)	14	0
Amortization or curtailment recognition of prior service (cost) credit	(396)	(264)	0
Amortization or settlement recognition of net gain (loss)	(3)	(3)	0
Total recognized in other comprehensive loss (income)	$ (545)	$ 2,696	$ 0

Benefit Plans (Summary of Ch108

Benefit Plans (Summary of Changes in Benefit Obligation) (Details) - Amended and Restated SERP Plan [Member] - USD ($) $ in Thousands	8 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Benefit obligation at beginning of period	$ 0	$ 9,434
Benefit obligation transferred from the Spin-off	5,964	0
Service cost	1,270	1,347	$ 1,270	$ 0
Interest cost	190	299	237	$ 0
Plan amendments	2,921	0
Benefits paid	0	(2,275)
Actuarial (gain) loss	(911)	(146)
Benefit obligation at end of period	$ 9,434	$ 8,659	$ 9,434

Benefit Plans (Summary of We109

Benefit Plans (Summary of Weighted-Average Assumptions Used to Determine Benefit Obligation) (Details) - Amended and Restated SERP Plan [Member]	Dec. 31, 2017	Dec. 31, 2016
Defined Benefit Plan Disclosure [Line Items]
Discount rate	3.30%	3.60%
Rate of compensation increase	2.00%	2.00%

Benefit Plans (Summary of Expec

Benefit Plans (Summary of Expected Future Benefit Payments) (Details) - Amended and Restated SERP Plan [Member] $ in Thousands	Dec. 31, 2017USD ($)
Defined Benefit Plan Disclosure [Line Items]
2,018	$ 0
2,019	0
2,020	0
2,021	948
2,022	0
Five years thereafter	10,448
Total expected future benefit payments	$ 11,396

Related Party Transactions (Sum

Related Party Transactions (Summary of Allocated Costs from Parent Prior to Spin-off) (Details) - Community Health Systems, Inc [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Management Fees From Parent [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	$ 11,792	$ 36,466
Corporate Allocations [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	81,059	243,018
Corporate Allocations [Member] | Insurance Costs [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	44,246	134,290
Corporate Allocations [Member] | Management Fees From Parent [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	11,792	36,466
Corporate Allocations [Member] | All Other Allocated Costs [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	$ 25,021	$ 72,262

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	Apr. 29, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Apr. 29, 2016
Related Party Transaction [Line Items]
Interest Expense, Related Party		$ 0	$ 35,814	$ 98,007
Community Health Systems, Inc [Member]
Related Party Transaction [Line Items]
Interest Expense, Related Party			35,800	98,000
Terms of transitional service agreements	5 years
Community Health Systems, Inc [Member] | Transition Services Agreements Following Spin-Off [Member]
Related Party Transaction [Line Items]
Total expenses incurred and allocation from parent		63,500	44,700
Community Health Systems, Inc [Member] | Transition Services Agreements and Allocation from Parent Prior to Spin-Off [Member]
Related Party Transaction [Line Items]
Total expenses incurred and allocation from parent		$ 63,500	$ 66,400	$ 60,200
Community Health Systems, Inc [Member] | Transition Services Agreements
Related Party Transaction [Line Items]
Terms of transitional service agreements	5 years
Community Health Systems, Inc [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Related party transaction, rate					4.00%
Community Health Systems, Inc [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Related party transaction, rate					7.00%

Commitments and Contingencie113

Commitments and Contingencies (Narrative) (Details)	Aug. 04, 2017USD ($)Agreement	Dec. 23, 2016	Apr. 29, 2016	Dec. 31, 2017USD ($)Hospital	Dec. 31, 2016USD ($)	Dec. 31, 2014Hospital	Dec. 31, 2015USD ($)
Other Commitments [Line Items]
Property and equipment, at cost				$ 1,405,184,000	$ 1,519,975,000
Community Health Systems, Inc [Member]
Other Commitments [Line Items]
Number of Hospitals | Hospital						4
Terms of transitional service agreements			5 years
McKenzie – Willamette Medical Center Project [Member] | Asset Under Construction [Member] | Construction and Capital Commitments [Member]
Other Commitments [Line Items]
Property and equipment, at cost				34,100,000	$ 38,500,000		$ 10,400,000
Construction costs incurred during the period				83,000,000
Project placed into service				76,100,000
Total estimated costs of project, including equipment costs				$ 105,000,000
Expected project to be completed period				Late 2,018
Helena Regional Medical Center Master Lease [Member] | Construction and Capital Commitments [Member]
Other Commitments [Line Items]
Estimated capital expenditure of remaining lease term				$ 1,000,000
Lease Expiration Date				Jan. 1, 2025
Other Renovation Projects [Member] | Construction and Capital Commitments [Member]
Other Commitments [Line Items]
Number of Hospitals | Hospital				1
Expected project to begin and be completed year				2,018
Total estimated cost of projects				$ 4,700,000
Physician Recruiting Commitments, Income Guarantee [Member]
Other Commitments [Line Items]
Maximum potential amount of future payments in excess of liabilities recorded				400,000
Guarantee period					1 year
Commitment periods over which physician agrees to practice in designated community					3 years
Physician guarantee contract liabilities				200,000	$ 1,600,000
Professional and General Liability Insurance [Member]
Other Commitments [Line Items]
Self-insured retention level				$ 5,000,000
Professional and General Liability Insurance [Member] | All Other Self-insurance Reserves [Member]
Other Commitments [Line Items]
Discounted weighted-average risk-free rate				2.00%	2.00%
Estimated discounted claims liability				$ 35,500,000	$ 14,700,000
Estimated undiscounted claims liability				$ 39,200,000	$ 16,400,000
Professional and General Liability Insurance [Member] | Insurance Reserves Indemnified By CHS, Inc. [Member]
Other Commitments [Line Items]
Discounted weighted-average risk-free rate				1.90%	1.50%
Estimated undiscounted claims liability				$ 71,700,000	$ 86,600,000
Worker's Compensation Liability [Member]
Other Commitments [Line Items]
Self-insured retention level				$ 500,000
Worker's Compensation Liability [Member] | All Other Self-insurance Reserves [Member]
Other Commitments [Line Items]
Discounted weighted-average risk-free rate				2.00%	2.00%
Estimated discounted claims liability				$ 7,100,000	$ 3,200,000
Estimated undiscounted claims liability				7,400,000	$ 3,500,000
Quorum Health Resources [Member] | Professional and General Liability Insurance [Member]
Other Commitments [Line Items]
Self-insured retention level				$ 6,000,000
Quorum Health Resources [Member] | United Tort Claimants and Douthitt-Dugger, et al. [Member]
Other Commitments [Line Items]
Lawsuit filing date				June 11, 2010
Plaintiffs' claims liability not covered by insurance				$ 5,100,000
Percentage of fault of company for plaintiffs' injuries		16.50%
Trial of the claims				The plaintiffs have made attempts to assert new allegations against QHR in an effort to increase the percentage of liability attributed to QHR, but the bankruptcy court has ruled against the plaintiffs as to each attempt. On January 24, 2018, the New Mexico state court ruled that collateral estoppel applies as to all rulings issued by the bankruptcy court in these matters, which includes the percentage of liability. As a result of the rulings in both courts, all that remains to be determined is the amount of damages sustained, if any, by the individual plaintiffs. The bankruptcy court has heard evidence regarding damages as to four of the plaintiffs and issued an opinion setting forth its findings January 30, 2018. Additional trials will be set in the bankruptcy court to hear evidence as to the remaining plaintiffs in that action. A jury will hear evidence as to the damages asserted by the plaintiffs in state court beginning November 26, 2018. QHR’s insurer, Lexington Insurance Company, is providing a defense in these cases, subject to a reservation of rights. Lexington has sued QHR in Williamson County, Tennessee seeking a declaration that plaintiffs’ claims and at least some portion of the cost of defending QHR are not covered by Lexington. (Lexington Insurance Company v. Quorum Health Resources, LLC, et al. (Williamson County, Tennessee Chancery Court)). No trial date has been set for Lexington’s claim against QHR with respect to insurance coverage, which QHR also is vigorously defending. The Tennessee court has ruled that Lexington is not entitled to reimbursement of defense costs. Lexington is seeking appellate review of this ruling.
Arbitration with Community Health Systems, Inc. [Member]
Other Commitments [Line Items]
Number of transition services agreements | Agreement	2
Payment related to transaction service agreements sought	$ 9,000,000

Commitments and Contingencies -

Commitments and Contingencies - (Summary of Insurance Reserves Related to Professional and General Liability and Workers Compensation Liability) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	$ 21,465	$ 17,580
Insurance reserve for workers' compensation liability, current receivable	3,032	4,863
Total self-insurance reserves, current receivable	24,497	22,443
Insurance reserves for professional and general liability, long-term receivable	44,377	59,652
Insurance reserve for workers' compensation liability, long-term receivable	14,545	15,958
Total self-insurance reserves, long-term receivable	58,922	75,610
Insurance reserves for professional and general liability, current liability	24,348	17,810
Insurance reserve for workers' compensation liability, current liability	6,152	6,599
Total self-insurance reserves, current liability	30,500	24,409
Insurance reserves for professional and general liability, long-term liability	76,993	74,194
Insurance reserve for workers' compensation liability, long-term liability	18,558	17,416
Total self-insurance reserves, long-term liability	95,551	91,610
Insurance Reserves Indemnified By CHS, Inc. [Member]
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	21,465	17,580
Insurance reserve for workers' compensation liability, current receivable	3,032	4,863
Insurance reserves for professional and general liability, long-term receivable	44,377	59,652
Insurance reserve for workers' compensation liability, long-term receivable	14,545	15,958
Insurance reserves for professional and general liability, current liability	21,465	17,580
Insurance reserve for workers' compensation liability, current liability	3,032	4,863
Insurance reserves for professional and general liability, long-term liability	44,377	59,652
Insurance reserve for workers' compensation liability, long-term liability	14,545	15,958
All Other Self-insurance Reserves [Member]
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	0	0
Insurance reserve for workers' compensation liability, current receivable	0	0
Insurance reserves for professional and general liability, long-term receivable	0	0
Insurance reserve for workers' compensation liability, long-term receivable	0	0
Insurance reserves for professional and general liability, current liability	2,883	230
Insurance reserve for workers' compensation liability, current liability	3,120	1,736
Insurance reserves for professional and general liability, long-term liability	32,616	14,542
Insurance reserve for workers' compensation liability, long-term liability	$ 4,013	$ 1,458

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) $ in Thousands	Mar. 01, 2018USD ($)bed	Feb. 01, 2018bed	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Subsequent Event [Line Items]
Proceeds from the sale of hospitals			$ 32,081	$ 13,746	$ 0
Impairment of long-lived assets			47,281	291,870	13,000
Georgia [Member] | Definitive Agreement to Clearview Regional Medical Center and Affiliated Outpatient Facilities [Member] | Licensing Agreements [Member]
Subsequent Event [Line Items]
Impairment of long-lived assets				1,200
Georgia [Member] | Subsequent Event [Member] | Definitive Agreement to Clearview Regional Medical Center and Affiliated Outpatient Facilities [Member]
Subsequent Event [Line Items]
Disposal date		Feb. 1, 2018
Number of beds in hospital sold | bed		77
Vista West [Member] | Illinois [Member]
Subsequent Event [Line Items]
Pre-tax gain (loss) from discontinued operation			(2,300)	4,900	$ 5,700
Vista West [Member] | Illinois [Member] | Property, Equipment and Capitalized Software [Member]
Subsequent Event [Line Items]
Impairment of long-lived assets			11,100	4,100
Vista West [Member] | Illinois [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Disposal date	Mar. 1, 2018
Number of beds in hospital sold | bed	70
Proceeds from the sale of hospitals	$ 1,200
Affinity [Member] | Ohio [Member] | Property, Equipment and Capitalized Software [Member]
Subsequent Event [Line Items]
Impairment of long-lived assets			$ 16,100	$ 20,200

Quarterly Financial Data (Un116

Quarterly Financial Data (Unaudited) (Summary of Company's Quarterly Operating Results) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]
Total net operating revenues	$ 515,082	$ 499,302	$ 530,146	$ 527,640	$ 515,240	$ 543,939	$ 529,737	$ 549,551	$ 2,072,170	$ 2,138,467	$ 2,187,338
Net income (loss)	(26,023)	(28,554)	(30,575)	(27,205)	(90,092)	(6,452)	(243,966)	(4,687)	(112,357)	(345,197)	4,735
Less: Net income (loss) attributable to noncontrolling interests	785	637	55	356	574	507	1,095	315	1,833	2,491	3,398
Net income (loss) attributable to Quorum Health Corporation	$ (26,808)	$ (29,191)	$ (30,630)	$ (27,561)	$ (90,666)	$ (6,959)	$ (245,061)	$ (5,002)	$ (114,190)	$ (347,688)	$ 1,337
Earnings (loss) per share attributable to Quorum Health Corporation stockholders:
Basic and diluted	$ (0.95)	$ (1.03)	$ (1.09)	$ (0.99)	$ (3.19)	$ (0.24)	$ (8.63)	$ (0.18)	$ (4.06)	$ (12.24)	$ 0.05
Weighted-average shares outstanding:
Basic and diluted	28,248,527	28,245,833	28,145,215	27,800,597	28,416,801	28,413,532	28,412,720	28,412,054	28,113,566	28,413,247	28,412,054

Quarterly Financial Data (Un117

Quarterly Financial Data (Unaudited) (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
California Hospital Quality Assurance Fee [Member]
Effect Of Fourth Quarter Events [Line Items]
Operating revenues, net of provider taxes	$ 22	$ 22	$ 34.4	$ 31.5

Guarantor and Non-Guarantor 118

Guarantor and Non-Guarantor Supplemental Information (Narrative) (Details)	12 Months Ended
	Dec. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Percentage of owned domestic subsidiaries which guaranteed senior notes	100.00%

Guarantor and Non-Guarantor 119

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts									$ 2,327,655	$ 2,419,053	$ 2,445,858
Provision for bad debts									255,485	280,586	258,520
Net operating revenues	$ 515,082	$ 499,302	$ 530,146	$ 527,640	$ 515,240	$ 543,939	$ 529,737	$ 549,551	2,072,170	2,138,467	2,187,338
Operating costs and expenses:
Salaries and benefits									1,034,797	1,057,119	1,016,696
Supplies									250,523	258,639	249,792
Other operating expenses									623,063	645,802	634,233
Depreciation and amortization									82,155	117,288	128,001
Rent									50,230	49,883	48,729
Electronic health records incentives earned									(4,745)	(11,482)	(25,779)
Legal, professional and settlement costs									6,001	7,342	0
Impairment of long-lived assets and goodwill									47,281	291,870	13,000
Loss (gain) on sale of hospitals, net									(5,243)	2,150	0
Transaction costs related to the Spin-off									253	5,488	16,337
Total operating costs and expenses									2,084,315	2,424,099	2,081,009
Income (loss) from operations									(12,145)	(285,632)	106,329
Interest expense, net									122,077	113,440	98,290
Equity in earnings of affiliates									0	0	0
Income (loss) before income taxes									(134,222)	(399,072)	8,039
Provision for (benefit from) income taxes									(21,865)	(53,875)	3,304
Net income (loss)	(26,023)	(28,554)	(30,575)	(27,205)	(90,092)	(6,452)	(243,966)	(4,687)	(112,357)	(345,197)	4,735
Less: Net income (loss) attributable to noncontrolling interests	785	637	55	356	574	507	1,095	315	1,833	2,491	3,398
Net income (loss) attributable to Quorum Health Corporation	$ (26,808)	$ (29,191)	$ (30,630)	$ (27,561)	$ (90,666)	$ (6,959)	$ (245,061)	$ (5,002)	(114,190)	(347,688)	1,337
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts									0	0	0
Provision for bad debts									0	0	0
Net operating revenues									0	0	0
Operating costs and expenses:
Salaries and benefits									0	0	0
Supplies									0	0	0
Other operating expenses									3,002	0	0
Depreciation and amortization									0	0	0
Rent									0	0	0
Electronic health records incentives earned									0	0	0
Legal, professional and settlement costs									0	0
Impairment of long-lived assets and goodwill									0	0	0
Loss (gain) on sale of hospitals, net									0	0
Transaction costs related to the Spin-off									0	0	0
Total operating costs and expenses									3,002	0	0
Income (loss) from operations									(3,002)	0	0
Interest expense, net									124,060	78,266	0
Equity in earnings of affiliates									15,291	258,078	0
Income (loss) before income taxes									(142,353)	(336,344)	0
Provision for (benefit from) income taxes									(28,163)	(2,318)	0
Net income (loss)									(114,190)	(334,026)	0
Less: Net income (loss) attributable to noncontrolling interests									0	0	0
Net income (loss) attributable to Quorum Health Corporation									(114,190)	(334,026)	0
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts									1,815,355	1,811,586	1,833,226
Provision for bad debts									215,021	211,921	204,968
Net operating revenues									1,600,334	1,599,665	1,628,258
Operating costs and expenses:
Salaries and benefits									715,713	715,925	687,596
Supplies									182,172	180,098	177,421
Other operating expenses									504,809	505,778	507,514
Depreciation and amortization									68,770	97,318	105,320
Rent									29,923	27,741	27,871
Electronic health records incentives earned									(3,681)	(8,948)	(21,001)
Legal, professional and settlement costs									6,001	7,342
Impairment of long-lived assets and goodwill									47,281	242,685	13,000
Loss (gain) on sale of hospitals, net									0	0
Transaction costs related to the Spin-off									195	4,105	12,161
Total operating costs and expenses									1,551,183	1,772,044	1,509,882
Income (loss) from operations									49,151	(172,379)	118,376
Interest expense, net									(2,054)	32,541	86,363
Equity in earnings of affiliates									29,673	58,605	(16,857)
Income (loss) before income taxes									21,532	(263,525)	48,870
Provision for (benefit from) income taxes									(3,508)	(35,576)	16,904
Net income (loss)									25,040	(227,949)	31,966
Less: Net income (loss) attributable to noncontrolling interests									0	0	(621)
Net income (loss) attributable to Quorum Health Corporation									25,040	(227,949)	32,587
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts									512,300	607,467	612,632
Provision for bad debts									40,464	68,665	53,552
Net operating revenues									471,836	538,802	559,080
Operating costs and expenses:
Salaries and benefits									319,084	341,194	329,100
Supplies									68,351	78,541	72,371
Other operating expenses									115,252	140,024	126,719
Depreciation and amortization									13,385	19,970	22,681
Rent									20,307	22,142	20,858
Electronic health records incentives earned									(1,064)	(2,534)	(4,778)
Legal, professional and settlement costs									0	0
Impairment of long-lived assets and goodwill									0	49,185	0
Loss (gain) on sale of hospitals, net									(5,243)	2,150
Transaction costs related to the Spin-off									58	1,383	4,176
Total operating costs and expenses									530,130	652,055	571,127
Income (loss) from operations									(58,294)	(113,253)	(12,047)
Interest expense, net									71	2,633	11,927
Equity in earnings of affiliates									0	0	0
Income (loss) before income taxes									(58,365)	(115,886)	(23,974)
Provision for (benefit from) income taxes									9,806	(15,981)	(13,600)
Net income (loss)									(68,171)	(99,905)	(10,374)
Less: Net income (loss) attributable to noncontrolling interests									1,833	2,491	4,019
Net income (loss) attributable to Quorum Health Corporation									(70,004)	(102,396)	(14,393)
Eliminations [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts									0	0	0
Provision for bad debts									0	0	0
Net operating revenues									0	0	0
Operating costs and expenses:
Salaries and benefits									0	0	0
Supplies									0	0	0
Other operating expenses									0	0	0
Depreciation and amortization									0	0	0
Rent									0	0	0
Electronic health records incentives earned									0	0	0
Legal, professional and settlement costs									0	0
Impairment of long-lived assets and goodwill									0	0	0
Loss (gain) on sale of hospitals, net									0	0
Transaction costs related to the Spin-off									0	0	0
Total operating costs and expenses									0	0	0
Income (loss) from operations									0	0	0
Interest expense, net									0	0	0
Equity in earnings of affiliates									(44,964)	(316,683)	16,857
Income (loss) before income taxes									44,964	316,683	(16,857)
Provision for (benefit from) income taxes									0	0	0
Net income (loss)									44,964	316,683	(16,857)
Less: Net income (loss) attributable to noncontrolling interests									0	0	0
Net income (loss) attributable to Quorum Health Corporation									$ 44,964	$ 316,683	$ (16,857)

Guarantor and Non-Guarantor 120

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	$ (26,023)	$ (28,554)	$ (30,575)	$ (27,205)	$ (90,092)	$ (6,452)	$ (243,966)	$ (4,687)	$ (112,357)	$ (345,197)	$ 4,735
Amortization and recognition of unrecognized pension cost components, net of income taxes									804	(2,760)	0
Comprehensive income (loss)									(111,553)	(347,957)	4,735
Less: Comprehensive income (loss) attributable to noncontrolling interests									1,833	2,491	3,398
Comprehensive income (loss) attributable to Quorum Health Corporation									(113,386)	(350,448)	1,337
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)									(114,190)	(334,026)	0
Amortization and recognition of unrecognized pension cost components, net of income taxes									804	(2,760)	0
Comprehensive income (loss)									(113,386)	(336,786)	0
Less: Comprehensive income (loss) attributable to noncontrolling interests									0	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation									(113,386)	(336,786)	0
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)									25,040	(227,949)	31,966
Amortization and recognition of unrecognized pension cost components, net of income taxes									804	(2,760)	0
Comprehensive income (loss)									25,844	(230,709)	31,966
Less: Comprehensive income (loss) attributable to noncontrolling interests									0	0	(621)
Comprehensive income (loss) attributable to Quorum Health Corporation									25,844	(230,709)	32,587
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)									(68,171)	(99,905)	(10,374)
Amortization and recognition of unrecognized pension cost components, net of income taxes									0	0	0
Comprehensive income (loss)									(68,171)	(99,905)	(10,374)
Less: Comprehensive income (loss) attributable to noncontrolling interests									1,833	2,491	4,019
Comprehensive income (loss) attributable to Quorum Health Corporation									(70,004)	(102,396)	(14,393)
Eliminations [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)									44,964	316,683	(16,857)
Amortization and recognition of unrecognized pension cost components, net of income taxes									(804)	2,760	0
Comprehensive income (loss)									44,160	319,443	(16,857)
Less: Comprehensive income (loss) attributable to noncontrolling interests									0	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation									$ 44,160	$ 319,443	$ (16,857)

Guarantor and Non-Guarantor 121

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Apr. 29, 2016	Apr. 27, 2016	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 5,617	$ 25,455			$ 1,106	$ 2,559
Patient accounts receivable, net of allowance for doubtful accounts of $352,509 and $360,796 at December 31, 2017 and 2016, respectively	343,145	380,685
Inventories	53,459	58,124
Prepaid expenses	21,167	23,028
Due from third-party payors	97,202	116,235
Current assets of hospitals held for sale	8,112	1,502
Other current assets	47,440	57,942
Total current assets	576,142	662,971
Intercompany receivable	0	0
Property and equipment, net	675,279	733,900
Goodwill	409,229	416,833			541,704
Intangible assets, net	64,850	84,982
Long-term assets of hospitals held for sale	7,734	6,851
Other long-term assets	95,607	88,833
Net investment in subsidiaries	0	0
Total assets	1,828,841	1,994,370
Current liabilities:
Current maturities of long-term debt	1,855	5,683
Accounts payable	171,250	169,684
Accrued liabilities:
Accrued salaries and benefits	77,803	98,803
Accrued interest	10,466	19,915
Due to third-party payors	47,705	42,537
Current liabilities of hospitals held for sale	2,577	492
Other current liabilities	43,687	53,268
Total current liabilities	355,343	390,382
Long-term debt	1,212,035	1,241,142	$ 1,250,497	$ 24,179
Intercompany payable	0	0
Deferred income tax liabilities, net	7,774	31,474
Other long-term liabilities	137,954	108,996
Total liabilities	1,713,106	1,771,994
Redeemable noncontrolling interests	2,325	6,807			8,958	2,362
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	3	3
Additional paid-in capital	549,610	537,911
Accumulated other comprehensive income (loss)	(1,956)	(2,760)
Accumulated deficit	(448,216)	(334,026)
Total Quorum Health Corporation stockholders' equity	99,441	201,128
Nonredeemable noncontrolling interests	13,969	14,441
Total equity	113,410	215,569			15,943	7,918
Total liabilities and equity	1,828,841	1,994,370
Reportable Legal Entities [Member] | Parent Issuer [Member]
Current assets:
Cash and cash equivalents	1,051	21,609			0	0
Patient accounts receivable, net of allowance for doubtful accounts of $352,509 and $360,796 at December 31, 2017 and 2016, respectively	0	0
Inventories	0	0
Prepaid expenses	33	0
Due from third-party payors	0	0
Current assets of hospitals held for sale	0	0
Other current assets	0	0
Total current assets	1,084	21,609
Intercompany receivable	3	3
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long-term assets of hospitals held for sale	0	0
Other long-term assets	0	0
Net investment in subsidiaries	1,488,021	1,485,213
Total assets	1,489,108	1,506,825
Current liabilities:
Current maturities of long-term debt	0	3,819
Accounts payable	132	158
Accrued liabilities:
Accrued salaries and benefits	0	0
Accrued interest	10,466	19,915
Due to third-party payors	0	0
Current liabilities of hospitals held for sale	0	0
Other current liabilities	516	0
Total current liabilities	11,114	23,892
Long-term debt	1,188,224	1,215,836
Intercompany payable	182,555	34,495
Deferred income tax liabilities, net	7,774	31,474
Other long-term liabilities	0	0
Total liabilities	1,389,667	1,305,697
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	3	3
Additional paid-in capital	549,610	537,911
Accumulated other comprehensive income (loss)	(1,956)	(2,760)
Accumulated deficit	(448,216)	(334,026)
Total Quorum Health Corporation stockholders' equity	99,441	201,128
Nonredeemable noncontrolling interests	0	0
Total equity	99,441	201,128
Total liabilities and equity	1,489,108	1,506,825
Reportable Legal Entities [Member] | Other Guarantors [Member]
Current assets:
Cash and cash equivalents	4,222	3,498			524	2,452
Patient accounts receivable, net of allowance for doubtful accounts of $352,509 and $360,796 at December 31, 2017 and 2016, respectively	262,690	277,155
Inventories	43,276	46,318
Prepaid expenses	16,980	17,874
Due from third-party payors	93,323	109,793
Current assets of hospitals held for sale	8,112	1,502
Other current assets	32,867	41,673
Total current assets	461,470	497,813
Intercompany receivable	402,817	126,035
Property and equipment, net	543,073	624,457
Goodwill	243,618	252,433
Intangible assets, net	58,240	73,404
Long-term assets of hospitals held for sale	7,730	6,851
Other long-term assets	74,918	72,967
Net investment in subsidiaries	0	0
Total assets	1,791,866	1,653,960
Current liabilities:
Current maturities of long-term debt	1,434	1,560
Accounts payable	146,193	147,521
Accrued liabilities:
Accrued salaries and benefits	56,522	69,896
Accrued interest	0	0
Due to third-party payors	46,381	40,595
Current liabilities of hospitals held for sale	2,577	492
Other current liabilities	30,664	46,002
Total current liabilities	283,771	306,066
Long-term debt	23,809	24,899
Intercompany payable	173,341	86,084
Deferred income tax liabilities, net	0	0
Other long-term liabilities	195,132	144,950
Total liabilities	676,053	561,999
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	1,291,581	1,333,347
Accumulated other comprehensive income (loss)	(1,956)	(2,760)
Accumulated deficit	(173,812)	(238,626)
Total Quorum Health Corporation stockholders' equity	1,115,813	1,091,961
Nonredeemable noncontrolling interests	0	0
Total equity	1,115,813	1,091,961
Total liabilities and equity	1,791,866	1,653,960
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	344	348			582	107
Patient accounts receivable, net of allowance for doubtful accounts of $352,509 and $360,796 at December 31, 2017 and 2016, respectively	80,455	103,530
Inventories	10,183	11,806
Prepaid expenses	4,154	5,154
Due from third-party payors	3,879	6,442
Current assets of hospitals held for sale	0	0
Other current assets	14,573	16,269
Total current assets	113,588	143,549
Intercompany receivable	172,098	84,827
Property and equipment, net	132,206	109,443
Goodwill	165,611	164,400
Intangible assets, net	6,610	11,578
Long-term assets of hospitals held for sale	4	0
Other long-term assets	20,689	15,866
Net investment in subsidiaries	0	0
Total assets	610,806	529,663
Current liabilities:
Current maturities of long-term debt	421	304
Accounts payable	24,925	22,005
Accrued liabilities:
Accrued salaries and benefits	21,281	28,907
Accrued interest	0	0
Due to third-party payors	1,324	1,942
Current liabilities of hospitals held for sale	0	0
Other current liabilities	12,507	7,266
Total current liabilities	60,458	60,424
Long-term debt	2	407
Intercompany payable	219,022	90,286
Deferred income tax liabilities, net	0	0
Other long-term liabilities	31,100	22,651
Total liabilities	310,582	173,768
Redeemable noncontrolling interests	2,325	6,807
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	471,767	412,705
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(187,837)	(78,058)
Total Quorum Health Corporation stockholders' equity	283,930	334,647
Nonredeemable noncontrolling interests	13,969	14,441
Total equity	297,899	349,088
Total liabilities and equity	610,806	529,663
Eliminations [Member]
Current assets:
Cash and cash equivalents	0	0			$ 0	$ 0
Patient accounts receivable, net of allowance for doubtful accounts of $352,509 and $360,796 at December 31, 2017 and 2016, respectively	0	0
Inventories	0	0
Prepaid expenses	0	0
Due from third-party payors	0	0
Current assets of hospitals held for sale	0	0
Other current assets	0	0
Total current assets	0	0
Intercompany receivable	(574,918)	(210,865)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long-term assets of hospitals held for sale	0	0
Other long-term assets	0	0
Net investment in subsidiaries	(1,488,021)	(1,485,213)
Total assets	(2,062,939)	(1,696,078)
Current liabilities:
Current maturities of long-term debt	0	0
Accounts payable	0	0
Accrued liabilities:
Accrued salaries and benefits	0	0
Accrued interest	0	0
Due to third-party payors	0	0
Current liabilities of hospitals held for sale	0	0
Other current liabilities	0	0
Total current liabilities	0	0
Long-term debt	0	0
Intercompany payable	(574,918)	(210,865)
Deferred income tax liabilities, net	0	0
Other long-term liabilities	(88,278)	(58,605)
Total liabilities	(663,196)	(269,470)
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	(1,763,348)	(1,746,052)
Accumulated other comprehensive income (loss)	1,956	2,760
Accumulated deficit	361,649	316,684
Total Quorum Health Corporation stockholders' equity	(1,399,743)	(1,426,608)
Nonredeemable noncontrolling interests	0	0
Total equity	(1,399,743)	(1,426,608)
Total liabilities and equity	$ (2,062,939)	$ (1,696,078)

Guarantor and Non-Guarantor 122

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Cash Flows (Details) - USD ($) $ in Thousands	Apr. 29, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		$ 66,970	$ 81,086	$ 42,889
Cash flows from investing activities:
Capital expenditures for property and equipment		(61,530)	(79,920)	(59,455)
Capital expenditures for software		(6,898)	(7,269)	(8,845)
Acquisitions, net of cash acquired		(1,920)	(785)	(8,019)
Proceeds from the sale of hospitals		32,081	13,746	0
Proceeds from asset sales		0	1,082	3,114
Changes in intercompany balances with affiliates, net		0	0
Other investing activities		0	0	(5,387)
Net cash provided by (used in) investing activities		(38,267)	(73,146)	(78,592)
Cash flows from financing activities:
Borrowings under revolving credit facilities		508,000	50,000	0
Repayments under revolving credit facilities		(508,000)	(50,000)	0
Borrowings of long-term debt		376	1,256,281	372
Repayments of long-term debt		(39,195)	(15,222)	(1,563)
Increase (decrease) in Due to Parent, net		0	24,796	262,775
Increase (decrease) in receivables facility, net		0	0	(224,774)
Payments of debt issuance costs	$ (29,146)	(3,119)	(29,146)	0
Cash paid to Parent related to the Spin-off		0	(1,217,336)	0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		(1,508)	(13)	0
Cash distributions to noncontrolling investors		(3,851)	(2,850)	(1,623)
Purchases of shares from noncontrolling investors		(1,244)	(101)	(937)
Changes in intercompany balances with affiliates, net		0	0
Net cash provided by (used in) financing activities		(48,541)	16,409	34,250
Net change in cash and cash equivalents		(19,838)	24,349	(1,453)
Cash and cash equivalents at beginning of period		25,455	1,106	2,559
Cash and cash equivalents at end of period		5,617	25,455	1,106
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		(121,079)	(66,266)	0
Cash flows from investing activities:
Capital expenditures for property and equipment		0	0	0
Capital expenditures for software		0	0	0
Acquisitions, net of cash acquired		0	0	0
Proceeds from the sale of hospitals		0	0
Proceeds from asset sales			0	0
Changes in intercompany balances with affiliates, net		0	0
Other investing activities		0	0	0
Net cash provided by (used in) investing activities		0	0	0
Cash flows from financing activities:
Borrowings under revolving credit facilities		508,000	50,000
Repayments under revolving credit facilities		(508,000)	(50,000)
Borrowings of long-term debt		0	1,255,464	0
Repayments of long-term debt		(37,261)	(11,581)	0
Increase (decrease) in Due to Parent, net			0	0
Increase (decrease) in receivables facility, net				0
Payments of debt issuance costs		(3,119)	(29,146)
Cash paid to Parent related to the Spin-off			(1,217,336)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		0	0
Cash distributions to noncontrolling investors		0	0	0
Purchases of shares from noncontrolling investors		0	0	0
Changes in intercompany balances with affiliates, net		140,901	90,474
Net cash provided by (used in) financing activities		100,521	87,875	0
Net change in cash and cash equivalents		(20,558)	21,609	0
Cash and cash equivalents at beginning of period		21,609	0	0
Cash and cash equivalents at end of period		1,051	21,609	0
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		206,248	173,382	87,313
Cash flows from investing activities:
Capital expenditures for property and equipment		(24,777)	(73,327)	(37,321)
Capital expenditures for software		(6,090)	(3,854)	(6,935)
Acquisitions, net of cash acquired		(29)	(549)	(3,467)
Proceeds from the sale of hospitals		11,925	0
Proceeds from asset sales			1,498	3,114
Changes in intercompany balances with affiliates, net		(183,829)	(116,674)
Other investing activities		0	0	(1,416)
Net cash provided by (used in) investing activities		(202,800)	(192,906)	(46,025)
Cash flows from financing activities:
Borrowings under revolving credit facilities		0	0
Repayments under revolving credit facilities		0	0
Borrowings of long-term debt		376	740	217
Repayments of long-term debt		(1,592)	(3,025)	(1,043)
Increase (decrease) in Due to Parent, net			24,796	152,971
Increase (decrease) in receivables facility, net				(194,835)
Payments of debt issuance costs		0	0
Cash paid to Parent related to the Spin-off			0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		(1,508)	(13)
Cash distributions to noncontrolling investors		0	0	0
Purchases of shares from noncontrolling investors		0	0	(526)
Changes in intercompany balances with affiliates, net		0	0
Net cash provided by (used in) financing activities		(2,724)	22,498	(43,216)
Net change in cash and cash equivalents		724	2,974	(1,928)
Cash and cash equivalents at beginning of period		3,498	524	2,452
Cash and cash equivalents at end of period		4,222	3,498	524
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		(18,199)	(26,030)	(44,424)
Cash flows from investing activities:
Capital expenditures for property and equipment		(36,753)	(6,593)	(22,134)
Capital expenditures for software		(808)	(3,415)	(1,910)
Acquisitions, net of cash acquired		(1,891)	(236)	(4,552)
Proceeds from the sale of hospitals		20,156	13,746
Proceeds from asset sales			(416)	0
Changes in intercompany balances with affiliates, net		0	0
Other investing activities		0	0	(3,971)
Net cash provided by (used in) investing activities		(19,296)	3,086	(32,567)
Cash flows from financing activities:
Borrowings under revolving credit facilities		0	0
Repayments under revolving credit facilities		0	0
Borrowings of long-term debt		0	77	155
Repayments of long-term debt		(342)	(616)	(520)
Increase (decrease) in Due to Parent, net			0	109,804
Increase (decrease) in receivables facility, net				(29,939)
Payments of debt issuance costs		0	0
Cash paid to Parent related to the Spin-off			0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		0	0
Cash distributions to noncontrolling investors		(3,851)	(2,850)	(1,623)
Purchases of shares from noncontrolling investors		(1,244)	(101)	(411)
Changes in intercompany balances with affiliates, net		42,928	26,200
Net cash provided by (used in) financing activities		37,491	22,710	77,466
Net change in cash and cash equivalents		(4)	(234)	475
Cash and cash equivalents at beginning of period		348	582	107
Cash and cash equivalents at end of period		344	348	582
Eliminations [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		0	0	0
Cash flows from investing activities:
Capital expenditures for property and equipment		0	0	0
Capital expenditures for software		0	0	0
Acquisitions, net of cash acquired		0	0	0
Proceeds from the sale of hospitals		0	0
Proceeds from asset sales			0	0
Changes in intercompany balances with affiliates, net		183,829	116,674
Other investing activities		0	0	0
Net cash provided by (used in) investing activities		183,829	116,674	0
Cash flows from financing activities:
Borrowings under revolving credit facilities		0	0
Repayments under revolving credit facilities		0	0
Borrowings of long-term debt		0	0	0
Repayments of long-term debt		0	0	0
Increase (decrease) in Due to Parent, net			0	0
Increase (decrease) in receivables facility, net				0
Payments of debt issuance costs		0	0
Cash paid to Parent related to the Spin-off			0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		0	0
Cash distributions to noncontrolling investors		0	0	0
Purchases of shares from noncontrolling investors		0	0	0
Changes in intercompany balances with affiliates, net		(183,829)	(116,674)
Net cash provided by (used in) financing activities		(183,829)	(116,674)	0
Net change in cash and cash equivalents		0	0	0
Cash and cash equivalents at beginning of period		0	0	0
Cash and cash equivalents at end of period		$ 0	$ 0	$ 0